Juntos por uma sociedade mais saudável

(A free translation of the original in Portuguese)

Raia Drogasil S.A.

Individual and Consolidated
Financial Statements
At December 31, 2024

(A free translation of the original in Portuguese)

Contents

(A free translation of the original in Portuguese)

Comments on Company performance

São Paulo, February 25, 2025. RD Saúde (Raia Drogasil S.A. – B3: RADL3) announces its results for the 4th quarter of 2024 (4Q24). The Company's parent company and consolidated financial statements for the periods ended December 31, 2024 and 2023 have been prepared in accordance with the accounting practices adopted in Brazil, including the rules issued by the Brazilian Securities Commission (CVM), the Brazilian Accounting Standards – General Technical (NBC TG) and the pronouncements issued by the Brazilian Accounting Pronouncements Committee (CPC), and are in conformity with the International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB), and provide all the significant information related solely to the financial statements, which is consistent with the information used by management. The financial statements were prepared in Reais and all growth rates, unless otherwise stated, relate to the same period of the previous year.

IFRS 16: Our financial statements are prepared in accordance with IFRS 16. In order to better represent the economics of the business, the figures in this report are presented under IAS 17, the previous reporting standard. A reconciliation with IFRS 16 can be found in a dedicated chapter within this document.

2023 reclassifications: In the 1Q24, we concluded the reclassification of certain revenues and expenses to ensure their maximum correlation with the Company's activities. These reclassifications refer to the results of 2023 and do not affect the EBITDA, balance sheet or cash flow. More details can be found in the 1Q24 earnings release.

2024 CONSOLIDATED HIGHLIGHTS:

- **PHARMACIES: 3,230 units in operation (300 openings and 23 closures);**
- **GROSS REVENUE: R$ 41.8 billion, an increase of 15.1% with 6.5% of mature-store growth (13.9% in the 4Q24 with 5.6% of mature-store growth);**
- **MARKET SHARE: 16.5% national share in the 4Q24, a 0.3 pp increase;**
- **DIGITAL: R$ 7.1 billion, an increase of 41.7% and retail penetration of 20.2% in the 4Q24;**
- **ADJUSTED EBITDA: R$ 2,992 million, an increase of 15.0% and a margin of 7.2% (R$ 677.5 million in the 4Q24 with a 6.2% margin);**
- **ADJUSTED NET INCOME*: R$ 1,289 million, an increase of 16.6% and a margin of 3.1% (R$ 381.4 million in the 4Q24 with a 3.5% net margin);**
- **CASH FLOW: R$ 188.5 million positive free cash flow, R$ 651.4 million total cash consumption.**

** Includes the effects of the taxation of investment subsidies, in accordance with Law No. 14,789/2023.*

RADL3

R$ 18.90/share

Closing: Feb 24, 2025

MARKET CAP

R$ 32.5 billion

NUMBER OF SHARES

1,718,007,200

IR TEAM:

Flávio Correia
André Stolfi
Mariana Santo
Victor Torres
Felipe Correa

ir.rdsaude.com.br
ri@rdsaude.com.br

Summary (R$ thousands)	2023	2024	4Q23	1Q24	2Q24	3Q24	4Q24
# of pharmacies	**2,953**	**3,230**	**2,953**	**3,010**	**3,076**	**3,139**	**3,230**
Organic openings	270	300	87	62	70	72	96
Closures	(14)	(23)	(2)	(5)	(4)	(9)	(5)
Headcount (EoP)	57,691	64,758	57,691	57,708	59,341	62,402	64,758
Pharmacist count (EoP)	12,047	12,894	12,047	12,306	12,429	12,689	12,894
# of tickets (thousands)	361,721	404,357	94,401	95,846	102,141	102,620	103,751
# of active customers (MM	47.6	49.1	47.6	48.2	48.8	49.1	49.1
Gross revenue	**36,298,767**	**41,781,973**	**9,538,836**	**9,767,156**	**10,402,635**	**10,749,830**	**10,862,353**
Growth (YoY)	+17.3%	+15.1%	+14.3%	+15.3%	+15.4%	+15.9%	+13.9%
Gross profit	10,164,259	11,556,068	2,670,232	2,659,264	2,931,999	2,970,685	2,994,119
% of gross revenue	28.0%	27.7%	28.0%	27.2%	28.2%	27.6%	27.6%
Adjusted EBITDA	**2,603,246**	**2,992,482**	**614,544**	**679,850**	**824,396**	**810,715**	**677,521**
% of gross revenue	7.2%	7.2%	6.4%	7.0%	7.9%	7.5%	6.2%
Adjusted net income	**1,104,787**	**1,288,546**	**283,315**	**213,700**	**356,613**	**336,819**	**381,414**
% of gross revenue	3.0%	3.1%	3.0%	2.2%	3.4%	3.1%	3.5%
Net income	1,150,801	1,275,031	284,651	213,014	348,425	362,117	351,476
% of gross revenues	3.2%	3.1%	3.0%	2.2%	3.3%	3.4%	3.2%
Free cash flow	**(41,122)**	**188,481**	**150,930**	**(118,057)**	**(182,564)**	**693,260**	**(204,158)**

LETTER FROM THE ADMINISTRATION

In 2024, we got even closer to our customers, understanding and improving their journey and the omnichannel behaviour. We have advanced in Primary Care, bringing a more diverse portfolio of services to the people and communities we serve. We consolidated our strategic pillars - Caring for People; Executing with Focus; Building the Future – which reinforce our long-term vision. To crown this new role for the Company, we are now called RD Saúde. We continue to grow, expanding at a unique speed, gaining market share and maintaining the highest consolidated profitability in the sector, with sustained margin gains in retail. Finally, we carried out the internal succession of the CEO in a well planned and executed manner, with the nomination of Renato Raduan to replace Marcilio Pousada, who will be appointed as Member and new President of the company's Board of Directors. With this, we seek a new cycle of prosperity and reinvention, but with continuity and preservation of the Purpose, Culture and Values that brought us here.

For the first time, a HEALTH company was listed among the most valuable brands in the country. According to the Interbrand Best Brazilian Brands ranking of 2024, our brands Drogasil and Raia occupy, respectively, the 14th and 18th positions in the survey, an important recognition of our mission to become the group that contributes the most towards a healthier society in Brazil. Our brands are consolidated as the two most important in pharmaceutical retail, with Drogasil and Raia classified as the 1st and 2nd largest brands in Brazilian pharmaceutical retail in terms of revenue and number of stores.

We continue to grow and gain market share. At the end of the year, we reached a share of 16.5%. We are the only truly national company in the industry, operating with scale, profitability and attractive and consistent marginal returns in each of the country's regions. Since the merger in 2011, we have multiplied our revenue by 9x, but gained only 7.5 market share points, which denotes a thriving market, in rapid growth, resulting from the country's demographic aging. According to the national bureau of statistics IBGE, our market will continue to expand at a high rate, adding more than 1 million people over the age of 60 every year for the next 3 decades.

We opened 300 new pharmacies in 2024 and increased our expansion guidance to between 330 and 350 new units in 2025. We are present in 619 municipalities, covering 66% of the Brazilian population, including 313 of the 319 Brazilian cities with more than 100 thousand inhabitants. Our growth occurs in a healthy manner in all states of the country and increasingly includes smaller cities, areas where we previously did not have a significant presence. This expansion occurs in all clusters of stores - premium, hybrid and popular - suitable for the most different strata of the population. We increased our geographic coverage, serving within a radius of 1.5 km 94% of the A class population, 81% of the B1 class and significantly expanding our presence among classes B2, C1 and C2. We recorded real IRRs (internal rates of return) above the historical average of 20%, net of cannibalization, and we had a closing rate of maturing stores of just 1.7%, reflecting the assertiveness in choosing real estate and the success in its operation. Finally, we closed 18 mature stores during the year, optimizing our portfolio, transferring sales to nearby pharmacies, freeing up assets for reallocation and reducing fixed costs, allowing an increase in the company's efficiency and ROIC.

The focus on digitalization has been fundamental to increasing engagement and loyalty. Digitalized customers generate 20% to 25% more revenue than physical customers. The share of digital channels went from 2% to 20% in just 5 years, driving sustainable growth in mature stores above inflation. We also reached 42% of digital market share in pharma retail, with 6.4 million monthly active users (MAU). Today, 76% of digital revenue is driven through our apps, becoming the channel with the highest recurrence and loyalty compared to websites and third-party platforms, which we also activate in a more tactical way. We improved the profitability of the channel, with price optimization and gains in scale and efficiency, allowing us to achieve profitable and sustainable growth. Finally, 98% of the digital transactions are fulfilled by our store network, which covers 60% of the population within a radius of 5 km and enables the delivery of 96% of orders in less than 1 hour. Our more than 3 thousand pharmacies are a relevant and competitive advantage vs. pure digital players.

All these achievements were driven by our digital transformation. We now operate with a microservices architecture and with the use artificial intelligence (AI) in systems development, in addition to having more than 70 AI use cases focused on productivity and experience. We increased the number of monthly deliveries of new features by 60x vs. 2021 and improved systems integration and our technological architecture. The migration of digital operations to the cloud and the strengthening of information security were also essential steps in this process.

We maintain our customer-centric culture, committed to customer satisfaction and increasing LTV (Lifetime Value). We count more than 49 million active customers, with an average frequency of 8 purchases per year, representing more than 1 million daily transactions. We regularly measure engagement and CAV (Customer Annual Value), as well as the gradual change in behavior, through our engagement bonds. Personalizing the relationship offers significant benefits: (i) an increase in average spending per customer, with offerings and interactions adjusted to each customer's specific needs; (ii) loyalty, allowing a higher recurrence, with 3x more repurchases; (iii) greater satisfaction, with improved experience and ratings; and (iv) operational efficiency, allowing to optimize stocks, marketing campaigns and the layout of pharmacies. We have more than 20 engagement bonds that are continuously monitored and managed. Our digitalized loyal customers already account for 26% of our total revenues. Finally, the NPS (Net Promoter Score) in our pharmacies remains unmatched in Brazilian retail, having remained at 91 in 2024, while the digital NPS reached 76, a gain of 7 points throughout the year.

In 2024, we advanced towards becoming a gateway to Primary Care, enabling the identification and treatment of low-complexity acute conditions, monitoring of chronic conditions, clinical examinations, vaccines and immunization. This year, we performed more than 6.3 million pharmaceutical services, having reached a 38% market share in vaccines among pharmacies (equivalent to 5% of the total private market) through 379 pharmacies in 140 cities, which offer a complete child and adult vaccination calendar. We provided more than 2 million monitoring services for chronic conditions, including blood pressure and glucose. Our Na Rotina adherence program has 700,000 registered customers, increasing adherence to chronic treatments by 9%. We also established partnerships with recognized institutions such as Hospital Alemão Oswaldo Cruz, with Dr. Drauzio Varella and Marcio Atalla, reinforcing the credibility and seriousness of our efforts on health.

In addition to Retailing and Health, we continue to advance in the other verticals. 4Bio has been sustaining growth greater than the retail business and already represents R$ 3.5 billion of our consolidated gross revenue. Our marketplace, with an annualized GMV of R$ 255 million, counts 249 thousand SKUs from 1.2 thousand different sellers and already offers same day delivery in the city of São Paulo. Our private brand products reached the R$ 1.5 billion mark in 2024, with Needs being the 3rd largest consumer health brand in Brazilian pharmaceutical retail, according to IQVIA. Stix, our loyalty coalition with major retail brands of Brazil, reached 11.3 million customers, with 90% active and 45% accumulating and/or redeeming points at 2 or more partners. Other initiatives, such as compounding medicine and digital media/ads, continue their expected maturation curves. These verticals reinforce the potential to generate additional revenue and increase the company's value in the long term.

We reached gross revenue of R$ 41.8 billion in the year, with a 15.1% growth and adding R$ 5.5 billion. This result was driven by a 6.5% growth in mature stores, which for the fourth year in a row surpassed inflation (real gain of 2.0 pp in 2024). EBITDA reached R$ 3.0 billion with growth of 15.0% and a constant margin of 7.2%, while net profit reached R$ 1.3 billion, an increase of 16.6% with a 3.1% net margin, leading to an ROIC of 16.7% (or 18.8% if we disregard the additional taxation on investment subsidies, which we continue to challenge in court). Our Parent Company's pre IFRS adjusted EBITDA, which mainly reflects the retailing activity, continues to grow and expand margin, increasing 16.1% over 2023 with a margin of 7.7%, a 0.1 pp expansion in the year.

We also highlight other achievements in People, Culture and Sustainability. We achieved excellent ratings in ESG rankings (A in MSCI and 82.7 points in ISE) and maintained our position among the best companies in IDIVERSA, demonstrating our commitment to sustainable practices. We made progress in diversity, with an increase in female participation in leadership, greater representation of various races and people over 50. We adhered to the "1% Commitment" and donated 1% of our net profit to social institutions and another R$ 40 million in donations of our own resources, of customers and merchandise. We increased the demand for healthcare, encouraging the role of the pharmacist as a community agent. In our journey towards a "Healthier Planet", we reached 100% of pharmacies using energy from renewable sources; We carried out 3.8% of our DC's deliveries through electric methods and, to increase this percentage, we acquired another 45 electric trucks. Furthermore, we reduced diesel consumption by 9% reducing CO2 emissions. We launched our Projeto Farol ("Lighthouse Project"), which is a laboratory for building new prevention and health promotion journeys focused on D and E class communities. More details about our initiatives will be disclosed in the 2024 Annual and Sustainability Report.

The development and constant training of people is another central element of our culture. Our pharmacy career path with training starting at entry-level positions allows us to foster our culture, beliefs and operational know-how, resulting in better engagement and turnover. We are today the largest employer of pharmacists in Brazil and we count 65 thousand employees, an increase of 7 thousand vs. 2023. To face new opportunities in Primary Care, we launched our graduation course in Pharmacy in 2024, which already has more than 750 students. Furthermore, we offered more than 2 million hours of training focused on health, digitalization and leadership tracks, investing significantly in employee development, in partnership with recognized business schools.

At the beginning of 2025, we implemented an important transition in the company's leadership, with Renato Raduan assuming the presidency replacing Marcilio Pousada, who will be appointed as Member and President of the Board of Directors. During his cycle, which began in 2013, Marcilio completed the merger of Raia and Drogasil, led the strong acceleration of our expansion, the digitalization of customer relationships and the design of a culture focused on efficiency and sustainability, processes that resulted in the multiplication of the number of pharmacies by 4x, gross revenue by 9x, EBITDA by 10x and increasing the NPS from 60 to 91, considering the levels of 2011, the year of the merger.









With the appointment of Renato Raduan and the refreshing of our corporate structure, we seek to obtain a new cycle of value creation, with sustained gains in margin and ROIC, while preserving the Purpose, Values and Culture that brought RD Saúde to its current position. Raduan has been vice president of the company for 11 years, having led the company's Retail Operation, Digital Channels, Expansion and Logistics. He brings in a new management approach, increasing the obsession to offer the best customer experience, with even greater productivity and efficiency, using technology, innovation and team development as tools. Raduan will also seek to accelerate captures in invested companies and integrate them into RD Saúde's strategy and operations.

Other important movements accompanied this new organizational design. Marcello De Zagottis, previously VP of Commercial and Marketing and who has been with the company for 19 years, was appointed COO, taking charge of Operations and Supply Chain. Melissa Cabral, with 27 years at the company, was appointed VP of Retail Operations and Juliana Lopes Paixão, with 6 years at the company, VP of Commercial and Private Label. With these changes, among the 8 C-Level executives at RD Saúde, 3 are women.

Finally, we would like to thank our shareholders for their support and trust; our customers, who trusted us with their health and rewarded us with their loyalty; and to our employees, who work every day with total dedication to caring for our customers.

The Administration

RELEVANT TOPICS FOR 2025 AND MARKET OUTLOOK

As we begin this new management cycle, we have established the following priorities for 2025:

OBSESSION FOR CUSTOMER CENTRICITY AND EVOLVING TOWARDS THE BEST PHYSICAL & DIGITAL EXPERIENCES: We will be even more obsessed about customer centricity, starting from their needs to develop innovative solutions that make healthcare more accessible, convenient and effective. We believe in proximity, whether physically at our pharmacies, with experiences and services, or digitally, with practicality and focusing on the use of digital platforms. We will continue to improve pharmaceutical dispensing journeys, seeking to achieve greater efficiency and improve the customer experience both when purchasing through PBM programs and with electronic prescriptions, whether in store or through apps. We also want to improve the beauty journey in our pharmacies and especially in digital channels. We understand that the combination of our more than 3 thousand pharmacies with our digital platform represents our greatest strength in increasing customer engagement and LTV. We will also remain attentive to the movements of non traditional competitors and pure digital players to ensure the constant innovation of our activity and the strength of our omnichannel approach.

ORGANIC EXPANSION AND MARKET SHARE GAINS: We will continue to accelerate our expansion. We have established a new expansion guidance of between 330 and 350 new pharmacies for 2025. We have a highly structured expansion process that produces consistent results year after year, with a real IRR, net of cannibalization, above 20% and with a very low error rate and will keep leveraging the strength of our brands nationwide and our scale and efficiency differentials. This is a relevant competitive advantage that uniquely positions us to continue gaining market share and leading the consolidation of pharmaceutical retail in Brazil.

PRIMARY HEALTHCARE: We always refer to the historical role of pharmacies in the healthcare system. We want to be an innovative and relevant element to serve supplementary and complementary health through our assets and pilot strategic partnerships with other players in the chain. Our focus for 2025 is to implement the "4 Ps": Promotion of Health (clinical exams and educational content), Prevention (early diagnosis and monitoring of chronic conditions), Protection (vaccines and immunization) and Primary Care (diagnosis and treatment of acute and low-complexity conditions), building an omnichannel health journey, taking advantage of the capillarity and infrastructure installed in our pharmacies, positioning the pharmacist as a health agent for the communities around them. We will also audit and approve our healthcare protocols through partnerships such as the one established with Hospital Alemão Oswaldo Cruz and develop pilots with in store service for members of health insurers. In addition to improving customer LTV, we believe that in a few years we will be able to bring marginal profitability through this strategy.

EFFICIENCY AND INCREASED PROFITABILITY: In 2025 we will face the challenge of a CMED price increase below inflation, which will generate a smaller inflationary gain on inventories. We hope to neutralize this pressure throughout the year by rebalancing discounts, in line with occurs across the market. We are also strengthening our pharmacy staff, seeking to improve our service and the engagement of our teams. We will seek to finance this movement through reviewing our administrative expenses, which have increased in recent years to support the digital transformation. We hope to sustain the growth of mature stores above inflation, in line with recent years. We also hope to reduce the pressure stemming from 4Bio's greater mix through an emphasis on margins and ROIC and less focus on growth as seen in recent years, which saw the company grow from R$ 125 million in gross revenue in 2014 to R$ 3.5 billion in 2024. We will also seek to leverage Impulso (the new name of RD Ads) and accelerate, integrate and/or rationalize the other invested companies as we did with Vitat, having its activities now integrated into RD Saúde's core business with efficiency gains. Finally, we also understand that the current macroeconomic cycle with rising interest rates tends to benefit us, as seen historically. Due to our low debt and solid capital structure, we will maintain our operational robustness protected in a context in which less capitalized distributors and retailers tend to limit their expansion, reduce inventories and put pressure on store service levels. Therefore, we believe in our ability to gain efficiency and sustain or expand the consolidated margin even in a year with a CMED increase below inflation.

USE OF AI: We understand that the investment cycle in digital transformation that began in 2018 is already bringing tangible and important results, with a large capture of additional revenue and greater customer engagement. Nevertheless, we are experiencing a great transformational moment in technology with the emergence and dissemination of Generative Artificial Intelligence. We understand that our new development cycle necessarily involves mastering and incorporating this new technology, applied to the most varied fronts of our business, whether improving customer experience or improving our internal processes and efficiency. We started this path with the "Go Deep" approach (data science, data owners and use cases) and the "Go Wide" approach (transversally training teams and democratizing tools), allowing unique insights in our sector. We have an important journey in developing automation, data processing and analysis, content creation, personalization, user assistance and innovation support. Our new cycle will definitely be marked by the way we benefit from AI to boost our activities.

CULTURE AND SUSTAINABILITY: We are committed to building a long lasting legacy focused on the health and well being of the people and communities we serve. Our culture of caring for customers and employees constitutes a continuous competitive advantage that is difficult to replicate, as it is based on building genuine relationships and deeply rooted values. This is also a central feature of Renato Raduan's management in his 11 years at the helm of Operations, leading a strong increase of 30 pharmacy NPS points since his arrival, culminating in an NPS of 91 in 2024, a unique index in Brazilian retail. We will continue to optimize this environment of trust and loyalty in which customers feel valued and employees motivated, thus strengthening the continuity and success of our organization. This pillar of "Caring for People", in addition to our other pillars of "Executing with Focus" (efficiency) and "Building the Future" (innovation and ESG), will remain at the center of our strategy, reinforcing our long term vision of becoming the group that contributes the most to a healthier society in Brazil.

STORE DEVELOPMENT

Pharmacy count



	4Q23	1Q24	2Q24	3Q24	4Q24	LTM
Gross openings	**+87**	**+62**	**+70**	**+72**	**+96**	**+300**
Closures	-2	-5	-4	-9	-5	-23
- Maturing	*-*	*-2*	*-1*	*-2*	*-*	*-5*
- Mature	*-2*	*-3*	*-3*	*-7*	*-5*	*-18*
Net openings	**+85**	**+57**	**+66**	**+63**	**+91**	**+277**

Pharmacy portfolio

Age structure



We ended 2024 with a total of 3,230 pharmacies in operation. We opened 300 new pharmacies in the year (96 in the 4Q24), reaching the top of the guidance of 280–300 gross openings established for 2024. For 2025, we reiterate our guidance of 330-350 gross openings.

We closed 23 units in the year (5 in the 4Q24), with 5 still in the maturation process (0 in the 4Q24). This equates to an error ratio of 1.7% of the 300 openings in the period, a result of the high assertiveness of our expansion process. The remaining 18 closures were of mature units with an average of 14 years of operation, a result of the optimization of our portfolio, transferring revenues to our remaining nearby locations, releasing assets for efficient redeployment and eliminating fixed costs, thus increasing both the Company's EBITDA and ROIC.

At the end of the quarter, a total of 25.5% of our pharmacies were still maturing and had not yet reached their full potential both in terms of revenue and profitability.

Number of cities with pharmacies



Pharmacies by region



Pharmacies by format



Our expansion continues to diversify our pharmacy network, both geographically and demographically. We have extended our presence to 619 cities, 45 more than in the 4Q23, a unique capillarity in Brazilian retail. Additionally, out of the 319 Brazilian cities with over 100 thousand inhabitants, we already have, or are in the process of opening, pharmacies in 313 of them.

We also highlight an acceleration of expansion in São Paulo, our main market, which increased from 20% of openings in 2021 and 2022 to 35% in 2024. Although we already have more than 1.3 thousand pharmacies in the state, the opportunities we continue to identify and the solid performance of recently opened stores highlight the potential we still have to expand our presence in a highly profitable manner throughout the country. Lastly, 84% of our openings in the last 12 months have popular or hybrid formats, which already comprise 61% of our total store portfolio.

Geographic presence



Market share



Source: IQVIA. Southeast excludes SP.

We are present in all Brazilian states and operate 14 distribution centers that support our more than 3.2 thousand pharmacies. Our logistics network allows us to replenish 81% of our stores on a daily basis and 90% with a lead-time of up to 24 hours. improving service levels, optimizing working capital and reinforcing our operational efficiency, thus constituting an important competitive advantage.

Our national share was of 16.5%, an annual increase of +0.3 pp. We recorded a market share of 29.2% in São Paulo (+0.6 pp), of 12.1% in the Southeast (+0.7 pp), which is a solid growth in the two most important regions that represent 48% of Brazilian pharmaceutical retail, of 19.8% in the Midwest (-0.6 pp), of 10.7% in the South (+0.4 pp), of 11.7% in the Northeast (+0.1 pp), and of 9.8% in the North (+0.4 pp).

We highlight that the Midwest recorded an atypically higher growth of +22.3% in the indirectly informed sales to IQVIA (sell-in), 5.0 pp greater than the sales of direct informants (sell-out). The indirect data from distributors to small pharmacies may represent sales to other states, underestimating our true market share.

DIGITAL, HEALTH AND CUSTOMER ENGAGEMENT

One of our key drivers for value creation is the increase of the Lifetime Value of our customers, built upon a strategy of creating relevant bonds and greater engagement. We ended 2024 with 49.1 million active customers and 404.4 million purchases in the period, an average of 8.2 purchases per year.

Digital sales and penetration

R$ millions, % of retail gross revenue



Digital channel mix

% of digital sales



* Call center represents < 1% of the mix.

Delivery mix

% of digital sales



We continue to advance in our digital strategy, strengthening this important bond with the customer. We reached R$ 7.1 billion in revenues through our digital channels (R$ 2.0 billion in the quarter), an absolute increase of R$ 2.1 billion in 2024 and a growth of 41.7% over the previous year (37.8% in the 4Q24). These channels, which would be among the top 4 pharmacies in the country if considered isolated, reached a retail penetration of 18.6% (20.2% in the 4Q24), an increase of 3.6 pp in the year and also in the quarter.

We highlight the evolution of our app penetration within digital sales, which advanced from 64% to 74% in the last year, reflecting the customer's mobile experience, oriented towards an increasingly complete and omnichannel integral health journey. Another highlight comes from deliveries in up to 60 minutes, which already represent 26% of digital sales. When combined with Click & Collect and deliveries by third-party apps, we cover 96% of digital sales delivered or collected within 60 minutes. This unique capability at a national scale is only possible with the capillarity of our pharmacy footprint which covers 94% of the Brazilian A class population within a 1.5 km radius.

In the quarter, we recorded 176.7 million visits to our digital channels and our digitalized frequent customers spent on average 21% more than the average frequent customers. Additionally, we continue to advance in the development of our Marketplace to improve the customer experience within our digital channels through an expanded assortment of approximately 249 thousand SKUs in health and wellness provided by 1.2 different sellers.

Another important bond with our customers is Stix, the leading coalition of loyalty programs in Brazilian retail, which is built upon more than 9 thousand stores of the brands Drogasil, Raia, Pão de Açúcar, Extra Mercado, Shell, C&A and Sodimac, and includes the financial partners Livelo and Itaú. Of the 11.3 million enrolled customers, 90% are active and 45% earned and/or redeemed points in 2 or more partners, underscoring the customer recurrence and coalition power of Stix.

Lastly, we continue to reinforce the role of our pharmacies in the integral health journey of our customers, positioning them as health hubs within the communities they serve and strengthening customer bonds by providing health services. We already count 2.4 thousand health hubs offering an expanded portfolio of services, as well as 379 units licensed for vaccines. In 2024, more than 6.3 million pharmaceutical services were carried out, including CATs (clinical analysis tests), vaccinations and other services, recording a better NPS than pharmacies.

GROSS REVENUES





* Services.

We ended 2024 with a gross revenue of R$ 41,782 million (R$ 10,862 million in the 4Q24), a growth of 15.1% (13.9% in the 4Q24). Our retail sales grew 14.3% in the year (13.2% in the 4Q24), with 4Bio contributing with 0.8 pp in the period (0.7 pp in the quarter).

The highlights of the year were prescription medicine, with Branded Rx growing 15.6% in 2024 (17.1% in the 4Q24) and generics with a growth of 16.4% (19.4% in the 4Q24). While, front-store items recorded a growth in OTC of 12.4% in 2024 (10.6% in the 4Q24) and in HPC of 12.0% (5.6% in the 4Q24). We have observed a gradual normalization of the sales mix since the distortions caused by the COVID-19 pandemic, with growth in the 2022-2024 biennium of 31.6% in Branded Rx, 37.4% in Generics, 19.9% in OTC and 37.5% in HPC.



We recorded in 2024 a same-store sales growth of 9.0%. In the 4Q24, we recorded an average same-store sales growth of 7.9%. We highlight the fact that our stores have a maturation curve of approximately 3 years and, with 25.5% of pharmacies still in the maturation process, same-store sales growth includes the effects of this initial ramp-up.

Considering mature stores, we recorded a growth of 6.5% in 2024 and of 5.6% in the 4Q24, 2.0 pp and 1.1 pp above the CMED price readjustment of 4.5%, respectively.

GROSS PROFIT



* Includes the taxation of PIS/COFINS on investment subsidies, in accordance to Law No. 14,789/2023.

Gross profit totaled R$ 11,556.1 million in 2024, with a gross margin of 27.7%, a contraction of 0.3 pp when compared to the 2023. This annual retraction includes a pressure of 0.1 pp from the start of collection of PIS/COFINS taxes on investment subsidies since Jan/24, as established by Law No. 14,789/2023, a pressure of 0.1 pp from lower inflationary gains on inventories (stemming from a CMED price adjustment of 4.5% in 2024 vs. 5.6% in 2023), a pressure of 0.1 pp from the non-cash NPV effect, mainly due to the lower average SELIC interest rate and a pressure of 0.2 pp resulting from mix effect of 4Bio, generated by the strong sales in the business which structurally operates with a lower gross margin. These pressures were partially offset by commercial gains of 0.2 pp.

In the 4Q24, our gross profit totaled R$ 2,994.1 million, with a gross margin of 27.6%, a contraction of 0.4 pp when compared to the 4Q23. This includes a pressure of 0.1 pp from start collection of PIS/COFINS on investment subsidies and a negative mix effect of 0.1 pp from the strong sales growth of 4Bio, in addition to 0.2 pp from others pressures.

SELLING EXPENSES



Selling expenses totaled R$ 7,255.2 million in 2024, equivalent to 17.4% of gross revenue and a 0.1 pp dilution compared to 2023. We recorded pressures of 0.1 pp in software licenses, of 0.1 pp in payment methods expenses and of 0.1 pp in other expenses, more than offset by a dilution of 0.2 pp in personnel and of 0.2 pp in rentals.

In the 4Q24, selling expenses totaled R$ 1,953.0 million, equivalent to 18.0% of gross revenue and a 0.1 pp dilution compared to the same period of the previous year. We recorded pressures of 0.1 pp in software licenses and of 0.1 pp in one-off chargeback expenses, more than offset by dilutions of 0.1 pp in personnel, of 0.1 pp in last-mile expenses and of 0.1 pp in rentals.

We highlight that, when compared to the 3Q24, we recorded an increase mainly in personnel, due to the normalization of pharmacy staff and DCs, in pre-operational expenses, due to the higher volume of openings in the 4Q24, in addition to typical seasonal increases in electricity, marketing and rentals. We expect a partial reversion of these seasonal effects in the 1Q25.

CONTRIBUTION MARGIN



The contribution margin in 2024 was R$ 4,300.9 million, an increase of 13.3% over 2023. This represents 10.3% of gross revenue, a 0.2 pp contraction vs. 2023.

In the 4Q24, the contribution margin was R$ 1,041.1 million, an increase of 10.3% vs. the 4Q23. This represents 9.6% of gross revenue, a 0.3 pp contraction vs. the 4Q23.

GENERAL & ADMINISTRATIVE EXPENSES



General and administrative expenses totaled R$ 1,308.4 million in 2024, equivalent to 3.1% of gross revenue, a dilution of 0.2 pp compared to 2023. We recorded dilutions of 0.2 pp in personnel and 0.1 pp in consulting services, more than offsetting a pressure of 0.1 pp in other expenses.

In the 4Q24, general and administrative expenses totaled R$ 363.5 million, equivalent to 3.3% of gross revenue, representing a dilution of 0.1 pp vs. the 4Q23. We recorded a one-off pressure of 0.2 pp in labor contingencies, provisioned in a concentrated manner in the quarter,that we do not expect to repeat in the following quarters, and of 0.1 pp in other expenses, more than offset by dilutions of 0.3 pp in personnel and 0.1 pp in consulting services.

EBITDA



We recorded an adjusted EBITDA of R$ 2,992.5 million in 2024, a 15.0% increase compared to 2023. The EBITDA margin was 7.2%, stable when compared to the previous year.

We highlight that the main factors that impacted the 2024 result include the pressures on the gross margin of 0.1 pp due to the start of the collection of PIS/COFINS on investments subsidies, which we continue to contest in court, and of 0.2 pp due to the 4Bio mix effect. These pressures were offset by the operating leverage generated by the dilution of sales expenses and efficiency in G&A expenses.

In the 4Q24, adjusted EBITDA totaled R$ 677.5 million, an increase of 10.3% compared to the 4Q23. The EBITDA margin was of 6.2%, a contraction of 0.2 pp, due to the effects mentioned above, including non-recurring pressures of 0.1 pp in chargeback expenses and of 0.2 pp due to the concentration of labor contingencies in the quarter.

EBITDA RECONCILIATION AND NON-RECURRING RESULTS

EBITDA Reconciliation (R$ millions)	**1Q24**	**2Q24**	**3Q24**	**4Q24**	**2024**
Net income	**213.0**	**348.4**	**362.1**	**351.5**	**1,275.0**
Income tax	95.8	97.3	113.6	(69.6)	237.1
Equity equivalence	(2.5)	0.5	0.2	(2.5)	(4.3)
Financial result	155.5	142.7	141.6	114.4	554.3
EBIT	**461.8**	**588.9**	**617.5**	**393.8**	**2,062.2**
Depreciation and amortization	217.0	223.0	231.5	238.3	909.9
EBITDA	**678.8**	**812.0**	**849.0**	**632.2**	**2,972.0**
Asset write-offs	(1.6)	0.9	2.0	47.1	48.4
Social investments and donations	2.1	4.0	3.9	1.5	11.4
Taxes and other non-recurring effects	0.6	7.5	(44.2)	(3.2)	(39.4)
Non-recurring/non-operating expenses	**1.0**	**12.4**	**(38.3)**	**45.4**	**20.5**
Adjusted EBITDA	**679.9**	**824.4**	**810.7**	**677.5**	**2,992.5**

In 2024, we recorded R$ 20.5 million in net non-recurring expenses (R$ 45.4 million in the 4Q24). This includes R$ 48.4 million in asset write-offs (R$ 47.1 million in the 4Q24), with no cash effect and predominantly from the impairment of Vitat, whose activities were incorporated by the parent company. We also recorded R$ 11.4 million in social investments and donations (R$ 1.5 million in the 4Q24). These effects were partially offset by R$ 39.4 million in taxes and other non-recurring effects from previous years (R$ 3.2 million in the 4Q24).

DEPRECIATION, NET FINANCIAL EXPENSES AND EARNINGS BEFORE TAXES

Depreciation & amortization

R$ millions, % of gross revenue



Net financial expenses

R$ millions, % of gross revenue



Earnings before taxes

R$ millions, % of gross revenue



Depreciation expenses amounted to R$ 909.9 million in 2024 (R$ 238.3 million in the 4Q24), equivalent to 2.2% of gross revenue (2.2% in the 4Q24), stable when compared to the same periods of the previous year.

Net financial expenses represented 1.3% of gross revenue in 2024 (1.1% in the 4Q24), a dilution of 0.2 pp compared to 2023 (increase of 0.1 pp compared to the 4Q23). Of the R$ 554.3 million recorded in 2024 (R$ 114.4 million in the 4Q23), R$ 325.7 million refer to the actual financial interest accrued on financial liabilities (R$ 63.9 million in the 4Q24), corresponding to 0.8% of gross revenue (0.6% in the 4Q24), a reduction of 0.1 pp compared to 2023 (increase of 0.1 pp in the 4Q24). We also recorded R$ 192.9 million in net financial expenses which refer to the non-cash NPV adjustment of 2024 (R$ 50.5 million in the 4Q24) and R$ 35.7 million in 2024 which refers to the reevaluation and the interest on the option to acquire the remaining shares of invested companies (R$ 0 in the 4Q24).

In 2024, we recorded an EBT of R$ 1,532.6 million (R$ 327.3 million in the 4Q24), with a 23.4% increase vs. 2023 (8.2% vs. the 4Q23). This equates to a margin of 3.7% of gross revenue (3.0% in the 4Q24) with a 0.3 pp margin expansion vs. 2023 (a 0.2 pp margin contraction vs. the 4Q23).

✦ INCOME TAXES AND NET INCOME





We booked a total of R$ 244.1 million in income tax in 2024 (R$ -54.2 million in the 4Q24), equivalent to 0.6% of gross revenue (-0.5% in the 4Q24), an increase of 0.2 pp in the year (reduction of 0.7 pp in the 4Q23).

The effective tax rate for the year was of 15.9% of the EBT, an increase of 4.8 pp. We highlight that we recorded a 77.3% increase in booked income taxes vs. 2023, driven by the start of taxation on investment subsidies, in accordance to Law No. 14,789/2023. Excluding non-recurring effects of the year, mostly booked in the 4Q24 and detailed below, the effective tax rate in 2024 would be 21.8% of EBT, an increase of 10.7 pp vs. 2023, mainly due to the additional taxation on investment subsidies.

In the 4Q24, we recorded R$ 77.5 million in non-recurring tax credits. We also note that the 4Q24 also included recurring effects of the year concentrated in the quarter, mainly from the fiscal incentive for technology development ("Lei do Bem").

This resulted in an adjusted net income of R$ 1,288.5 million in 2024 (R$ 381.4 million in the 4Q24), an increase of 16.6% vs. 2023 (34.6% vs. the 4Q23). Net margin was 3.1% of gross revenue (3.5% in the 4Q24), an expansion of 0.1 pp vs. 2023 (0.5 pp in the 4Q24), despite the additional taxation resulting from Law No. 14,789/2023.

CASH CYCLE

Cash cycle*

COGS days, Gross revenue days



* Adjusted for discounted receivables and advanced payments to suppliers.

The cash cycle in the 4Q24 was of 60.4 days, an increase of 1.0 days vs. the 4Q23, adjusted for discounted receivables and advanced payments to suppliers.

CASH FLOW

Cash flow (R$ millions)	**2024**	**2023**	**4Q24**	**3Q24**
Adjusted EBIT	**2,082.6**	**1,803.6**	**439.2**	**579.2**
NPV adjustment	(185.0)	(185.9)	(57.5)	(47.1)
Non-recurring expenses	(20.5)	69.7	(45.4)	38.3
Income tax (34%)	(638.2)	(573.7)	(114.4)	(194.0)
Depreciation	912.0	797.7	240.9	232.8
Others	18.0	381.4	159.6	(76.2)
Resources from operations	**2,168.9**	**2,292.7**	**622.5**	**533.1**
Cash cycle*	(602.4)	(1,019.5)	79.0	376.4
Other assets (liabilities)**	(96.8)	(79.9)	(458.6)	153.0
Operating cash flow	**1,469.7**	**1,193.3**	**242.9**	**1,062.4**
Investments	(1,281.3)	(1,234.4)	(447.1)	(369.2)
Free cash flow	**188.5**	**(41.1)**	**(204.2)**	**693.3**
M&A and other investments	(131.7)	(72.7)	-	-
Interest on equity and dividends	(474.6)	(465.9)	(235.9)	(1.1)
Income tax paid over interest on equity	(54.3)	(27.9)	(33.1)	(10.9)
Net financial expenses***	(361.4)	(358.0)	(63.9)	(94.5)
Share buyback	(73.3)	-	(73.3)	-
Tax benefit (fin. exp., IoE, dividends)	255.3	244.2	63.9	70.9
Total Cash Flow	**(651.4)**	**(721.3)**	**(546.5)**	**657.6**

*Includes adjustments to discounted receivables.

**Includes NPV adjustments.

***Excludes NPV adjustments.

In 2024, we recorded a positive free cash flow of R$ 188.5 million and a total cash consumption of R$ 651.4 million. Resources from operations totaled R$ 2,235.8 million, equivalent to 5.4% of gross revenue. We recorded a working capital consumption of R$ 766.1 million, resulting in an operating cash flow of R$ 1,469.7 million that nearly financed the entire CAPEX of R$ 1,281.3 million.

In the 4Q24, we recorded a negative free cash flow of R$ 204.2 million, with a total cash consumption of R$ 546.5 million. Resources from operations totaled R$ 689.5 million, equivalent to 6.3% of gross revenue. We recorded a working capital of R$ 446.5 million, resulting in an operating cash flow of R$ 242.9 million. CAPEX in the period was of R$ 447.1 million in the period.

Of the R$ 1,281.3 million invested in 2024 (R$ 447.1 million in the 4Q24), R$ 509.9 million were used for the opening of new pharmacies (R$ 159.8 million in the 4Q24), R$ 209.3 million for the renovation or expansion of existing units (R$ 49.3 million in the 4Q24), R$ 377.1 million for IT (R$ 140.1 million in the 4Q24), R$ 130.3 million in logistics (R$ 67.3 million in the 4Q24) and R$ 54.4 million in other projects (R$ 30.6 million in the 4Q24). Additionally, we allocated R$ 131.7 million into investments in subsidiaries (R$ 0 in the 4Q24).

Net financial expenses resulted in payments of R$ 361.4 million in 2024 (R$ 63.9 million in the 4Q24). These payments were partially offset by R$ 255.3 million in tax benefits related to net financial expenses and interest on equity (R$ 63.9 million in the 4Q24).

Lastly, we announced a payout of R$ 579.8 million in 2024 vs. R$ 522.2 million in 2023. This includes R$ 389.5 million in interest on equity and R$ 190.3 million in dividends. In the 4Q24, we announced R$ 123.9 million vs. R$ 170.1 million in the 4Q23.

INDEBTEDNESS

We ended the 4Q24 with an adjusted net debt of R$ 3,418.4 million, corresponding to a leverage of 1.1x the adjusted EBITDA of the last 12 months. Our adjusted net debt considers R$ 728.7 million in discounted receivables, R$ 89.9 million in advanced payments to suppliers, and R$ 13.6 million in liabilities related to the put option granted and/or call option obtained for the acquisition of the remaining equity of invested companies.

At the end of the quarter, our gross debt totaled R$ 3,293.9 million, of which 97% corresponds to debentures and Certificates of Real Estate Receivables (CRIs), with the remaining 3% corresponding to other credit lines. Of the total debt, 81% is due in the long-term and 19% in the short-term. We ended the quarter with a total cash and equivalents position of R$ 528.0 million.

Net Debt (R$ millions)	**4Q23**	**1Q24**	**2Q24**	**3Q24**	**4Q24**
Short-term Debt	604.6	311.9	415.4	619.0	637.1
Long-term Debt	2,526.1	2,528.0	3,003.3	2,655.1	2,656.8
Total Gross Debt	**3,130.7**	**2,839.9**	**3,418.7**	**3,274.2**	**3,293.9**
(-) Cash and Equivalents	412.3	412.6	369.7	410.5	528.0
Net Debt	**2,718.4**	**2,427.3**	**3,049.1**	**2,863.7**	**2,765.9**
Discounted Receivables	-	449.7	523.5	32.2	728.7
Advances to suppliers	(49.6)	(60.1)	(56.0)	(37.2)	(89.9)
Investment Put/Call options (estimated)	98.2	129.3	12.9	13.2	13.6
Adjusted Net Debt	**2,766.9**	**2,946.3**	**3,529.5**	**2,871.9**	**3,418.4**
LTM Adjusted EBITDA	2,603.2	2,720.1	2,776.9	2,929.5	2,992.5
Adjusted Net Debt / EBITDA	**1.1x**	**1.1x**	**1.3x**	**1.0x**	**1.1x**

RETURN ON INVESTED CAPITAL & SHARED VALUE CREATION

We recorded a ROIC of 16.7% in 2024, a 1.1 pp reduction due to the additional taxation as defined by Law No. 14,789/23 which we are challenging in court. Excluding this effect, the ROIC was of 18.8%.

We also highlight that the calculated ROIC excludes the goodwill from the merger between Raia and Drogasil, since it was a share exchange at market value without any effective payments by either party.

ROIC



* Excludes the additional taxation as defined by Law No. 14,789/23.

Total value added*

R$ billions

* Adjusted for effective rentals and excludes NPV impacts.

Value added per stakeholder

R$ billions, % of the yearly total



In 2024 we shared R$ 11.2 billion in added value with our stakeholders, a 6.3% increase when compared to the previous year. This value was divided as follows: R$ 4.4 billion was shared with the government at the federal, state and municipal levels in the form of taxes and fees, R$ 3.8 billion was shared with our employees, R$ 1.7 billion with the landlords of the properties we rent and with financial institutions, and finally R$ 1.2 billion was shared with our shareholders.

TOTAL SHAREHOLDER RETURNS

Our share price decreased by 25.2% in 2024, while the IBOVESPA fell by 10.4%. During the period, the average daily trading volume (ADTV) was of R$ 184 million.

Since the IPO of Drogasil in 2007, we achieved a cumulative share appreciation of 1,864% compared to an appreciation of only 121% for the IBOVESPA. Including the payment of interest on equity and dividends, we generated an average annual total return to shareholders of 19.4%.

Considering the IPO of Raia in 2010, the cumulative return amounted to 685% compared to an increase of only 77% for the IBOVESPA. Considering the payment of interest on equity and dividends, this resulted in an average annual total return to shareholders of 16.5%.

Stock price appreciation



IFRS-16

Since 2019, our financial statements have been prepared in accordance with IFRS 16. In order to preserve historic comparability, the figures in this report are presented under IAS 17, the previous reporting standard, which we believe best represents the economic performance of our operations.

Financial statements in both IAS 17 and IFRS 16 are also available at our website ir.rdsaude.com.br under Results Spreadsheet.

Income Statement *(R$ millions)*	4Q24			2024		
	IAS 17	IFRS 16	Change	IAS 17	IFRS 16	Change
Gross Revenue	**10,862.4**	**10,862.4**	**0.0**	**41,782.0**	**41,782.0**	**0.0**
Gross Profit	**2,994.1**	**2,994.6**	**0.5**	**11,556.1**	**11,556.8**	**0.7**
Gross Margin	27.6%	27.6%	0.0%	27.7%	27.7%	0.0 pp
Selling Expenses	(1,953.0)	(1,649.0)	304.1	(7,255.2)	(6,092.2)	1,163.0
G&A	(363.5)	(365.2)	(1.6)	(1,308.4)	(1,304.6)	3.8
Total Expenses	**(2,316.6)**	**(2,014.2)**	**302.4**	**(8,563.6)**	**(7,396.8)**	**1,166.8**
as % of Gross Revenue	21.3%	18.5%	(2.8%)	20.5%	17.7%	(2.8 pp)
Adjusted EBITDA	**677.5**	**980.4**	**302.9**	**2,992.5**	**4,160.0**	**1,167.5**
as % of Gross Revenue	6.2%	9.0%	2.8%	7.2%	10.0%	2.8 pp
Non-Recurring Expenses / Revenues	(45.4)	(38.4)	6.9	(20.5)	(7.3)	13.2
Depreciation and Amortization	(238.3)	(452.1)	(213.7)	(909.9)	(1,801.6)	(891.8)
Financial Results	(114.4)	(209.3)	(94.9)	(554.3)	(933.1)	(378.8)
Equity Equivalence	2.5	1.5	(1.0)	4.3	1.1	(3.2)
Income Tax	69.6	68.1	(1.5)	(237.1)	(207.6)	29.5
Net Income	**351.5**	**350.3**	**(1.2)**	**1,275.0**	**1,211.4**	**(63.6)**
as % of Gross Revenue	3.2%	3.2%	(0.0%)	3.1%	2.9%	(0.2 pp)

Balance Sheet *(R$ millions)*	4Q24		Change
	IAS 17	IFRS 16	Δ 4Q24
Assets	**18,136.9**	**22,163.8**	**4,026.9**
Current Assets	**12,703.7**	**12,703.7**	**0.0**
Non-Current Assets	**5,433.2**	**9,460.0**	**4,026.9**
Income Tax and Social Charges deferred	158.0	298.4	140.4
Other Credits	13.4	12.9	(0.4)
Right of use	0.0	3,887.0	3,887.0
Liabilities and Shareholder's Equity	**18,136.9**	**22,163.8**	**4,026.9**
Current Liabilities	**8,250.0**	**9,195.0**	**945.0**
Financial Leases	0.0	951.0	951.0
Other Accounts Payable	412.8	406.7	(6.1)
Non-Current Liabilities	**3,088.8**	**6,521.9**	**3,433.1**
Financial Leases	0.0	3,473.5	3,473.5
Income Tax and Social Charges Deferred	40.4	0.0	(40.4)
Shareholder's Equity	**6,798.1**	**6,446.9**	**(351.2)**
Income Reserves	2,529.3	2,178.2	(351.1)
Non Controller Interest	13.5	13.4	(0.1)

Cash Flow *(R$ millions)*	4Q24 IAS 17	4Q24 IFRS 16	4Q24 Change	2024 IAS 17	2024 IFRS 16	2024 Change
Adjusted EBIT	**439.2**	**528.4**	**89.2**	**2,082.6**	**2,358.3**	**275.7**
Non-Recurring Expenses	(45.4)	(38.4)	6.9	(20.5)	(7.3)	13.2
Income Tax (34%)	(114.4)	(147.0)	(32.7)	(638.2)	(736.4)	(98.2)
Depreciation	240.9	452.1	211.1	912.0	1,801.8	889.8
Rental Expenses	0.0	(309.4)	(309.4)	0.0	(1,180.0)	(1,180.0)
Others	226.6	261.3	34.8	85.0	184.5	99.5
Resources from Operations	**689.5**	**689.5**	**0.0**	**2,235.8**	**2,235.8**	**0.0**
Operating Cash Flow	**242.9**	**242.9**	**0.0**	**1,469.7**	**1,469.7**	**0.0**
Investments	**(447.1)**	**(447.1)**	**0.0**	**(1,281.3)**	**(1,281.3)**	**0.0**
Free Cash Flow	**(204.2)**	**(204.2)**	**0.0**	**188.5**	**188.5**	**0.0**
Total Cash Flow	**(546.5)**	**(546.5)**	**0.0**	**(651.4)**	**(651.4)**	**0.0**

*Includes adjustments to discounted receivables.
**Includes NPV adjustments
***Excludes NPV adjustments

RESULTS CONFERENCE CALLS

February 26th 2025, 10:00 AM (BRT), with simultaneous translation to English.

Access Link
https://www.resultadosrdsaude.com.br/

For more information, please contact our Investor Relations department: ri@rdsaude.com.br

Consolidated Adjusted Income Statement (R$ thousands)	4Q23 Reclassified	4Q24	2023 Reclassified	2024
Gross Revenue	**9,538,836**	**10,862,353**	**36,298,767**	**41,781,973**
Taxes, Discounts and Returns	(629,678)	(767,667)	(2,368,068)	(2,910,451)
Net Revenue	**8,909,158**	**10,094,686**	**33,930,699**	**38,871,522**
Cost of Goods Sold	(6,238,926)	(7,100,566)	(23,766,440)	(27,315,454)
Gross Profit	**2,670,232**	**2,994,119**	**10,164,259**	**11,556,068**
Operational (Expenses) Revenues				
Sales	(1,726,605)	(1,953,050)	(6,369,420)	(7,255,202)
General and Administrative	(329,083)	(363,549)	(1,191,593)	(1,308,384)
Operational Expenses	**(2,055,688)**	**(2,316,598)**	**(7,561,012)**	**(8,563,586)**
EBITDA	**614,544**	**677,521**	**2,603,246**	**2,992,482**
Depreciation and Amortization	(212,194)	(238,324)	(799,689)	(909,852)
Operational Earnings before Financial Results	**402,350**	**439,197**	**1,803,557**	**2,082,630**
Financial Expenses	(236,586)	(253,311)	(979,196)	(998,843)
Financial Revenue	142,106	138,875	428,735	444,592
Financial Expenses/Revenue	**(94,480)**	**(114,436)**	**(550,461)**	**(554,251)**
Equity Equivalence	(5,547)	2,492	(10,621)	4,260
Earnings before Income Tax and Social Charges	**302,323**	**327,253**	**1,242,476**	**1,532,639**
Income Tax and Social Charges	(19,008)	54,161	(137,689)	(244,093)
Net Income	**283,315**	**381,414**	**1,104,787**	**1,288,546**

Demonstração do Resultado Consolidado (em milhares de R$)	4T23 Reclassificado	4T24	2023 Reclassificado	2024
Receita bruta de vendas e serviços	**9.538.836**	**10.862.353**	**36.298.767**	**41.781.973**
Deduções	(629.678)	(767.667)	(2.368.068)	(2.910.451)
Receita líquida de vendas e serviços	**8.909.158**	**10.094.686**	**33.930.699**	**38.871.522**
Custo das mercadorias vendidas	(6.238.926)	(7.100.566)	(23.766.440)	(27.315.454)
Lucro bruto	**2.670.232**	**2.994.119**	**10.164.259**	**11.556.068**
Despesas				
Com vendas	(1.726.605)	(1.953.050)	(6.369.420)	(7.255.202)
Gerais e administrativas	(329.083)	(363.549)	(1.191.593)	(1.308.384)
Outras despesas operacionais, líquidas	2.024	(45.361)	69.717	(20.477)
Despesas operacionais	**(2.053.664)**	**(2.361.959)**	**(7.491.295)**	**(8.584.064)**
EBITDA	**616.568**	**632.160**	**2.672.964**	**2.972.004**
Depreciação e Amortização	(212.194)	(238.324)	(799.689)	(909.852)
Lucro operacional antes do resultado financeiro	**404.374**	**393.836**	**1.873.275**	**2.062.152**
Despesas financeiras	(236.586)	(253.311)	(979.196)	(998.843)
Receitas financeiras	142.106	138.875	428.735	444.592
Despesas / Receitas Financeiras	**(94.480)**	**(114.436)**	**(550.461)**	**(554.251)**
Equilavência Patrimonial	(5.547)	2.492	(10.621)	4.260
Lucro antes do IR e da contribuição social	**304.348**	**281.892**	**1.312.193**	**1.512.162**
Imposto de renda e contribuição social	(19.696)	69.584	(161.393)	(237.131)
Lucro líquido do exercício	**284.651**	**351.476**	**1.150.801**	**1.275.031**

Assets (R$ thousands)	**4Q23**	**4Q24**
Cash and Cash Equivalents	412,322	528,002
Financial Investments	-	15,707
Accounts Receivable	3,084,940	2,666,758
Inventories	7,197,426	8,407,429
Taxes Receivable	353,374	483,452
Other Accounts Receivable	414,755	486,709
Anticipated Expenses	98,855	112,611
Deposit in Court	-	3,019
Current Assets	11,561,672	12,703,688
Deposit in Court	228,447	250,763
Taxes Receivable	246,008	287,939
Income Tax and Social Charges deferred	74,702	158,041
Other Credits	11,092	13,377
Investments	14,976	14,786
Property, Plant and Equipment	2,453,423	2,682,672
Intangible	1,917,279	2,025,604
Non-Current Assets	4,945,926	5,433,181
TOTAL ASSETS	**16,507,598**	**18,136,869**

Liabilities and Shareholder's Equity (R$ thousands)	4Q23	4Q24
Suppliers	5,095,166	5,825,381
Loans and Financing	604,601	637,109
Salaries and Social Charges Payable	636,393	686,526
Taxes Payable	360,572	364,903
Dividend and Interest on Equity	23,508	241,476
Provision for Lawsuits	57,224	81,829
Other Accounts Payable	451,405	412,763
Current Liabilities	7,228,869	8,249,987
Loans and Financing	2,526,102	2,656,820
Provision for Lawsuits	256,234	282,059
Income Tax and Social Charges deferred	48,188	40,357
Other Accounts Payable	125,984	109,538
Non-Current Liabilities	2,956,508	3,088,775
Common Stock	4,000,000	4,000,000
Capital Reserves	146,560	111,309
Revaluation Reserve	11,211	11,085
Income Reserves	1,871,200	2,529,320
Equity Adjustments	3,261	62,969
Non Controller Interest	72,391	13,529
Additional Dividend Proposed	217,598	69,895
Shareholder's Equity	6,322,221	6,798,107
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	**16,507,598**	**18,136,869**

Cash Flow (R$ thousands)	4Q23	4Q24	2023	2024
Earnings before Income Tax and Social Charges	**435,004**	**351,476**	**1,312,193**	**1,275,031**
Adjustments				
Depreciation and Amortization	209,473	240,915	797,690	911,965
Compensation plan with restricted shares, net	9,943	16,980	33,215	38,034
Interest over additional stock option	-	(30,799)	33,486	2,041
PP&E and Intangible Assets residual value	56,337	43,884	68,430	56,142
Provisioned Lawsuits	213,848	81,399	268,582	124,349
Provisioned Inventory Loss	(2,298)	6,122	(1,322)	25,037
Provision for Doubtful Accounts	5,476	(61,143)	12,781	(45,627)
Provisioned Store Closures	5,410	1,857	(2,208)	(5,664)
Interest Expenses	97,275	125,970	347,217	398,021
Debt Issuance Costs Amortization	1,594	2,391	5,302	9,371
Equity Equivalence Result	7,190	(1,530)	12,509	(1,069)
Gains from business combination	-	1	-	59,709
	1,039,252	**777,523**	**2,887,875**	**2,847,340**
Assets and Liabilities variation				
Clients and Other Accounts Receivable	(184,469)	757,098	(788,191)	463,809
Inventories	(269,151)	(281,019)	(1,069,935)	(1,235,040)
Other Short Term Assets	(62,946)	(3,054)	(188,916)	(85,782)
Long Term Assets	(60,008)	(3,214)	16,898	(23,656)
Suppliers	313,985	246,807	692,418	857,332
Salaries and Social Charges	(98,617)	(130,021)	74,771	50,133
Taxes Payable	(102,129)	(245,665)	(251,080)	(258,889)
Other Liabilities	(37,941)	(52,444)	42,074	111,999
Rents Payable	5,550	3,307	6,597	8,840
Cash from Operations	**543,526**	**1,069,318**	**1,422,511**	**2,736,086**
Interest Paid	(64,130)	(83,916)	(328,894)	(373,244)
Income Tax and Social Charges Paid	(534)	(95,973)	(68,659)	(367,356)
Paid lawsuits	(14,157)	(22,547)	(62,419)	(82,906)
Net Cash from (invested) Operational Activities	**464,705**	**866,882**	**962,539**	**1,912,580**
Investment Activities Cash Flow				
Acquisition of share in investee, without change in control	-	-	-	(117,817)
Cash acquired from business combination	256	-	256	-
PP&E and Intangible Acquisitions	(398,577)	(431,370)	(1,304,581)	(1,283,653)
PP&E Sale Payments	154	-	154	4,265
Restricted Investments	-	(15,706)	-	(15,706)
Cash from incorporated company	(235)	-	(2,859)	-
Net Cash from Investment Activities	**(398,402)**	**(447,076)**	**(1,307,030)**	**(1,412,911)**
Financing Activities Cash Flow				
Funding	31,146	38,869	1,058,864	688,869
Payments	(39,648)	(32,000)	(269,691)	(525,000)
Share Buyback	-	(73,285)	-	(73,285)
Interest on Equity and Dividends Paid	(239,066)	(235,898)	(465,901)	(474,573)
Net Cash from Funding Activities	**(247,568)**	**(302,314)**	**323,272**	**(383,989)**
Cash and Cash Equivalents in the beggining of the period	**593,587**	**410,510**	**433,541**	**412,322**
Cash and Cash Equivalents net increase	(181,265)	117,492	(21,219)	115,680
Cash and Cash Equivalents in the end of the period	**412,322**	**528,002**	**412,322**	**528,002**

PROFIT ALLOCATION

Following legal and statutory provisions, we propose the following allocation for the retained earnings which amount to R$ 1,200,331 thousand:

Legal Reserve	R$ 59,993 thousand
Statutory Reserve	R$ 540,838 thousand
Interest on Capital (R$ 0.211971383 per share)	R$ 389,500 thousand
Additional dividend proposed	R$ 210,000 thousand

We also propose that the interest on capital be attributed to the mandatory dividend.

INDEPENDENT AUDITOR

In compliance with the CVM Instruction 381/2003 and Circular Letter 01/2007, the Company informs herein that, during 2024, Ernst & Young Auditores Independentes S.S. provided independent audit services related to the financial statements for 2024.

The Company's policy towards its independent auditors, with regard to the provision of services not related to the independent audit, is based on the principles that preserve the auditor's independence. These principles are based on the fact that the auditor should not audit his own work, nor perform managerial functions or advocate for his client. In the year ended **December 31, 2024**, Ernst & Young Auditores Independentes S.S. provided independent audit services to the Company. The amount of fees incurred with the independent auditors in fiscal year **2024** was R$ 1,849 thousand referring to independent audit services related to the financial statements.

Ernst & Young Auditores Independentes is not aware of any relationship between the parties that could be considered as conflicting as regards its independence.

Balance sheets
December 31, 2024
All amounts in thousands of reais

Assets	Note	Parent Company Dec/24	Parent Company Dec/23	Consolidated Dec/24	Consolidated Dec/23
Current assets					
Cash and cash equivalents	5	460,292	318,002	528,002	412,321
Financial investments	6	27,774	26,506	15,706	-
Trade receivables	7	1,919,599	2,515,546	2,666,758	3,084,940
Inventories	8	7,973,862	6,882,254	8,407,430	7,197,427
Recoverable taxes	9	440,153	348,650	483,484	353,401
Other current assets	-	398,251	337,227	444,813	369,277
Prepaid expenses	-	110,622	96,356	112,611	98,855
Related parties	26	49,146	45,453	41,887	45,453
Judicial deposits	17	3,019	-	3,019	-
		11,382,718	**10,569,994**	**12,703,710**	**11,561,674**
Non-current assets					
Long-term receivables					
Judicial deposits	17	27,616	19,183	250,762	228,446
Recoverable taxes	9	266,840	213,917	287,939	246,008
Deferred income tax and social contribution	18.2	141,278	104,134	298,405	177,730
Prepaid expenses	-	12,743	4,301	12,743	4,301
Related parties	26	-	213	-	-
Other non-current assets	-	142	5,103	204	6,360
		448,619	**346,851**	**850,053**	**662,845**
Investments	10	1,129,043	659,633	14,740	14,953
Property, plant and equipment	11	2,639,455	2,419,685	2,682,672	2,453,687
Intangible assets	12	1,729,324	1,608,164	2,025,604	1,917,253
Right-of-use assets	16	3,881,567	3,479,929	3,886,977	3,484,000
		9,379,389	**8,167,411**	**8,609,993**	**7,869,893**
		9,828,008	**8,514,262**	**9,460,046**	**8,532,738**
Total assets		**21,210,726**	**19,084,256**	**22,163,756**	**20,094,412**

Liabilities and equity	Note	Parent Company Dec/24	Parent Company Dec/23	Consolidated Dec/24	Consolidated Dec/23
Current liabilities					
Suppliers	14	5,085,766	4,493,044	5,614,817	4,939,203
Suppliers - Forfait	14.1	-	9,009	-	9,009
Suppliers - FIDC	14.1	220,728	156,991	200,267	143,242
Borrowings	15	547,528	377,207	637,110	604,601
Leases payable	16	949,350	856,427	951,044	858,467
Salaries and social charges	-	655,777	601,699	686,526	636,393
Taxes and contributions	-	267,070	224,320	296,049	240,832
Dividends and interest on capital	-	241,476	23,508	241,476	23,508
Income tax and social contribution	-	64,601	116,549	68,855	119,739
Provision for legal claims	17	81,829	57,224	81,829	57,224
Payables for acquisition of subsidiaries	-	-	98,197	-	98,197
Related parties	26	19,114	16,567	19,114	16,567
Other current liabilities	-	354,709	312,210	397,872	332,515
		8,487,948	**7,342,952**	**9,194,959**	**8,079,497**
Non-current liabilities					
Borrowings	15	2,656,820	2,526,102	2,656,820	2,526,102
Leases payable	16	3,469,643	3,076,154	3,473,493	3,078,294
Provision for legal claims	17	86,680	100,535	282,059	256,234
Payables for acquisition of subsidiaries	-	13,573	-	13,573	-
Provisions for losses on investments	10	-	-	-	1,848
Other non-current liabilities	-	62,602	82,512	95,965	124,136
		6,289,318	**5,785,303**	**6,521,910**	**5,986,614**
Total liabilities		**14,777,266**	**13,128,255**	**15,716,869**	**14,066,111**
Equity	20				
Attributable to owners of the Company					
Issued capital	-	4,000,000	4,000,000	4,000,000	4,000,000
Capital reserves	-	111,309	146,560	111,309	146,560
Revenue reserves	-	2,178,202	1,577,370	2,178,202	1,577,370
Proposed additional dividend	-	69,895	217,599	69,895	217,599
Carrying value adjustments	-	74,054	14,472	74,054	14,472
		6,433,460	**5,956,001**	**6,433,460**	**5,956,001**
Noncontrolling interests	-	-	-	13,427	72,300
Total equity		**6,433,460**	**5,956,001**	**6,446,887**	**6,028,301**
Total liabilities and equity		**21,210,726**	**19,084,256**	**22,163,756**	**20,094,412**

All amounts in thousands of reais, except earnings per capital share

Statements of income

	Note	Parent Company		Consolidated	
		Dec/24	Dec/23	Dec/24	Dec/23
Net sales revenue	21	35,644,330	31,345,990	38,871,522	33,973,790
Cost of sales and services	22	(24,390,727)	(21,416,143)	(27,314,741)	(23,766,426)
Gross profit		**11,253,603**	**9,929,847**	**11,556,781**	**10,207,364**
Operating (expenses) income					
Selling	22	(7,479,652)	(6,567,441)	(7,627,819)	(6,689,275)
General and administrative	22	(1,441,231)	(1,397,405)	(1,570,628)	(1,503,526)
Other operating income/(expenses)	23	11,714	129,637	(7,297)	78,435
Equity in the results of subsidiaries	10	65,541	4,148	1,069	(12,509)
		(8,843,628)	**(7,831,061)**	**(9,204,675)**	**(8,126,875)**
Operating profit before finance results		**2,409,975**	**2,098,786**	**2,352,106**	**2,080,489**
Finance income (costs)					
Finance income	24	331,032	330,365	444,589	428,735
Finance costs	24	(1,272,105)	(1,203,131)	(1,377,701)	(1,292,531)
		(941,073)	**(872,766)**	**(933,112)**	**(863,796)**
Profit before income tax and social contribution		**1,468,902**	**1,226,020**	**1,418,994**	**1,216,693**
Income tax and social contribution	18				
Current	-	(306,117)	(291,481)	(328,232)	(314,521)
Deferred	-	37,079	120,434	120,611	184,971
	-	**(269,038)**	**(171,047)**	**(207,621)**	**(129,550)**
Profit for the year		**1,199,864**	**1,054,973**	**1,211,373**	**1,087,143**
Attributable to:					
Owners of the Company	-	1,199,864	1,054,973	1,199,864	1,054,973
Noncontrolling interests	-	-	-	11,509	32,170
		1,199,864	**1,054,973**	**1,211,373**	**1,087,143**
Basic earnings per share	19	0.72753	0.62233	0.72753	0.62233
Diluted earnings per share	19	0.72500	0.63564	0.72500	0.63564

Statements of comprehensive income

	Note	Parent Company		Consolidated	
		Dec/24	Dec/23	Dec/24	Dec/23
Profit for the year		**1,199,864**	**1,054,973**	**1,211,373**	**1,087,143**
Components of comprehensive income					
Other comprehensive income that will affect the result in a subsequent period	-	-	-	-	-
Total comprehensive income for the year		**1,199,864**	**1,054,973**	**1,211,373**	**1,087,143**
Attributable to:					
Owners of the Company	-	1,199,864	1,054,973	1,199,864	1,054,973
Noncontrolling interests	-	-	-	11,509	32,170
Total		**1,199,864**	**1,054,973**	**1,211,373**	**1,087,143**

Statements of changes in equity
Years ended December 31, 2024 and 2023
All amounts in thousands of reais

		Attributable to owners of the Company														
		Capital reserves				Revenue reserves						Carrying value adjustments				
	Share capital	Special monetary adjustment	Goodwill on issue / sale of shares	Treasury shares	Restricted shares and other	Legal	Statutory	Tax incentives	Retained earnings	Proposed additional dividend	Revaluation reserve	Transactions with noncontrolling interests	Other comprehensive income	Total	Noncontrolling interests	Total equity
At December 31, 2022	**2,500,000**	**10,191**	**134,127**	**(80,606)**	**49,049**	**265,756**	**1,761,339**	**522,147**	**-**	**167,526**	**11,354**	**3,262**	**(3,283)**	**5,340,862**	**62,079**	**5,402,941**
Capital increase	1,500,000	-	-	-	-	-	(1,500,000)	-	-	-	-	-	-	-	-	-
Interest on capital expired	-	-	-	-	-	-	-	-	513	-	-	-	-	513	-	513
Interest on capital for 2023 approved at the AGM of April 17, 2024	-	-	-	-	-	-	-	-	-	(167,526)	-	-	-	(167,526)	-	(167,526)
Realization of revaluation reserve, net of income tax and social contribution	-	-	-	-	-	-	-	-	142	-	(142)	-	-	-	-	-
Restricted share plan - vesting period	-	-	-	-	33,528	-	-	-	-	-	-			33,528	-	33,528
Restricted share plan - delivery	-	-	(121)	13,099	(12,978)	-	-	-	-	-	-	-	-	-	-	-
Restricted shares - delivery of 4Bio shares	-	-	-	292	(22)	-	-	-	-	-	-	-	-	270	-	270
Profit for the year	-	-	-	-	-	-	-	-	1,054,973	-	-	-	-	1,054,973	32,170	1,087,143
Allocation of profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Legal reserve	-	-	-	-	-	52,749	-	-	(52,749)	-	-	-	-	-	-	-
Tax incentive reserve	-	-	-	-	-	-	-	294,450	(294,450)	-	-	-	-	-	-	-
IOC - R$ 0.211973 per share (Note 20)	-	-	-	-	-	-	-	-	(360,200)	360,200	-	-	-	-	-	-
Proposed dividends - R$ 0.097586 per share (Note 20)	-	-	-	-	-	-	-	-	(167,300)	167,300	-	-	-	-	-	-
Statutory reserve	-	-	-	-	-	-	180,929	-	(180,929)	-	-	-	-	-	-	-
Early dividends approved at the BDM of December 15, 2023 (Note 20)	-	-	-	-	-	-	-	-	-	(83,000)	-	-	-	(83,000)	-	(83,000)
Withholding tax on IOC (Note 20)	-	-	-	-	-	-	-	-	-	(49,923)	-	-	-	(49,923)	-	(49,923)
Reclassification of minimum mandatory dividends to current liabilities	-	-	-	-	-	-	-	-	-	(176,979)	-	-	-	(176,979)	-	(176,979)
Other comprehensive income - adjustments to financial instruments	-	-	-	-	-	-	-	-	-	-	-	-	3,283	3,283	-	3,283
Other changes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	(21,949)	(21,949)
At December 31, 2023	**4,000,000**	**10,191**	**134,006**	**(67,215)**	**69,577**	**318,505**	**442,268**	**816,597**	**-**	**217,598**	**11,212**	**3,262**	**-**	**5,956,001**	**72,300**	**6,028,301**
Interest on capital expired	-	-	-	-		-	-	-	342	-	-	-	-	342	-	342
Interest on capital for 2023 approved at the AGM of April 17, 2024	-	-	-	-		-	-	-	-	(217,598)	-	-	-	(217,598)	-	(217,598)
Realization of revaluation reserve, net of income tax and social contribution	-	-	-	-		-	-	-	125	-	(125)	-	-	-	-	-
Restricted share plan - vesting period	-	-	-	-	37,507	-	-	-	-	-	-	-	-	37,507	-	37,507
Restricted share plan - delivery	-	-	1,866	13,143	(16,724)	-	-	-	-	-	-	-	-	(1,715)	-	(1,715)
Restricted shares - delivery of 4Bio shares	-	-	-	2,366	(123)	-	-	-		-	-	-	-	2,243	-	2,243
Repurchase of shares	-	-	-	(73,285)	-	-	-	-		-	-	-	-	(73,285)	-	(73,285)
Acquisition of shares from noncontrolling interests through exercise of call option – 4Bio	-	-	-	-	-	-	-	-	-	-	-	-	59,709	59,709	(70,382)	(10,673)
Profit for the year	-	-	-	-	-	-	-	-	1,199,864	-	-	-	-	1,199,864	11,509	1,211,373
Allocation of profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest on capital proposed		-	-	-	-	-	-	-	(389,500)	389,500	-	-	-	-	-	-
Legal reserve	-	-	-	-	-	59,993	-	-	(59,993)	-	-	-	-	-	-	-
Tax incentive reserve	-	-	-	-	-	-	-		-	-	-	-	-	-	-	-
Proposed dividends - R$ 0.097586 per share (Note 20)	-	-	-	-	-	-	-	-	(210,000)	210,000	-	-	-	-	-	-
Statutory reserve	-	-	-	-	-	-	540,838	-	(540,838)	-	-	-	-	-	-	-
Early dividends approved at the BDM of April 17, 2024	-	-	-	-	-	-	-	-	-	(84,300)	-	-	-	(84,300)	-	(84,300)
Early dividends approved at the BDM of September 30, 2024	-	-	-	-	-	-	-	-	-	(106,000)	-	-	-	(106,000)	-	(106,000)
Withholding tax on IOC (Note 20)	-	-	-	-	-	-	-	-	-	(54,306)	-	-	-	(54,306)	-	(54,306)
Reclassification of minimum mandatory dividends to current liabilities	-	-	-	-	-	-	-	-	-	(284,999)	-	-	-	(284,999)	-	(284,999)
Other comprehensive income - adjustments to financial instruments	-	-	-	-	-	-	-	-	-	-	-	-	(3)	(3)	-	(3)
At December 31, 2024	**4,000,000**	**10,191**	**135,872**	**(124,991)**	**90,237**	**378,498**	**983,106**	**816,597**	**-**	**69,895**	**11,087**	**3,262**	**59,706**	**6,433,460**	**13,427**	**6,446,887**

Voltar

All amounts in thousands of reais

	Note	Parent Company Dec/24	Parent Company Dec/23	Consolidated Dec/24	Consolidated Dec/23
Cash flows from operating activities					
Profit before income tax and social contribution	-	**1,468,902**	**1,226,020**	**1,418,994**	**1,216,693**
Adjustments					
Depreciation and amortization	22	1,834,751	1,695,078	1,851,892	1,707,296
Compensation plan with restricted shares, net	-	38,034	33,799	38,034	33,215
Interest on additional stock option	-	2,041	33,486	2,041	33,486
Profit on sale/write-off of fixed assets and intangible assets	-	35,541	39,566	56,142	68,430
Provision for legal claims	17	84,669	113,040	124,349	268,582
(Reversal of) provision for inventory losses	8	25,037	(1,322)	25,037	(1,322)
(Reversal of) provision for impairment of trade receivables	7	7,012	7,039	21,292	12,781
(Reversal of) provision for pharmacies closure	11 and 12	(5,664)	(2,208)	(5,664)	(2,208)
Expenses net of interest on borrowings	-	344,501	322,895	366,868	347,217
Interest expenses – leases	16	400,081	330,574	400,361	330,782
Amortization of transaction costs of debentures	15	9,371	5,302	9,371	5,302
Equity in the results of subsidiaries	10	(65,541)	(4,148)	(1,069)	12,509
Increase in the percentage of interest in subsidiaries	10	-	-	59,709	-
Discounts on property rental	-	-	(73)	-	(73)
		4,178,735	**3,799,048**	**4,367,357**	**4,032,690**
Changes in assets and liabilities					
Trade and other receivables	-	588,935	(599,645)	396,890	(788,191)
Inventories	-	(1,116,645)	(880,423)	(1,235,040)	(1,069,936)
Other current assets	-	(73,045)	(129,567)	(82,702)	(188,823)
Long-term receivables	-	(17,448)	(51,853)	(26,490)	(104,223)
Suppliers	-	578,687	507,251	661,579	694,460
Suppliers - Forfait	-	(9,009)	2,453	(9,009)	2,453
Suppliers - FIDC	-	63,737	156,991	57,025	143,242
Salaries and social charges	-	54,078	59,116	50,133	74,769
Taxes and contributions	-	(153,624)	54,619	(290,393)	(122,396)
Other obligations	-	58,111	(212,098)	95,175	(107,425)
Rentals payable	-	10,581	9,418	10,605	9,461
Other					
Interest paid	15	(349,196)	(306,581)	(373,244)	(328,894)
Income tax and social contribution paid	-	(367,356)	(68,659)	(367,356)	(68,659)
Interest paid – leases	16	(400,081)	(330,574)	(400,361)	(330,782)
Legal claims - paid	17	(82,906)	(62,419)	(82,906)	(62,419)
Net cash provided by operating activities		**2,963,554**	**1,947,077**	**2,771,263**	**1,785,327**
Cash flows from investing activities					
Acquisition and capital contribution in investees, net of cash acquired	10	(352,587)	(112,559)	-	-
Acquisition of interest in subsidiary, without change of control		(117,817)	-	(117,817)	-
Cash acquired in business combination	-	-	-	-	256
Net assets acquired in business combination	-	-	-	-	(2,952)
Purchases of fixed assets and intangible assets		(1,251,922)	(1,234,533)	(1,283,653)	(1,304,581)
Proceeds from sale of fixed assets		4,265	154	4,265	154
Financial investments		-	-	(15,706)	-
Loans (granted to)/received from subsidiary	-	235	-	-	-
Net cash used in investing activities		**(1,717,826)**	**(1,346,938)**	**(1,412,911)**	**(1,307,123)**
Cash flows from financing activities					
Borrowings taken	15	600,000	686,567	688,869	1,058,865
Repayment of borrowings	15	(300,000)	(44,480)	(525,000)	(269,691)
Repurchase of shares	25	(73,285)	-	(73,285)	-
Leases paid	-	(855,580)	(822,697)	(858,682)	(822,697)
Interest on capital and dividends paid	-	(474,573)	(465,901)	(474,573)	(465,901)
Net cash used in financing activities		**(1,103,438)**	**(646,511)**	**(1,242,671)**	**(499,424)**
Increase (decrease) in cash and cash equivalents		142,290	(46,372)	115,681	(21,220)
Cash and cash equivalents at January 1	5	318,002	364,374	412,321	433,541
Cash and cash equivalents at December 31	5	**460,292**	**318,002**	**528,002**	**412,321**

The accompanying notes are an integral part of these financial statements.

All amounts in thousands of reais

	Parent Company		Consolidated	
	Dec/24	Dec/23	Dec/24	Dec/23
Revenue	**37,626,276**	**32,884,334**	**41,112,572**	**35,652,998**
Gross sales and services	37,639,732	32,885,743	41,134,730	35,657,675
Other income	9,481	8,744	10,417	8,744
Provision for (reversal of) impairment of trade receivables	(22,937)	(10,153)	(32,575)	(13,421)
Inputs acquired from third parties	**(25,523,969)**	**(21,479,921)**	**(28,574,540)**	**(23,950,324)**
Cost of sales and services	(22,921,746)	(19,345,443)	(25,864,968)	(21,690,700)
Materials, energy, outsourced services and other	(2,602,223)	(2,134,478)	(2,709,572)	(2,259,624)
Gross value added	**12,102,307**	**11,404,413**	**12,538,032**	**11,702,674**
Depreciation and amortization	(1,783,685)	(1,647,067)	(1,801,431)	(1,661,347)
Net value added generated by the entity	**10,318,622**	**9,757,346**	**10,736,601**	**10,041,327**
Value added received through transfer	**417,259**	**353,551**	**462,827**	**411,581**
Equity in the results of subsidiaries	65,541	4,148	1,069	(12,509)
Finance income	333,900	332,882	443,940	407,569
Other	17,818	16,521	17,818	16,521
Total value added to distribute	**10,735,881**	**10,110,897**	**11,199,428**	**10,452,908**
Distribution of value added				
Personnel	**3,707,169**	**3,317,718**	**3,828,600**	**3,422,448**
Direct remuneration	2,895,550	2,602,348	2,973,454	2,669,567
Benefits	556,159	491,881	593,878	524,055
Unemployment compensation fund	255,460	223,489	261,268	228,826
Taxes and contributions	**4,254,486**	**4,292,697**	**4,500,677**	**4,425,984**
Federal	1,262,165	798,757	1,243,707	781,921
State	2,945,541	3,462,454	3,203,648	3,519,114
Municipal	46,780	31,486	53,322	124,949
Providers of capital	**1,574,362**	**1,445,509**	**1,658,778**	**1,517,333**
Interest	1,271,766	1,202,752	1,351,495	1,269,722
Rentals	302,596	242,757	307,283	247,611
Interest on capital and dividends	**1,199,864**	**1,054,973**	**1,211,373**	**1,087,143**
Interest on capital	389,500	360,200	389,500	360,200
Additional dividends and interest on capital proposed	210,000	167,300	210,000	167,300
Retained earnings for the year	600,364	527,473	600,364	527,473
Noncontrolling interests in retained earnings	-	-	11,509	32,170
Value added distributed and retained	**10,735,881**	**10,110,897**	**11,199,428**	**10,452,908**

The accompanying notes are an integral part of these financial statements.

(All amounts in thousands of reais unless otherwise stated)

1. Operations

Raia Drogasil S.A. ("Company" or "RD Saúde" or "Parent Company") is a publicly-held company with its headquarters at Av. Corifeu de Azevedo Marques, 3.097, São Paulo – SP, listed on the Novo Mercado ("New Market" listing segment of B3 S.A. - Brasil, Bolsa, Balcão, under ticker RADL3. RD Saúde was created in November 2011 from the merger between Droga Raia and Drogasil chains that, together, combine more than 200 years of history. Droga Raia was founded in 1905 and Drogasil in 1935 and today form the leading chain, both in number of pharmacies and in revenues.

On March 18, 2024, the Company changed its brand to "RD Saúde", reflecting its goal to lead health promotion in Brazil. In addition to the pharmaceutical retail segment, RD Saúde focuses on comprehensive health, seeking the well-being of the community and offering high-quality services and products.

RD Saúde and its subsidiaries (together "Group" or "Consolidated") are mainly engaged in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics and dermocosmetics and specialty medicines. The Group conducts its sales through 3,230 pharmacies (2,953 pharmacies – Dec/23), present in all 26 Brazilian states and the Federal District (26 states and the Federal District – Dec/23), as presented below:

	Consolidated	
State	**Dec/24**	**Dec/23**
Southeast region	**1,835**	**1,699**
São Paulo	1,307	1,208
Rio de Janeiro	233	213
Minas Gerais	227	218
Espírito Santo	68	60
Northeast region	**485**	**443**
Bahia	114	102
Pernambuco	105	96
Ceará	97	89
Maranhão	43	39
Sergipe	29	27
Rio Grande do Norte	28	27
Paraíba	24	21
Alagoas	24	22
Piauí	21	20
South region	**428**	**382**
Paraná	187	162
Rio Grande do Sul	136	128
Santa Catarina	105	92
Midwest region	**344**	**308**
Goiás	134	117
Federal District	98	91
Mato Grosso do Sul	61	55
Mato Grosso	51	45
North region	**138**	**121**
Pará	57	51
Amazonas	25	21
Tocantins	25	20
Rondônia	15	14
Acre	6	6
Amapá	5	5
Roraima	5	4
Total	**3,230**	**2,953**

During the current year, 300 pharmacies were opened and 23 pharmacies were closed (270 pharmacies were opened and 16 pharmacies were closed in 2023). All pharmacies closures were carried out to optimize our pharmacies portfolio, with positive expectations of return. RD Saúde's pharmacies, as well as the Group's e-commerce demands, are supplied by fifteen distribution centers located in twelve states: São Paulo, Rio de Janeiro, Minas Gerais, Paraná, Goiás, Pernambuco, Bahia, Ceará, Rio Grande do Sul, Mato Grosso, Amazonas and Pará.

4Bio Medicamentos S.A. ("4Bio") markets special medicines through telesales and the delivery is made directly to the customer's location or through its six call centers in the states of São Paulo, Tocantins, Pernambuco, Paraná, Rio de Janeiro and Bahia.

RD Ventures Fundo de Investimento em Participações – Multiestratégia ("FIP RD Ventures") is an exclusive fund created as a platform that seeks to invest in businesses that contribute to the Company's growth strategy and accelerate the journey of digitalization in health.

Dr. Cuco Desenvolvimento de Software Ltda. ("Dr. Cuco") is a digital care platform focused on adherence to treatment.

Impulso Soluções de Mídia Ltda. ("Impulso") is RD's Retail Media solution, a platform that offers a high reach potential through personalized audiences with retail data and high accuracy of results. This allows advertisers to analyze the performance of online and offline campaigns and to be present at all times of the consumer journey.

SafePill Comércio Varejista de Medicamentos Manipulados Ltda. ("Dose Certa + Cuidado") is focused on adherence to treatments and offers services for Management of Self-Care Home Treatments.

ZTO Tecnologia e Serviços de Informação na Internet Ltda. ("Manipulação Raia Drogasil") is the first startup of the Brazilian compounding pharmacies market, operating as a marketplace platform that provides customers with immediate online access to compounding pharmacies.

RD Log Ltda. ("RD Log") is a transportation and logistics company established to expand the offer of logistics services to marketplace sellers.

Kymberg Farmacêutica do Brasil Ltda. ("Kymberg") is a pharmaceutical company specialized in the production of medicines.

RD Saúde holds all the subordinated quotas of RD Fundo de Investimento em Direitos Creditórios Crédito Corporativo ("RD FIDC"). The Company consolidates RD FIDC's financial information because it believes that a significant portion of the risks and rewards related to profitability is linked to the subordinated quotas held by RD Saúde.

Hereinafter, the entities mentioned above will be collectively referred to as "Subsidiaries".

2. Presentation of financial statements

In conformity with NBC TG 24(R2), authorization to issue these financial statements was granted by the Company's Board of Directors on February 25, 2025.

The individual and consolidated financial statements for the year ended December 31, 2024 have been prepared in accordance with the accounting practices adopted in Brazil, including the Brazilian General Technical Accounting Standards (NBC TG), the rules issued by the Brazilian Securities Commission (CVM), and the pronouncements issued by the Brazilian Accounting Pronouncements Committee (CPC), and are in conformity with the International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB), and provide all the significant information related solely to the financial statements, which is consistent with the information used by management. The Group adopted all standards, revised standards and interpretations issued by the IFRS and CPC that were effective as at December 31, 2024.

The individual financial statements are disclosed together with the consolidated financial statements, which include the financial statements of the Company and its subsidiaries 4Bio, Dr. Cuco, Manipulação Raia Drogasil, Dose Certa + Cuidado, Impulso, Kymberg, FIP RD Ventures, RD FIDC and RD Log, and have been prepared in accordance with consolidation practices and applicable legal provisions.

The accounting practices adopted by the Subsidiaries were applied uniformly and consistently with those adopted by the Company. Where applicable, all transactions, balances, income and expenses between the Subsidiary and the Company are fully eliminated in the consolidated financial statements.

These financial statements were prepared on the historical cost basis, except for: (i) certain financial instruments; and (ii) assets and liabilities arising from business combinations measured at their fair values, when applicable. Historical cost is generally based on the fair value of the consideration paid for goods or services.

The financial statements include accounting estimates and require management to exercise its judgment in the process of applying the Company's accounting policies regarding provision for inventory losses, provision for expected credit losses, appreciation of financial instruments, realization periods of recoverable taxes, the amortization and depreciation periods for fixed and intangible assets, estimate of impairment of intangible assets with indefinite useful life, provision for legal claims, fair value measurement of financial liabilities, determination of provision for taxes, recognition of revenues from commercial agreements, among others. The significant estimates and judgments are disclosed in Note 4(f).

The presentation of the individual and consolidated statements of value added is required by the Brazilian corporate legislation and the accounting practices adopted in Brazil for listed companies, while it is not required by IFRS. Therefore, under the IFRS, the presentation of such statements is considered supplementary information, and not part of the set of the financial statements.

The financial statements are presented in thousands of Brazilian reais (R$), which is the Group's functional and presentation currency.

(All amounts in thousands of reais unless otherwise stated)

3. New accounting procedures, amendments to and interpretations of standards

New or revised pronouncements applied for the first time in 2024

In 2024, the Company evaluated the new interpretations and amendments to the CPCs and IFRS, which became effective for the first time as from the financial year beginning on January 1, 2024. The main changes applicable to the Company are:

Amendments to IAS 1 / NBC TG 26 (R1): Classification of Liabilities as Current or Non-current	The amendments aim to promote consistency in the application of the standard's requirements, by helping entities determine if borrowings, as well as other liabilities with an uncertain settlement date, should be classified as current or non-current in the balance sheet. In addition, disclosure is required when a liability arising from a borrowing contract is classified as non-current and the entity's right to defer settlement depends on the compliance with future covenants within twelve months.
IAS 7 / NBC TG 03 (R3) and IFRS 7 / NBC TG 40 (R2) - Supplier Finance Arrangements	The amendments clarify the characteristics of supplier finance arrangements and require additional disclosures of these arrangements. The objective is to help users of the financial statements to understand the effects of the entity's supplier finance arrangements, cash flows and exposure to liquidity risk.

These changes did not have a significant impact on the Company's financial statements.

Standards issued but not yet effective

The new and amended standards and interpretations that are issued, but not yet effective, up to the date of issuance of the Company's financial statements are disclosed below. The Company intends to adopt these new and amended standards and interpretations, if applicable, when they become effective.

CBPS 1 / IFRS 1 - General Requirements for Disclosure of Sustainability-related Financial Information;	CBPS 1 / IFRS 1 - General Requirements for Disclosure of Sustainability-related Financial Information: This standard is to require an entity to disclose information about its sustainability-related risks and opportunities that is useful to primary users of general purpose financial reports in making decisions relating to providing resources to the entity. The Company is assessing the impact of this standard for early adoption or compliance with the term defined therein.
CBPS 2 / IFRS 2 - Climate-related Disclosures	CBPS 2 / IFRS 2 - Climate-related Disclosures: The objective of this standard is to establish the requirements to identify, measure and disclose information about climate-related risks and opportunities that is useful to primary users of general purpose financial reports in making decisions relating to providing resources to the entity. The Company is assessing the impact of this standard for early adoption or compliance with the term defined therein. Both pronouncements apply to fiscal years beginning on or after January 1, 2026, with voluntary early adoption as from January 1, 2025. The Company is assessing the possible impacts from this implementation on the presentation and disclosure of the financial statements.
IFRS 18 - Presentation and Disclosure in Financial Statements	IFRS 18 - Presentation and Disclosure in Financial Statements replaces IAS 1 – Presentation of Financial Statements in the preparation of financial statements beginning or after January 1, 2027. IFRS 18 (i) introduces new requirements for the presentation of the statement of income, with the inclusion of three new categories of income and expenses - operating, investments and financing - two mandatory subtotals, and changes in the grouping of balances; (ii) requires the disclosure in the explanatory notes of the performance measures defined by Management; and (iii) includes changes in the statement of cash flows and new requirements for the presentation of expenses by nature or function. The Company is assessing the possible impacts from this standard on the presentation and disclosure of the financial statements.
IFRS 19: Subsidiaries without Public Accountability: Disclosures	In May 2024, the IASB issued IFRS 19, which allows eligible entities to elect to apply its reduced disclosure requirements while still applying the recognition, measurement and presentation requirements in other IFRS accounting standards. To be eligible, at the end of the reporting period, an entity must be a subsidiary as defined in IFRS 10 (CPC – 36 (R3) – Consolidated Financial Statements), cannot have public accountability and must have a parent (ultimate or intermediate) that prepares consolidated financial statements, available for public use, which comply with IFRS accounting standards. IFRS 19 will become effective for reporting periods beginning on or after January 1, 2027, with earlier application permitted.

	The amendments are not expected to have a material impact on the Company's financial statements.
NBC TG 18 (R3)/IAS 28: Investments in Associates and Joint Ventures	In September 2024, the Accounting Pronouncements Committee (CPC) issued amendments to Technical Pronouncement CPC 18 (R3) and Technical Interpretation ICPC 09 (R3), in order to align the Brazilian standards with the international standards issued by the IASB.

Additionally, other standards, amendments and interpretations have been issued recently, however they are not yet effective or did not have a material impact on these financial statements. For the year ended December 31, 2024, the Company did not early adopt any standard and did not identify a significant impact on the financial statements.

4. Significant accounting practices

The accounting practices adopted in the preparation of these financial statements are presented and summarized below and, when related to significant balances, detailed in the notes to the financial statements. The accounting practices were consistently applied in the years.

(a) Consolidation

The consolidated financial statements include the financial statements of RD Saúde and the entities controlled by the Company, prepared up to December of each year. Subsidiaries are all entities over which the Company has control, which is obtained when RD Saúde: (i) has power over the investee; (ii) is exposed, or has rights, to variable returns from its involvement with the investee; and (iii) has the ability to affect those returns through its power over the investee.

Subsidiaries are fully consolidated from the date on which control is transferred to the Company and deconsolidated from the date that control ceases. RD Saúde re-assesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control.

Identifiable assets acquired and liabilities assumed for the acquisition of subsidiaries in a business combination are measured initially at their fair values at the acquisition date. The Company recognizes any noncontrolling interest in the acquiree on an acquisition-by-acquisition basis, either at fair value or at the noncontrolling interest's proportionate share of the fair value of the acquiree's identifiable net assets . Acquisition-related costs are expensed as incurred.

All transactions, balances and unrealized gains on transactions between Group companies are eliminated. Unrealized losses are also eliminated, unless the transaction provides evidence of impairment of the asset transferred. The financial statements of Subsidiaries are adjusted where necessary to conform their accounting policies and ensure consistency with the policies adopted by the Group.

(b) Transactions with noncontrolling interests

The Group treats transactions with noncontrolling interests as transactions with equity owners of the Group. For purchases from noncontrolling interests, the difference between any consideration paid and the proportion acquired of the carrying value of the net assets of the subsidiary is recorded in equity. Gains or losses on disposals to noncontrolling interests are also recorded directly in equity, in "carrying value adjustments".

(c) Payables to subsidiary's shareholder

The financial liability (non-current liability) represented by the share purchase obligation arising from the option granted is recognized at present value (in line item Payables for acquisition of subsidiary) and separately from the consideration transferred, through the adoption of the present access method, in which the noncontrolling interest is already recognized, since the noncontrolling shareholder is exposed to risks and has access to the returns associated with its interest, against "carrying value adjustments" in equity.

Over time, the re-establishment of the value of the call option for additional shares arising from the present value adjustment is recognized in the statement of income, in line item finance costs.

On the occurrence of a significant change in assumption during the year, assumptions that comprise the fair value of the option are revised/updated in order to reflect the fair value of the financial liability at year end. Any adjustments are recorded in the line item of Payables for acquisition of subsidiary (Note 10) against finance costs.

(d) Trade discounts and commercial negotiations on the purchase of goods

The Group's variable consideration refers mainly to trade agreements where products can be sold together with other products or with discounts that are substantially negotiations promoted by suppliers at the Group's points of sale in different ways. These negotiations are individual and distinct between suppliers. The main categories of trade agreements are:

(i) trade discounts granted by laboratories upon the sale to consumer and associates to the benefits program – this refers to benefits granted by the Group's supplier to the Group's final consumer aimed at establishing a process of loyalty of the consumer to the product or medicine. In most cases, from the moment a final consumer is registered in the supplier system, the final consumer benefits from a discount granted by the Group's supplier, paying for the product a price different from the usual price for this same product if it was not associated to a benefits program. Such discount offered by the supplier to the Group's customer is calculated in real time and recognized at the moment of sale of the product to the consumer, at an amount receivable from the supplier equivalent to the amount of the discount granted.

The Group recognizes the discounts offered as a reduction in the cost of sales against an amount receivable or a reduction of liabilities from contracts with suppliers.

(ii) marketing and advertising funds arising from the display of products in stores and promotion of offers at catalogues – these refer to Group's sales programs planned jointly with its suppliers. The supplier has interest in promoting its products at the Group's stores chain and sales points. For this, it negotiates forms of payment different from the Group in order that the final price of the product to the consumer be advantageous without any loss to the gross sales margins for the same products under other conditions than promotional ones. These negotiations normally occur with the Group's purchasing area together with the sales area for alignment with the Group's sales strategies.

From the moment the performance obligation is satisfied (sale of the product associated to the promotion), the Group recognizes the result of these commercial agreements as a credit to cost of sales, against an amount receivable from agreements or reduction of liabilities from contracts with suppliers.

(iii) rebates for volume targets, measured both upon purchases and sales – refer to bonus programs granted to the Group associated to targets of purchase and sale of products from a certain supplier. The Group considers the benefit obtained as a reduction of the amounts payable to suppliers, with a balancing entry in the inventories account, from the moment in which it concludes that it is highly probable that the benefit obtained will not be subject to reversal.

In the cases (ii) and (iii) above, these refer to different forms of negotiation that have as main purpose the purchase of products at the lowest cost offered by the supplier regardless of the manner in which the product purchase transaction was proposed.

(e) Segment reporting

The Group conducts its business activities considering a single operating segment, which is used as the basis for managing the entity and decision-making.

(f) Significant accounting judgments, estimates and assumptions

When applying Group accounting practices, management must make judgments and prepare estimates related to the carrying amounts of assets and liabilities not easily obtained from other sources. The estimates and respective assumptions are based on historical experience and other factors considered significant. Estimates and assumptions are continuously

revised and the related effects are recognized in the period in which these are reviewed and in any future periods affected.
Key estimates and assumptions concerning sources of uncertainty in future estimates and other important sources of estimation uncertainty at the balance sheet date are discussed below.

(i) Taxes recoverable

Tax credit recovery estimates are based on operations and taxable profit forecasts, taking into consideration various financial and business assumptions and considering the possibility that special conditions could be granted, such as special regimes, enabling the realization of such credits. These estimates may not materialize in the future, given the uncertainties inherent in these forecasts.

(ii) Fair value of the financial instruments

When the fair value of financial assets and liabilities stated in the balance sheet cannot be obtained from active markets, it is determined using valuation techniques, including the discounted cash flow method. The data for this method are based on market practice, whenever possible. However, when this is not possible, a certain level of judgment is required to establish the fair value. Judgment includes the consideration of the data used, concerning areas such as liquidity risk, credit risk and volatility. Changes in assumptions about these factors could affect the reported fair value of financial instruments.

(iii) Impairment

There are specific rules to assess the recoverability of assets, particularly property, plant and equipment, goodwill and other intangible assets. At year-end, the Group performs an analysis to determine whether there is evidence that the long-lived asset amounts may not be recoverable in accordance with the CGUs. To determine whether goodwill is impaired, it is necessary to estimate the value in use of the CGUs to which goodwill has been allocated. The calculation of value in use requires that management estimate expected future cash flows from the CGUs and an adequate discount rate to calculate present value. Significant assumptions used for determining the recoverable value of the different CGUs are detailed in Note 12.

(iv) Provision for tax, civil and labor risks

The Group is party to various legal and administrative proceedings, as mentioned in Note 17. Provision is recorded for all litigation contingencies the likelihood of loss of which is estimated as probable, in an amount that can be reliably estimated. The assessments of the likelihood of loss include the evaluation of available evidence, the hierarchy of laws, available case law, recent court decisions and their importance in the legal system, as well as the opinion of outside legal advisors and the Group's compensation history.

(v) Lessee’s incremental borrowing rate

The Group is unable to determine the implicit discount rate to be applied to its lease agreements. Therefore, the lessee's incremental borrowing rate, that is, of the Company itself, is used to calculate the present value of the lease liabilities on the initial recognition of the agreement.

The lessee’s incremental borrowing rate is the interest rate that a lessee would have to pay when borrowing for the acquisition of an asset similar to that which is the subject of the lease agreement, for a similar term and when pledging a similar guarantee.

This rate shall be obtained through a high degree of judgment and shall be an element of the lessee's credit risk, the operating lease agreement term, the nature and quality of the guarantee offered, and the economic environment in which the transaction takes place. The rate calculation process shall preferentially use information that is readily observable from which to make the necessary adjustments to determine the incremental borrowing rate.

(All amounts in thousands of reais unless otherwise stated)

The adoption of NBC - TG 06 (R3) / IFRS 16 allowed the incremental rate to be determined for a group of agreements, since this choice is associated with the validation that the grouped contracts have similar characteristics.

The Group adopted the aforementioned practical expedient of determining groupings for its lease agreements under this scope, as it understands that the effects of its application do not differ materially from its application to individual leases. The size and composition of the portfolios were defined according to the following assumptions: (a) similar assets and (b) remaining terms with respect to the similar initial application date.

(vi) Determination of the lease term

When determining a lease term, Management considers all the facts and circumstances that create an economic incentive for the exercise of an extension option or a termination option. Extension options (or periods after termination options) are included in the lease term only when there is reasonable certainty that the lease will be extended (or that it will not be terminated).

For leases of distribution centers and pharmacies, the following factors are usually the most relevant:

- If the termination (or non-extension) incurs significant fines, it is reasonably certain that the Group will use the extension (or will not terminate the agreement)
- If leasehold improvements are made to third-party properties with a significant residual balance, it is reasonably certain that the Group will extend (or not terminate) the lease; and
- In addition, the Group considers other factors, including past practices regarding the periods of use of the specific types of assets (leased or Company-owned), the duration of leases, and the costs and business disruption required to replace a leased asset.

Most options for extending office, residential properties and vehicle leases were not included in the lease liabilities because the Group can replace these assets without significant cost or business interruption.

This assessment is reviewed if there is a significant event or change in circumstances that affects the initial assessment and that is under the control of the lessee, such as for example, if an option is in fact exercised (or not exercised) or if the Group is required to exercise it (or not to exercise it).

5. Cash and cash equivalents

5.1. Accounting policy

These include cash on hand, bank deposits and highly liquid short-term investments, readily convertible into a known cash amount and posing low risk of any change in value. The financial investments included in cash equivalents are classified in the category of financial instruments at amortized cost.

5.2. Balance breakdown

	Parent Company		Consolidated	
Cash and cash equivalents items	**Dec/24**	**Dec/23**	**Dec/24**	**Dec/23**
Cash and banks	181,644	155,219	196,509	177,575
Repurchase agreements (i)	156,114	46,964	156,114	72,791
Automatic investments(ii)	122,534	115,819	140,904	122,013
Bank Deposit Certificates - CDB(iii)	-	-	34,475	37,773
Investment fund	-	-	-	2,169
Total	**460,292**	**318,002**	**528,002**	**412,321**

(i) Fixed-income investment with income linked to the variation of the Interbank Deposit Certificate - CDI, with immediate liquidity and without loss of income.

(ii) Short-term fixed income fund with short-term investments and automatic redemptions.

(All amounts in thousands of reais unless otherwise stated)

(iii) Investments in bank deposit certificate have daily liquidity and grace period of 30 days.

The Group's exposure to interest rate risks and the sensitivity analysis of financial assets and liabilities are disclosed in Note 25.3 (a) and (d).

6. Financial Investments

	Parent Company		Consolidated	
Cash and cash equivalents items	**Dec/24**	**Dec/23**	**Dec/24**	**Dec/23**
RD Fundo de Investimento em Direitos Creditórios Corporativos	27,774	26,506	-	-
Investment Fund	-	-	15,706	-
Total	**27,774**	**26,506**	**15,706**	**-**

RD Fundo de Investimento em Direitos Creditórios Corporativos ("RD FIDC")

The balance of R$ 27,774 in the Parent Company on December 31, 2024 refers to the investment on RD Fundo de Investimento em Direitos Creditórios Corporativos ("RD FIDC").

RD FIDC began its activities on February 16, 2023, established as a special fund, as provided for by CMN Resolution 2,907, of November 29, 2001, and by CVM Instruction 175/22, of December 23, 2022. On March 28, 2023, the Company made the first contribution to RD FIDC.

RD FIDC's capital structure at December 31, 2024 comprised 173,529 senior quotas held by third parties in the amount of R$ 200,227, representing 87.82% of the fund's equity, and 26,225 subordinated quotas held by RD in the amount of R$ 27,774, representing 12.18% of the fund's equity.

The purpose of RD FIDC is to provide to its quotaholders the valuation of their quotas through the investment of their funds exclusively in credit rights arising from payment transactions carried out by the Company, with the use of payment instruments for the acquisition of goods and services. The earnings of the senior quotas are paid monthly and are subject to a minimum remuneration of CDI plus 1.66% p.a.

Subordinated quotas were attributed to the Company and were recorded in current assets as interest in the securitization fund, with a balance of R$ 27,774 (R$ 26,506 – Dec/23). The subordinated quotas are exposed to the risk of absorbing any losses on receivables transferred and any losses attributed to the fund. The holders of senior quotas do not have right of recourse in relation to the other assets of the Company in the event of default of the amounts due by the suppliers. The interest held in subordinated quotas represented the maximum exposure to losses in discount transactions carried out using these structures.

Investment Fund

Balance held by FIP RD Ventures and by RD FIDC in short-term investment funds which aims to provide to its quotaholders the valuation of their quotas through the investment of their funds in a portfolio fully comprised of federal government securities. The investment has no grace period for redemption and convertibility of the quotas, the amount may be readily invested or redeemed and the financial settlement occurs on the same day.

(All amounts in thousands of reais unless otherwise stated)

7. Trade receivables

7.1. Accounting policy

Trade receivables are recorded at the original sales amount, less credit card operators charges, when applicable, and provision for expected credit losses. Provision for expected credit losses is set up when there is strong evidence that the Group will not be able to collect all the amounts due. The expected loss corresponds to the difference between carrying amount and recoverable amount, estimated based on the history of actual losses.

Installment sales were adjusted to present value at the transaction date at the rate of the weighted average cost based on 100% of the CDI. The adjustment to present value has as a balancing entry the trade receivables account and its realization is recognized as revenue from sales according to their maturity.

7.2. Balance breakdown

	Parent Company		Consolidated	
Trade receivables items	**Dec/24**	**Dec/23**	**Dec/24**	**Dec/23**
Trade receivables	1,939,373	2,537,295	2,715,360	3,120,350
(-) Expected credit losses	(978)	(2,462)	(19,169)	(10,367)
(-) Adjustment to present value	(18,796)	(19,287)	(29,433)	(25,043)
Total	**1,919,599**	**2,515,546**	**2,666,758**	**3,084,940**

The detailed aging of trade receivables is presented below:

	Parent Company		Consolidated	
Maturities	**Dec/24**	**Dec/23**	**Dec/24**	**Dec/23**
Not yet due	1,933,732	2,531,601	2,641,256	3,048,325
Overdue:				
Between 1 and 30 days	3,072	3,130	28,276	31,684
Between 31 and 60 days	2,056	974	11,500	16,700
Between 61 and 90 days	61	575	5,855	11,003
Between 91 and 180 days	442	501	11,476	6,764
Between 181 and 360 days	10	514	16,997	5,874
(-) Expected credit losses	(978)	(2,462)	(19,169)	(10,367)
(-) Adjustment to present value	(18,796)	(19,287)	(29,433)	(25,043)
Total	**1,919,599**	**2,515,546**	**2,666,758**	**3,084,940**

Days sales outstanding, represented by credit and debit cards and partnerships with companies and the Government, are approximately 43 days (42 days – Dec/2023), term that is considered part of the normal conditions inherent in the Group's operations. A substantial portion of the amounts overdue for more than 31 days is represented by collection through special plans, Medicine Benefit Program (PBM), and Popular Pharmacy Program.

The changes in expected credit losses are presented below:

Changes in expected losses	**Parent Company**	**Consolidated**
At January 1, 2023	**(1,431)**	**(6,068)**
Additions	(10,571)	(26,156)
Reversals	3,532	13,375
Losses	6,008	8,482
At December 31, 2023	**(2,462)**	**(10,367)**
Additions	(16,272)	(47,096)
Reversals	9,260	25,805
Losses	8,496	12,490
At December 31, 2024	**(978)**	**(19,168)**

Trade receivables are classified as financial assets at amortized cost and are therefore measured as described in Note 25.1 – Impairment to the financial statements for the year ended December 31, 2024.

(All amounts in thousands of reais unless otherwise stated)

8. Inventories

8.1. Accounting policy

Inventories are carried at the lower of cost and net realizable value. Costs of inventories are determined using the weighted average cost method. Net realizable value is the estimated selling price in the ordinary course of business, less selling expenses. Inventories balances are presented net of estimates for losses, breakage, and obsolescence, assessed based on historical averages and of adjustment to present value at the date of transactions that have as a balancing entry the suppliers account, aiming to demonstrate the net cost of the implicit interest effect in installment purchases, and their realization is recorded as cost of sales.

8.2. Balance breakdown

	Parent Company		Consolidated	
Inventory items	**Dec/24**	**Dec/23**	**Dec/24**	**Dec/23**
Goods for resale	8,133,609	6,930,474	8,567,404	7,245,647
Consumables	9,461	10,156	9,622	10,156
(-) Adjustment to present value	(85,795)	-	(86,183)	-
(-) Provision for inventory losses	(83,413)	(58,376)	(83,413)	(58,376)
Total inventories	**7,973,862**	**6,882,254**	**8,407,430**	**7,197,427**

Changes in the provision for expected losses on goods are as follows:

Changes in expected losses on goods	Parent Company	Consolidated
At January 1, 2023	**(59,698)**	**(59,698)**
Additions	(41,081)	(41,081)
Write-offs	42,403	42,403
At December 31, 2023	**(58,376)**	**(58,376)**
Additions	(35,682)	(35,682)
Write-offs	10,645	10,645
At December 31, 2024	**(83,413)**	**(83,413)**

For the year ended December 31, 2024, as described in Note 22, the cost of goods sold recognized in the statement of income was R$ 24,393,311 (R$ 21,412,578 – Dec/2023) for the Parent Company and R$ 27,254,259 (R$ 23,714,554 – Dec/2023) for the Consolidated accounts, including the amount of write-offs of inventories recognized as losses for the year amounting to R$ 373,089 (R$ 281,950 – Dec/2023) for the Parent Company and R$ 375,495 (R$ 282,798 – Dec/2023) for the Consolidated accounts.

The effect of the recognition, reversal or write-off of the provision for inventory losses is included in cost of sales in the statement of income.

(All amounts in thousands of reais unless otherwise stated)

9. Recoverable taxes

	Parent Company		Consolidated	
Recoverable taxes items	**Dec/24**	**Dec/23**	**Dec/24**	**Dec/23**
Taxes on profit recoverable				
Withholding Income Tax (IRRF)	2,241	3,743	4,232	4,676
Corporate Income Tax (IRPJ)	36,019	21,191	51,747	34,346
Social Contribution on Net Profit (CSLL)	14,992	14,366	19,772	16,747
Subtotal	**53,252**	**39,300**	**75,751**	**55,769**
Other recoverable taxes				
Value Added Tax on Sales and Services (ICMS) – credit balance (i)	225,254	150,854	243,708	162,570
ICMS – Refund of ICMS withheld in advance (i)	114,023	67,501	136,538	67,501
ICMS on acquisitions of fixed assets	119,716	108,171	119,716	108,171
Service Tax (ISS)	271	-	273	-
Social Integration Program (PIS)	34,364	34,927	34,521	36,257
Social Contribution on Revenue (COFINS)	158,555	161,253	159,291	168,541
Social Investment Fund (FINSOCIAL) - 1982 - securities issued to cover court-ordered debts	561	561	561	561
National Institute of Social Security (INSS)	997	-	1,064	39
Subtotal	**653,741**	**523,267**	**695,672**	**543,640**
Total	**706,993**	**562,567**	**771,423**	**599,409**
Current assets	440,153	348,650	483,484	353,401
Non-current assets	266,840	213,917	287,939	246,008

(i) The ICMS credits amounting to R$ 225,254 and R$ 114,023 (R$ 150,854 and R$ 67,501 - Dec/23) for the Parent Company and R$ 243,708 and R$ 136,538 (R$ 162,570 and R$ 67,501 - Dec/23) for the Consolidated accounts are the result of applying different ICMS rates and of refunds of ICMS-ST (the Substitute Taxpayer Regime). The respective tax credits have been progressively consumed.

Expected realization of credits

The expected realization of amounts classified in current and non-current assets is as follows:

	Parent Company		Consolidated	
Expected realization	**Dec/24**	**Dec/23**	**Dec/24**	**Dec/23**
In the next 12 months	440,153	348,650	483,484	353,401
Between 13 and 24 months	30,076	96,613	51,175	114,327
Between 25 and 36 months	29,502	19,000	29,502	22,692
Between 37 and 48 months	29,896	35,263	29,896	39,015
Between 49 and 60 months	177,366	63,041	177,366	69,974
Total	**706,993**	**562,567**	**771,423**	**599,409**

10.Investments

10.1. Accounting policy

Business combinations

Business combinations are accounted for using the acquisition method. The cost of an acquisition is measured as the aggregate of the consideration transferred, which is measured at acquisition date fair value, and the amount of any noncontrolling interests in the acquiree. For each business combination, the acquirer must measure the noncontrolling interest in the acquiree at fair value or at the proportionate share of the acquiree's identifiable net assets. Acquisition-related costs are expensed as incurred.

The Company determines that it has acquired a business when the acquired set of activities and assets include an input and a substantive process that together significantly contribute to the ability to create outputs. The acquired process is considered substantive if it is critical to the ability to continue producing outputs, and the inputs acquired include an organized workforce with the necessary skills, knowledge, or experience to perform that process or it significantly contributes to the ability to continue producing outputs and is considered unique or scarce or cannot be replaced without significant cost, effort, or delay in the ability to continue producing outputs.

When the Company acquires a business, it assesses the financial assets and liabilities assumed for appropriate classification and designation in accordance with the contractual terms, economic circumstances and pertinent conditions as at the acquisition date. This includes the separation of embedded derivatives in host contracts by the acquiree.

Any contingent consideration to be transferred by the acquirer will be recognized at fair value at the acquisition date. Contingent consideration classified as an asset or a liability is measured at fair value with the changes in fair value recognized in accordance with NBC TG 48, in the statement of income.

Goodwill is initially measured as the excess of the consideration transferred over the fair value of the net identifiable assets acquired less liabilities assumed. If the consideration transferred is less than the fair value of the net assets acquired, the difference is recognized as a gain in the statement of income.

After initial recognition, goodwill is measured at cost less any accumulated impairment losses. For the purpose of impairment testing, goodwill acquired in a business combination is, from the acquisition date, allocated to each of RD's cash-generating units that are expected to benefit from the combination, irrespective of whether other assets or liabilities of the acquiree are assigned to those units.

Investment in associates

An associate is an entity over which RD Sáude has significant influence. Significant influence is the power to participate in the financial and operating policy decisions of the investee, but is not control or joint control over those policies. The considerations made in determining significant influence are similar to those necessary to determine control over subsidiaries.

RD Saúde's investments in its associates are accounted for using the equity method. Under the equity method, the investment in an associate is initially recognized at cost. The carrying amount of the investment is adjusted to recognize changes in RD Saúde's share of net assets of the associates since the acquisition date. Goodwill relating to the associate is included in the carrying amount of the investment and is not tested for impairment separately.

The statement of income reflects RD Saúde's share of the results of operations of the associates. Any change in other comprehensive income of those investees is presented as part of RD Saúde's other comprehensive income. In addition, when there has been a change recognized directly in the equity of the associate, RD Saúde recognizes its share of any changes, when applicable, in the statement of changes in equity. Unrealized gains and losses resulting from transactions between RD Saúde and the associate are eliminated to the extent of the interest in the associate.

The financial statements of the associates are prepared for the same reporting periods as those of RD Saúde. When necessary, adjustments are made to bring the accounting policies in line with those of RD Saúde. After application of the equity method, RD Saúde determines whether it is necessary to recognize an impairment loss on its investment in its associates. At each reporting date, RD Saúde determines whether there is objective evidence that the investment in associates is impaired. If there is such evidence, RD Saúde calculates the amount of impairment as the difference between the recoverable amount of the associate and its carrying amount, and then recognizes the loss in the statement of income.

10.2. Realization of 4Bio call option

On April 30, 2024, Fundo de Investimento em Participações Kona ("Kona") submitted to RD Saúde the Notice of Exercise of the Second Put Option of shares equivalent to 15% of the capital of subsidiary 4Bio Medicamentos S.A. The transfer of shares occurred on May 3, 2024, through the payment of R$ 117,817, In addition, there is an amount of R$ 12,591 (which is recorded under other non-current liabilities) linked to the realization of certain future contractual conditions, the Company became the holder of 100% of the capital of 4Bio Medicamentos S.A.

10.3. Mergers

Aiming to optimize the Group's corporate structure, at December 31, 2024, RD Ads Ltda ("RD Ads") was merged into Impulso Soluções de Mídia Ltda. ("Impulso"), formerly Vitat Serviços em Saúde Ltda. This initiative represents an important step towards strengthening our synergy, improving processes and providing an even more complete and efficient experience to our customers and partners. The merger reflects our commitment with continuous innovation and improvement, consolidating an increasingly aligned and strategic operation.

(All amounts in thousands of reais unless otherwise stated)

10.4. Composition and changes in investments

At December 31, 2024, the Company's investment balances are presented below:

		Dec/24			Dec/23		
Investee	**Main activity**	**Interest (%)**	**Parent Company**	**Consolidated**	**Interest (%)**	**Parent Company**	**Consolidated**
Direct interest							
4Bio	Retail of special medicines	100.00%	733,451	-	85.00%	346,998	-
RD Ventures FIP	Private equity investment fund	100.00%	169,200	-	100.00%	143,760	-
Stix Fidelidade	Platform of products and services for the accumulation and redemption of points	33.33%	9,475	9,475	33.33%	5,108	5,108
Impulso	Advisory and consultancy in advertising and marketing	100.00%	123,132	-	100.00%	18,492	-
Dr. Cuco	Digital care platform focused on adherence to treatment	100.00%	15,061	-	100.00%	15,769	-
RD Ads	Advisory and consultancy in advertising and marketing	-	-	-	100.00%	51,349	-
Dose Certa + Cuidado	Management of Self-Care Home Treatments	100.00%	40,493	-	100.00%	39,158	-
Manipulação Raia Drogasil	Marketplace of Compounding Pharmacies	100.00%	20,285	-	100.00%	22,722	-
Kymberg	Pharmaceutical company specialized in the production of medicines	100.00%	17,930	-	100.00%	16,277	-
RD Log	Transportation and logistics company	100.00%	16	-	100.00%	-	-
Indirect interest							
Labi (i)	Healthtech focused on laboratory tests, tests, check-ups and vaccines.	25.01%	-	5,265	23.61%	-	(1,848)
Total			**1,129,043**	**14,740**		**659,633**	**3,260**
Reclassification to "Other liabilities", as provision for losses on investments						**-**	**1,848**
Classified as investments			**1,129,043**	**14,740**	**1.125.086**	**659,633**	**5,108**

The provision for losses on investments at December 31, 2023 is recorded in "Other provisions".

(All amounts in thousands of reais unless otherwise stated)

Changes in investment balances presented in the financial statements are shown below:

Changes in investments	4BIO	Stix	RD Ventures	Impulso	Cuco Health	RD ADS	Dose Certa +cuidado SafePill	Drogasil / Raia manipulação	Kymberg	RD Log	**Total**
	Subsidiary	Associate	Subsidiary	Subsidiary	Subsidiary	Subsidiary	Subsidiary	Subsidiary	Subsidiary	Subsidiary	
At January 1, 2023	279,118	2,396	139,134	45,960	14,804	37,644	52,174	9,944	-	-	**581,174**
Capital contribution	-	-	24,827	42,000	2,425	-	15,986	14,456	1,800	-	**101,494**
Business combinations	-	-	-	-	-	-	(21,174)	9,308	14,850	-	**2,984**
Write-off of surplus value and investment goodwill	-	-	-	(30,111)	-	-	-	-	-		**(30,111)**
Equity in the results of subsidiaries	67,936	2,712	(20,201)	(39,357)	(1,460)	13,705	(7,828)	(10,986)	(373)	-	**4,148**
Restricted share compensation plan	(56)	-	-	-	-	-	-	-	-	-	**(56)**
At December 31, 2023	**346,998**	**5,108**	**143,760**	**18,492**	**15,769**	**51,349**	**39,158**	**22,722**	**16,277**	**-**	**659,633**
Capital contribution	240,000	-	42,900	30,000	-	-	16,800	10,200	4,200	30	**344,130**
Increase in the percentage of interest in subsidiary	59,709	-	-	-	-	-	-	-	-	-	**59,709**
Restructuring due to merger	-	-	-	76,193	-	(76,193)	-	-	-	-	**-**
Equity in the results of subsidiaries	86,823	4,367	(17,460)	(1,662)	(708)	24,844	(15,465)	(12,637)	(2,547)	(14)	**65,541**
Restricted share compensation plan	(79)	-	-	109	-	-	-	-	-	-	**30**
At December 31, 2024	**733,451**	**9,475**	**169,200**	**123,132**	**15,061**	**-**	**40,493**	**20,285**	**17,930**	**16**	**1,129,043**

(All amounts in thousands of reais unless otherwise stated)

For the purpose of calculating the equity in subsidiaries and associates, the Company adjusts the assets, liabilities and the respective changes in the result. At 4Bio they are adjusted based on the purchase price allocation determined at the acquisition date. The table below shows the effects on profit (loss) for the year of subsidiaries and associate for the purposes of determining the equity in results of subsidiaries for the year ended December 31, 2024 and 2023:

	Parent Company										
Changes in investments	4BIO	stix	RD Ventures	vitat	Cuco Health	impulso	dose certa SafePill	Drogasil Raia manipulação	Kymberg	RD Log	**Total**
Profit (loss) for the year	68,142	2,712	(20,201)	(35,257)	(272)	13,705	(7,828)	(9,730)	(373)	-	**10,898**
Amortization of surplus value arising from business combination	(206)	-	-	(4,100)	(1,188)	-	-	(1,256)	-	-	**(6,750)**
Equity in the results of subsidiaries at 12/31/2023	**67,936**	**2,712**	**(20,201)**	**(39,357)**	**(1,460)**	**13,705**	**(7,828)**	**(10,986)**	**(373)**	**-**	**4,148**
Profit (loss) for the year	87,029	4,367	(17,460)	(1,662)	131	24,844	(15,465)	(11,477)	(2,547)	(14)	**67,746**
Amortization of surplus value arising from business combination	(206)	-	-	-	(839)	-	-	(1,160)	-	-	**(2,205)**
Equity in the results of subsidiaries at 12/31/2024	**86,823**	**4,367**	**(17,460)**	**(1,662)**	**(708)**	**24,844**	**(15,465)**	**(12,637)**	**(2,547)**	**(14)**	**65,541**

(All amounts in thousands of reais unless otherwise stated)

	Parent Company										
Adjusted equity	4BIO	Stix	RD Ventures	Vitat	Cuco Health	Impulso	Dose Certa +cuidado SafePill	Drogasil manipulação / Raia manipulação	Kymberg	RD Log	Dec/24
Investment at book value	719,352	9,475	169,200	123,259	2,244	(13,431)	6,511	2,045	5,232	16	**1,023,903**
Purchase price allocation (surplus value of assets)	2,167	-	-	-	2,321	-	-	5,844	-	-	**10,332**
Deferred income tax liability on allocation adjustments	(821)	-	-	-	-	-	-	-	-	-	**(821)**
Restricted share compensation plan	(154)	-	-	(127)	-	-	-	-	-	-	**(281)**
Total adjusted equity	**720,544**	**9,475**	**169,200**	**123,132**	**4,565**	**(13,431)**	**6,511**	**7,889**	**5,232**	**16**	**1,033,133**
Goodwill based on expected future profitability	12,907	-	-	-	10,496	13,431	33,982	12,396	12,698	-	**95,910**
Investment balance	**733,451**	**9,475**	**169,200**	**123,132**	**15,061**	**-**	**40,493**	**20,285**	**17,930**	**16**	**1,129,043**

	Parent Company									
Adjusted equity	4BIO	Stix	RD Ventures	Vitat	Cuco Health	Impulso	Dose Certa +cuidado SafePill	Drogasil manipulação / Raia manipulação	Kymberg	Dec/23
Investment at book value	332,778	5,108	143,760	18,492	1,709	37,918	5,176	2,936	3,579	**551,456**
Purchase price allocation (surplus value of assets)	2,209	-	-	-	3,564	-	-	7,390	-	**13,163**
Deferred income tax liability on allocation adjustments	(821)	-	-	-	-	-	-	-	-	**(821)**
Restricted share compensation plan	(75)	-	-	-	-	-	-	-	-	**(75)**
Total adjusted equity	**334,091**	**5,108**	**143,760**	**18,492**	**5,273**	**37,918**	**5,176**	**10,326**	**3,579**	**563,723**
Goodwill based on expected future profitability	12,907	-	-	-	10,496	13,431	33,982	12,396	12,698	**95,910**
Investment balance	**346,998**	**5,108**	**143,760**	**18,492**	**15,769**	**51,349**	**39,158**	**22,722**	**16,277**	**659,633**

11. Property, plant and equipment

11.1. Accounting policy

Fixed assets are stated at acquisition, formation or installation cost of pharmacies, net of accumulated depreciation/amortization and/or impairment losses, if any. Depreciation and amortization are calculated using the straight-line method, over the useful life of the assets, according to the rates shown in Note 11.2. RD Saúde's procedure is to review the residual values, useful lives of the assets, the amortization period, depreciation and amortization methods at least at the end of each reporting period and adjust them on a prospective basis, when applicable.

An item of fixed assets is derecognized upon disposal or when no future economic benefits are expected from its use or disposal. Gains and losses on disposals are determined by comparing the disposal proceeds with the asset's carrying amount, and are recognized in the statement of income for the year in which the asset is derecognized. When revalued assets are intended for sale, the amounts included in the revaluation reserve are recorded in retained earnings upon disposal. Repair and maintenance service costs are recorded in the statement of income when incurred.

Land and buildings: include the head office and certain owned stores, are stated at historical acquisition cost plus revaluation conducted in October 1987, based on valuation reports prepared by independent experts, and incorporated into the deemed cost upon the adoption of IFRS. In this adoption, the balance of the revaluation of land and existing buildings in equity was transferred to the carrying value adjustments line item, also in equity, net of deferred income tax and social contribution.

Fixed assets are reviewed annually to identify evidence of impairment, and also whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If that is the case, the recoverable amount is calculated to identify any indication of impairment. When there is such indication of impairment, it is recognized in the amount at which the net carrying amount of the asset exceeds its recoverable amount, which is the higher of the net sales price or value in use of the asset. The impairment of present and future transactions is recognized in the statement of income as expenses, reflecting the purpose of the asset item affected. For the purposes of assessing impairment, assets are grouped at the lowest level for which there are separately identifiable cash flows (CGUs). The Company's CGUs are the pharmacies.

(All amounts in thousands of reais unless otherwise stated)

11.2. Breakdown and changes

Fixed assets are broken down as follows:

		Parent Company					
		Dec/24			Dec/23		
	Average annual depreciation rates (%)	Cost	Accumulated depreciation	Net book value	Cost	Accumulated depreciation	Net book value
Land	-	32,124	-	**32,124**	32,124	-	**32,124**
Buildings	2.5 - 2.7	69,837	(34,056)	**35,781**	69,837	(32,312)	**37,525**
Furniture, fittings and facilities	7.4 - 10	1,893,280	(939,408)	**953,872**	1,665,730	(784,841)	**880,889**
Machinery and equipment	7.1 - 15.8	1,127,256	(719,864)	**407,392**	1,029,834	(623,733)	**406,101**
Vehicles	20 - 23.7	213,150	(94,344)	**118,806**	145,958	(74,286)	**71,672**
Property improvements	13 - 20	2,917,284	(1,825,804)	**1,091,480**	2,453,427	(1,462,053)	**991,374**
Total		**6,252,931**	**(3,613,476)**	**2,639,455**	**5,396,910**	**(2,977,225)**	**2,419,685**

		Consolidated					
		Dec/24			Dec/23		
	Average annual depreciation rates (%)	Cost	Accumulated depreciation	Net book value	Cost	Accumulated depreciation	Net book value
Land	-	32,124	-	32,124	32,124	-	**32,124**
Buildings	2.5 - 2.7	69,837	(34,056)	35,781	69,837	(32,312)	**37,525**
Furniture, fittings and facilities	7.4 - 10	1,903,450	(941,315)	962,135	1,673,676	(786,485)	**887,191**
Machinery and equipment	7.1 - 15.8	1,171,390	(733,166)	438,224	1,063,019	(632,265)	**430,754**
Vehicles	20 - 23.7	213,151	(94,345)	118,806	145,959	(74,287)	**71,672**
Property improvements	13 - 20	2,925,729	(1,830,127)	1,095,602	2,460,018	(1,465,597)	**994,421**
Total		**6,315,681**	**(3,633,009)**	**2,682,672**	**5,444,633**	**(2,990,946)**	**2,453,687**

(All amounts in thousands of reais unless otherwise stated)

Changes in the Parent Company's fixed assets are as follows:

Changes in cost	Jan 1, 2023	Additions	Disposals and write-offs	(Provision for) / Reversal of pharmacies closure	Dec/23	Additions	Disposals and write-offs	(Provision for) / Reversal of pharmacies closure	Dec/24
Land	**32,124**	-	-	-	**32,124**	-	-	-	**32,124**
Buildings	**69,837**	-	-	-	**69,837**	-	-	-	**69,837**
Furniture, fittings and facilities	**1,434,220**	236,556	(7,433)	2,387	**1,665,730**	235,049	(14,711)	7,212	**1,893,280**
Machinery and equipment	**931,454**	115,788	(16,400)	(1,008)	**1,029,834**	116,183	(19,769)	1,008	**1,127,256**
Vehicles	**114,212**	32,001	(255)	-	**145,958**	71,028	(3,836)	-	**213,150**
Property improvements	**1,981,381**	473,244	(3,849)	2,651	**2,453,427**	482,147	(22,914)	4,624	**2,917,284**
Total	**4,563,228**	**857,589**	**(27,937)**	**4,030**	**5,396,910**	**904,407**	**(61,230)**	**12,844**	**6,252,931**

Changes in accumulated depreciation	Jan 1, 2023	Additions	Disposals and write-offs	Provision for / (Reversal of) pharmacies closure	Dec/23	Additions	Disposals and write-offs	Provision for / (Reversal of) pharmacies closure	Dec/24
Buildings	**(30,531)**	(1,781)	-	-	**(32,312)**	(1,744)	-	-	**(34,056)**
Furniture, fittings and facilities	**(647,044)**	(141,083)	4,306	(1,020)	**(784,841)**	(159,043)	8,880	(4,404)	**(939,408)**
Machinery and equipment	**(526,858)**	(111,171)	14,203	93	**(623,733)**	(113,286)	17,249	(94)	**(719,864)**
Vehicles	**(58,513)**	(15,978)	205	-	**(74,286)**	(23,778)	3,720	-	**(94,344)**
Property improvements	**(1,118,450)**	(344,600)	2,152	(1,155)	**(1,462,053)**	(374,551)	14,207	(3,407)	**(1,825,804)**
Total	**(2,381,396)**	**(614,613)**	**20,866**	**(2,082)**	**(2,977,225)**	**(672,402)**	**44,056**	**(7,905)**	**(3,613,476)**

(All amounts in thousands of reais unless otherwise stated)

Changes in the Consolidated fixed assets are as follows:

Changes in cost	Jan 1, 2023	Addition by business combination	Additions	Disposals and write-offs	(Provision for) / Reversal of pharmacies closures	Dec/23	Additions	Disposals and write-offs	(Provision for) / Reversal of pharmacies closures	Dec/24
Land	**32,124**	-	-	-	-	**32,124**	-	-	-	**32,124**
Buildings	**69,837**	-	-	-	-	**69,837**	-	-	-	**69,837**
Furniture, fittings and facilities	**1,437,156**	2,197	239,388	(7,452)	2,387	**1,673,676**	237,687	(15,125)	7,212	**1,903,450**
Machinery and equipment	**946,424**	108	133,979	(16,484)	(1,008)	**1,063,019**	129,731	(22,368)	1,008	**1,171,390**
Vehicles	**114,213**	-	32,001	(255)	-	**145,959**	71,028	(3,836)	-	**213,151**
Property improvements	**1,986,701**	-	474,515	(3,849)	2,651	**2,460,018**	484,915	(23,828)	4,624	**2,925,729**
Total	**4,586,455**	**2,305**	**879,883**	**(28,040)**	**4,030**	**5,444,633**	**923,361**	**(65,157)**	**12,844**	**6,315,681**

Changes in accumulated depreciation	Jan 1, 2023	Addition by business combination	Additions	Disposals and write-offs	Provision for / (Reversal of) pharmacies closure	Dec/23	Additions	Disposals and write-offs	Provision for / (Reversal of) pharmacies closure	Dec/24
Buildings	**(30,531)**	-	(1,781)	-	-	**(32,312)**	(1,744)	-	-	**(34,056)**
Furniture, fittings and facilities	**(648,362)**	(4)	(141,410)	4,311	(1,020)	**(786,485)**	(159,601)	9,174	(4,403)	**(941,315)**
Machinery and equipment	**(531,347)**	(7)	(115,261)	14,257	93	**(632,265)**	(119,967)	19,159	(93)	**(733,166)**
Vehicles	**(58,514)**	-	(15,978)	205	-	**(74,287)**	(23,778)	3,720	-	**(94,345)**
Property improvements	**(1,121,296)**	-	(345,298)	2,152	(1,155)	**(1,465,597)**	(375,562)	14,439	(3,407)	**(1,830,127)**
Total	**(2,390,050)**	**(11)**	**(619,728)**	**20,925**	**(2,082)**	**(2,990,946)**	**(680,652)**	**46,492**	**(7,903)**	**(3,633,009)**

11.3. Changes in the provision for pharmacies closure

The changes in the Parent Company's provision for pharmacies closure are shown below:

	Provision	Depreciation	Total properties
At January 1, 2023	**(21,546)**	**11,429**	**(10,117)**
Additions	(26,374)	14,148	(12,226)
Reversals	30,404	(16,230)	14,174
Changes, net	**4,030**	**(2,082)**	**1,948**
At December 31, 2023	**(17,516)**	**9,347**	**(8,169)**
Additions	(16,821)	9,196	(7,625)
Reversals	29,665	(17,099)	12,566
Changes, net	**12,844**	**(7,903)**	**4,941**
At December 31, 2024	**(4,672)**	**1,444**	**(3,228)**

12. Intangible assets

12.1. Accounting policy

Intangible assets are stated at historical cost of acquisition or formation, net of accumulated amortization and accumulated impairment losses, if any. Amortization is calculated using the straight-line method, over the useful life of the assets, according to the rates shown in Note 12.2. RD Saúde's procedure is to review the residual values, useful lives of the assets, the amortization period, amortization methods at least at the end of each reporting period and adjusted on a prospective basis, when applicable.

An item of intangible assets is derecognized when no future economic benefits are expected from its use or disposal.

Goodwill on acquisition of companies: Goodwill arises on the acquisition of subsidiaries and represents the excess of (i) the consideration transferred; (ii) the amount of any noncontrolling interest in the acquiree; and (iii) the acquisition-date fair value of any previous equity interest in the acquiree over the fair value of the identifiable net assets acquired. If the total of consideration transferred, noncontrolling interest recognized and previously held interest measured at fair value is less than the fair value of the net assets of the subsidiary acquired, in the case of a bargain purchase, the difference is recognized directly in the statement of income. Goodwill on the acquisition of investment prior to 2009 (Drogaria Vison) was calculated as the difference between the acquisition amount and the carrying amount of the acquiree's net assets. Up to December 2008, goodwill was amortized based on the term, extent and proportion of projected results, not exceeding ten years. As from January 2009, goodwill is no longer amortized and is now tested for impairment on an annual basis, at the cash-generating unit (CGU) level.

Points of sales: These include points of sale acquired from pharmacy lease agreements, stated at acquisition cost and amortized using the straight-line method, which take into consideration the lease agreement terms, not exceeding twenty years.

Software use licenses or IT system development: are stated at acquisition cost and amortized using the straight-line method over their estimated useful lives. The ongoing costs of software research or maintenance are expensed as incurred. Development activities involve a project aimed at producing new products or solutions, with the intention of completing the asset in order to use it. Costs are capitalized only if directly attributable to identifiable and exclusive software programs, controlled by the Group, which can be reliably measured, if the product or process is technically feasible, if the Company and its subsidiaries have the intention and sufficient resources to complete the development and use or sell the asset and that are likely to generate economic benefits greater than the related costs for more than one year, are stated as intangible assets and amortized on a straight-line basis over their useful lives. Direct costs, when the criteria previously described are met, include the salaries of the software development team members and a fair share of related general expenses directly related to the preparation of this asset.

Intangible assets are reviewed annually to identify evidence of impairment, and also whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Intangible assets with indefinite useful lives, such as goodwill and surplus value related to trademarks, are tested for impairment at least on an annual basis, or whenever there is indication of impairment. If that is the case, the recoverable amount is calculated to identify any indication of impairment. When there is such indication of impairment, it is recognized in the amount at which the net carrying amount of the asset exceeds its recoverable amount, which is the higher of the net sales price or value in use of the asset. The impairment of present and future transactions is recognized in the statement of income as expenses, reflecting the purpose of the asset item affected. For the purposes of assessing impairment, assets are grouped at the lowest level for which there are separately identifiable cash flows (CGUs).

(All amounts in thousands of reais unless otherwise stated)

12.2. Breakdown and changes

		Parent Company					
	Average annual amortization rates (%)	Dec/24			Dec/23		
		Cost	Accumulated amortization	Net book value	Cost	Accumulated amortization	Net book value
Key money	17 - 23.4	296,437	(256,434)	**40,003**	280,953	(233,317)	**47,636**
Software license and systems implementation	20	1,322,318	(592,881)	**729,437**	992,300	(392,332)	**599,968**
Goodwill on business acquisition – Vison	(i)	22,275	(2,387)	**19,888**	22,275	(2,387)	**19,888**
Goodwill on business acquisition – Raia	(i)	780,084	-	**780,084**	780,084	-	**780,084**
Trademarks with finite useful life	20	22,232	(14,163)	**8,069**	20,743	(12,458)	**8,285**
Trademarks with indefinite useful life	(i)	151,000	-	**151,000**	151,000	-	**151,000**
Customers portfolio	6.7 - 25	41,700	(40,857)	**843**	41,700	(40,397)	**1,303**
Total		**2,636,046**	**(906,722)**	**1,729,324**	**2,289,055**	**(680,891)**	**1,608,164**

		Consolidated					
	Average annual amortization rates (%)	Dec/24			Dec/23		
		Cost	Accumulated amortization	Net book value	Cost	Accumulated amortization	Net book value
Key money	17 - 23.4	298,334	(256,431)	**41,903**	282,850	(233,315)	**49,535**
Software license and systems implementation	20	1,354,161	(602,995)	**751,166**	1,031,064	(398,459)	**632,605**
Goodwill on acquisitions of investees	(i)	1,059,015	(2,387)	**1,056,628**	1,059,015	(2,387)	**1,056,628**
Platform	20	8,886	(1,647)	**7,239**	8,886	(1,249)	**7,637**
Non-compete agreement	20	833	-	**833**	833	-	**833**
Trademarks with finite useful life	20	33,123	(22,334)	**10,789**	31,624	(19,681)	**11,943**
Trademarks with indefinite useful life	(i)	151,000	-	**151,000**	151,000	-	**151,000**
Customers portfolio (Raia S.A.)	6.7 - 25	41,700	(40,857)	**843**	41,700	(40,397)	**1,303**
Customer relationship	20	9,395	(4,192)	**5,203**	9,395	(3,626)	**5,769**
Total		**2,956,447**	**(930,843)**	**2,025,604**	**2,616,367**	**(699,114)**	**1,917,253**

(i) Assets with indefinite useful lives

(All amounts in thousands of reais unless otherwise stated)

Changes in the Company's intangible assets are as follows:

Changes in cost	Jan 1, 2023	Additions	Disposals and write-offs	(Provision for) / Reversal of pharmacies closure	Dec/23	Additions	Disposals and write-offs	(Provision for) / Reversal of pharmacies closure	Dec/24
Key money	**268,037**	13,572	(921)	265	**280,953**	13,150	(675)	3,009	**296,437**
Software license and systems implementation	**632,372**	362,270	(2,342)	-	**992,300**	349,002	(18,996)	12	**1,322,318**
Goodwill on business acquisition – Vison	**22,275**	-	-	-	**22,275**	-	-	-	**22,275**
Goodwill on business acquisition – Raia	**780,084**	-	-	-	**780,084**	-	-	-	**780,084**
Trademarks with finite useful life	**19,052**	1,691	-	-	**20,743**	1,489	-	-	**22,232**
Trademarks with indefinite useful life	**151,000**	-	-	-	**151,000**	-	-	-	**151,000**
Customers portfolio	**41,700**	-	-	-	**41,700**	-	-	-	**41,700**
Total	**1,914,520**	**377,533**	**(3,263)**	**265**	**2,289,055**	**363,641**	**(19,671)**	**3,021**	**2,636,046**

Changes in accumulated amortization	Jan 1, 2023	Additions	Disposals and write-offs	(Provision for) / Reversal of pharmacies closure	Dec/23	Additions	Disposals and write-offs	Provision for / (Reversal of) pharmacies closure	Dec/24
Key money	**(205,977)**	(28,116)	781	(5)	**(233,317)**	(21,321)	492	(2,288)	**(256,434)**
Software license and systems implementation	**(249,752)**	(142,678)	98	-	**(392,332)**	(201,353)	814	(10)	**(592,881)**
Goodwill on business acquisition – Vison	**(2,387)**	-	-	-	**(2,387)**	-	-	-	**(2,387)**
Trademarks with finite useful life	**(10,673)**	(1,785)	-	-	**(12,458)**	(1,705)	-	-	**(14,163)**
Customers portfolio	**(39,937)**	(460)	-	-	**(40,397)**	(460)	-	-	**(40,857)**
Total	**(508,726)**	**(173,039)**	**879**	**(5)**	**(680,891)**	**(224,839)**	**1,306**	**(2,298)**	**(906,722)**

Voltar

(All amounts in thousands of reais unless otherwise stated)

Changes in the Consolidated intangible assets are as follows:

Changes in cost	Jan 1, 2023	Addition by business combination	Additions	Transfers	Disposals and write-offs	Provision for / (Reversal of) pharmacies closure	Dec/23	Additions	Disposals and write-offs	Provision for / (Reversal of) pharmacies closure	Dec/24
Key money	269,934	-	13,572	-	(921)	265	**282,850**	13,150	(675)	3,009	**298,334**
Software license	649,878	3	385,787	(2,004)	(2,600)	-	**1,031,064**	361,767	(38,682)	12	**1,354,161**
Goodwill on acquisitions of investees	1,087,673	-	16,067	2,004	(46,729)	-	**1,059,015**	-	-	-	**1,059,015**
Surplus value - Platform	25,386	-	-	-	(16,500)	-	**8,886**	-	-	-	**8,886**
Non-compete agreement	4,833	-	-	-	(4,000)	-	**833**	-	-	-	**833**
Trademarks with finite useful life	25,962	-	2,732	2,930	-	-	**31,624**	1,499	-	-	**33,123**
Trademarks with indefinite useful life	153,930	-	-	(2,930)	-	-	**151,000**	-	-	-	**151,000**
Customers portfolio - Raia	41,700	-	-	-	-	-	**41,700**	-	-	-	**41,700**
Customer relationship	9,395	-	-	-	-	-	**9,395**	-	-	-	**9,395**
Total	**2,268,691**	**3**	**418,158**	**-**	**(70,750)**	**265**	**2,616,367**	**376,416**	**(39,357)**	**3,021**	**2,956,447**

Changes in accumulated amortization	Jan 1, 2023	Addition by business combination	Additions	Transfers	Disposals and write-offs	(Provision for) / Reversal of pharmacies closure	Dec/23	Additions	Disposals and write-offs	Provision for / (Reversal of) pharmacies closure	Dec/24
Key money	(205,975)	-	(28,116)	-	781	(5)	**(233,315)**	(21,321)	493	(2,288)	**(256,431)**
Software license	(253,882)	(3)	(144,923)	-	349	-	**(398,459)**	(205,914)	1,388	(10)	**(602,995)**
Goodwill on acquisitions of investees	(2,387)	-	-	-	-	-	**(2,387)**	-	-	-	**(2,387)**
Surplus value - Platform	(5,775)	-	(564)	(1,249)	6,339	-	**(1,249)**	(398)	-	-	**(1,647)**
Non-compete agreement	(1,966)	-	-	-	1,966	-	**-**	-	-	-	**-**
Trademarks with finite useful life	(17,238)	-	(3,692)	1,249	-	-	**(19,681)**	(2,653)	-	-	**(22,334)**
Customers portfolio - Raia	(39,937)	-	(460)	-	-	-	**(40,397)**	(460)	-	-	**(40,857)**
Customer relationship	(3,420)	-	(206)	-	-	-	**(3,626)**	(566)	-	-	**(4,192)**
Total	**(530,580)**	**(3)**	**(177,961)**	**-**	**9,435**	**(5)**	**(699,114)**	**(231,312)**	**1,881**	**(2,298)**	**(930,843)**

(All amounts in thousands of reais unless otherwise stated)

12.3. Goodwill on the acquisition of companies

Goodwill on the acquisition of companies is subject to annual impairment testing.

Company	Goodwill amount	Acquisition
Drogaria Vison Ltda.	19,888	2/13/2008
Raia S.A.	780,084	11/10/2011
4Bio Medicamentos S.A.	25,563	10/01/2015
Dr. Cuco Desenvolvimento de Software Ltda.	10,496	11/19/2021
Healthbit Performasys Tecnologia Inteligência S.A.	17,505	3/09/2021
Amplisoftware Tecnologia Ltda.	82,895	12/22/2021
Labi Exames S.A.	52,328	8/05/2022
Eloopz Serviços de Promoção de Vendas EIRELI	8,421	8/23/2022
SafePill Comércio Varejista de Medicamentos Manipulados Ltda.	33,982	11/23/2022
ZTO Tecnologia e Serviços de Informação na Internet Ltda.	12,396	11/28/2022
Infectoria Serviços Médicos Ltda.	98	2/27/2023
Raia Drogasil Farmácia e Manipulação Ltda.	275	2/28/2023
Kymberg Farmacêutica do Brasil Ltda.	12,698	10/02/2023

Drogaria Vison Ltda. - Goodwill in the amount of R$ 19,888 refers to the acquisition of Drogaria Vison Ltda., on February 13, 2008, which was included in the Company's operations as from June 30, 2008. Goodwill is based on expected future profitability, pursuant to an appraisal prepared by an independent expert, and was amortized from April to December 2008. As provided for in CPC Guidance (OCPC) 02 - Clarifications on the 2008 Financial Statements, since 2009, goodwill has no longer been amortized, but has been subject to annual impairment testing ever since. The recoverable amount of the cash generating unit of 'Vison' is R$ 189, 256 at December 31, 2024 and was determined based on the calculation of the value in use considering the cash flow projections based on financial estimates approved by Management for a period of five years. The pre-tax discount rate applied to cash flow projections is 12.6% (13.8% in 2023). The growth rate used to extrapolate the unit's cash flow for a period over five years is 3.5% (3.3% in 2023).

Raia S.A. - The Company computed goodwill of R$ 780,084 in the business combination with Raia S.A., occurred on November 10, 2011, which is based on expected future profitability arising from the difference between the balances of assets assigned and those received. In addition to the amount classified as goodwill, we also have the amount of R$ 155,457 allocated as Trademarks, totaling R$ 935,541 in intangible assets with indefinite useful lives linked to the cash-generating unit 'Raia'. The recoverable amount of the cash generating unit of 'Raia' is R$ 9,053,146 at December 31, 2024 and was determined based on the calculation of the value in use considering the cash flow projections based on financial estimates approved by Management for a period of five years. The pre-tax discount rate applied to cash flow projections is 12.6% (13.8% in 2023). The growth rate used to extrapolate the unit's cash flow for a period over five years is 3.5% (3.3% in 2023).

4Bio Medicamentos S.A. – The Company computed goodwill of R$ 25,563 in the business combination with 4Bio Medicamentos S.A., occurred on October 1, 2015, of which the balance was supplemented by the final adjustment of the price at March 31, 2016 of R$ 2,040, which is based on expected future profitability arising from the difference between the balances of assets assigned and those received. The recoverable amount of the cash generating unit of '4Bio' is R$ 472,754 at December 31, 2024 and was determined based on the calculation of the value in use considering the cash flow projections based on financial estimates approved by Management for a period of five years. The pre-tax discount rate applied to cash flow projections is 13.0% (13.2% in 2023). The growth rate used to extrapolate the unit's cash flow for a period over five years is 3.5% (3.3% in 2023).

Dr. Cuco Desenvolvimento de Software Ltda. - The Company computed goodwill of R$ 10,496 in the business combination with Dr. Cuco Desenvolvimento de Software Ltda., occurred on November 19, 2021, which is based on expected future profitability arising from the difference between the balances of assets assigned and those received. The recoverable amount of the cash generating unit of 'Dr Cuco' is R$ 25,421 at December 31, 2024 and was determined based on the calculation of the value in use considering the cash flow projections based on financial estimates approved by Management for a period of ten years. The pre-tax discount rate, applied to cash flow projections, is 15.0% (15.6% in 2023), and the growth rate used to extrapolate the unit's cash flow for a period over five years is 4.0% (3.3% in 2023).

Healthbit Performasys Tecnologia Inteligência S.A. - The Company computed goodwill of R$ 17,505 in the business combination with Healthbit Performasys Tecnologia Inteligência S.A., occurred on March 9, 2021, which is based on expected future profitability arising from the difference between the balances of assets assigned and those received. The recoverable amount of the cash generating unit of 'Healthbit' is R$ 80,580 at December 31, 2024 and was determined based on the calculation of the value in use considering the cash flow projections based on financial estimates approved by Management for a period of ten years. The pre-tax discount rate, applied to cash flow projections, is 15.6% (15.6% in 2023), and the growth rate used to extrapolate the unit's cash flow for a period over five years is 4.0% (3.3% in 2023).

Amplisoftware Tecnologia Ltda. - The Company computed goodwill of R$ 82,895 in the business combination with Amplisoftware Tecnologia Ltda., occurred on December 22, 2021, which is based on expected future profitability arising from the difference between the balances of assets assigned and those received. The recoverable amount of the cash generating unit of 'Amplimed' is R$ 89,481 at December 31, 2024 and was determined based on the calculation of the value in use considering the cash flow projections based on financial estimates approved by Management for a period of ten years. The pre-tax discount rate, applied to cash flow projections, is 15.6% (15.6% in 2023), and the growth rate used to extrapolate the unit's cash flow for a period over five years is 4.0% (3.3% in 2023).

Labi Exames S.A. - The Company computed goodwill of R$ 52,328 in the acquisition of interest in Labi Exames S.A., occurred on August 5, 2022, which is based on expected future profitability arising from the difference between the balances of assets assigned and those received. The recoverable amount of the cash generating unit of 'Labi' is R$ 317,356 at December 31, 2024 and was determined based on the calculation of the value in use considering the cash flow projections based on financial estimates approved by Management for a period of ten years. The pre-tax discount rate, applied to cash flow projections, is 15.6%, and the growth rate used to extrapolate the unit's cash flow for a period over five years is 4.0% (3.3% in 2023).

Eloopz Serviços de Promoção de Vendas EIRELI - The Company computed goodwill of R$ 8,421 in the acquisition of interest in Eloopz Serviços de Promoção de Vendas EIRELI, occurred on August 23, 2022, which is based on expected future profitability arising from the difference between the balances of assets assigned and those received. The recoverable amount of the cash generating unit of 'Eloopz' is R$ 364,099 at December 31, 2024 and was determined based on the calculation of the value in use considering the cash flow projections based on financial estimates approved by Management for a period of five years. The pre-tax discount rate, applied to cash flow projections, is 15.6%, and the growth rate used to extrapolate the unit's cash flow for a period over five years is 4.0%.

SafePill Comércio Varejista de Medicamentos Manipulados Ltda - Dose Certa + Cuidado - The Company computed goodwill of R$ 33,982 in the acquisition of interest in Dose Certa + Cuidado, occurred on November 25, 2022, which is based on expected future profitability arising from the difference between the balances of assets assigned and those received. The recoverable amount of the cash generating unit of 'Dose Certa + Cuidado is R$ 174,168 at December 31, 2024 and was determined based on the calculation of the value in use considering the cash flow projections based on financial estimates approved by Management for a period of ten years. The pre-tax discount rate, applied to cash flow projections, is 15.6% (15.6% in 2023), and the growth rate used to extrapolate the unit's cash flow for a period over five years is 4.0% (3.3% in 2023).

ZTO Tecnologia e Serviços de Informação na Internet Ltda - Manipulação Raia Drogasil - The Company computed goodwill of R$ 12,396 in the acquisition of interest in *Manipulação Raia Drogasil*, occurred on December 1, 2022, which is based on expected future profitability arising from the difference between the balances of assets assigned and those received. The recoverable amount of the cash generating unit of '*Manipulação Raia Drogasil* is R$ 87,693 at December 31, 2024 and was determined based on the calculation of the value in use considering the cash flow projections based on financial estimates approved by Management for a period of ten years. The pre-tax discount rate, applied to cash flow projections, is 15.6% (15.6% in 2023), and the growth rate used to extrapolate the unit's cash flow for a period over five years is 4.0% (3.3% in 2023).

Infectoria Serviços Médicos Ltda. - The Company computed goodwill of R$ 98 in the acquisition of interest in Infectoria, occurred on February 27, 2023, which is based on expected future profitability arising from the difference between the balances of assets assigned and those received.

(All amounts in thousands of reais unless otherwise stated)

Raia Drogasil Farmácia de Manipulação Ltda. (formerly Pharmaperez – Farmácia e Manipulação Ltda.) - The Company computed goodwill of R$ 275 in the acquisition of interest in *Raia Drogasil Manipulação*, occurred on February 28, 2023, which is based on expected future profitability arising from the difference between the balances of assets assigned and those received.

Kymberg Farmacêutica do Brasil Ltda. - The Company computed goodwill of R$ 12,698 in the acquisition of interest in Kymberg, occurred on October 2, 2023, which is based on expected future profitability arising from the difference between the balances of assets assigned and those received. The recoverable amount of the cash generating unit of 'Kymberg' is R$ 19,829 at December 31, 2024 and was determined based on the calculation of the value in use considering the cash flow projections based on financial estimates approved by Management for a period of ten years. The pre-tax discount rate, applied to cash flow projections, is 15.6%, and the growth rate used to extrapolate the unit's cash flow for a period over five years is 4.0%.

12.4. Changes in the provision for pharmacies closure

The changes in the Parent Company's provision for pharmacies closure are shown below:

	Provision	Amortization	Total intangible assets
At January 1, 2023	**(3,321)**	**2,318**	**(1,003)**
Additions	(4,520)	3,547	(973)
Reversals	4,785	(3,552)	1,233
Changes, net	**265**	**(5)**	**260**
At December 31, 2023	**(3,056)**	**2,313**	**(743)**
Additions	(164)	108	(56)
Reversals	3,185	(2,406)	779
Changes, net	**3,021**	**(2,298)**	**723**
At December 31, 2024	**(35)**	**15**	**(20)**

13. Employee benefits

(a) Profit sharing program

The Group has a profit sharing and bonus program intended mainly to measure the performance of employees during the year. Both programs have a formal plan and the amounts payable may be reasonably estimated before the information preparation period, and settled in the short term. On a monthly basis, a liability and an expense for profit sharing are recognized in the statement of income based on estimates of achievement of operating targets and specific objectives established and approved by Management. The recognition as liabilities is made in the account of salaries and social charges and in the statement of income the recognition is made in the accounts of selling expenses and general and administrative expenses (Note 22).

(b) Other benefits

Other short-term benefits are also granted to employees, such as life insurance, health and dental care, housing allowance, funeral assistance, maternity leave and scholarship, which are recognized on an accrual basis and whose right is extinguished at the end of the employment relationship with the Group. The Group does not grant post-employment benefits such as "Plano Gerador de Benefício Livre" (PGBL), "Vida Gerador de Benefício Livre" (VGBL), defined benefit pension plan and/or any retirement or post-employment assistance plan, severance pay benefits or other long-term benefits. Part of the benefits granted to the officers include a restricted share plan, classified as an equity instrument. The fair value of share-based payments is recognized in profit or loss in accordance with the granting period, against equity (see Note 20 d).

(All amounts in thousands of reais unless otherwise stated)

14.Suppliers and Suppliers – Forfait and FIDC - Credit Rights Investment Fund

14.1. Accounting policy

Installment sale transactions are adjusted to their present value at the transaction date. The discount rate used to adjust the suppliers balances to their present value was 100% of the CDI. The adjustment of purchases to present value is recorded under suppliers, with a balancing entry in the inventories account, against finance income (costs), over their term in the case of suppliers. The balance of suppliers is measured at amortized cost, using the effective interest rate method.

14.2. Balance breakdown

	Parent Company		Consolidated	
Supplier items	**Dec/24**	**Dec/23**	**Dec/24**	**Dec/23**
Goods suppliers	4,920,366	4,416,143	5,427,620	4,845,237
Service providers	364,263	239,485	371,017	245,450
Materials suppliers	61,536	52,115	62,183	52,704
Assets suppliers	26,979	10,854	27,097	11,819
Adjustment to present value	(66,680)	(59,553)	(72,833)	(63,756)
Total	**5,306,494**	**4,659,044**	**5,815,084**	**5,091,454**
Suppliers	5,085,766	4,493,044	5,614,817	4,939,203
Suppliers – FIDC – Credit Rights Investment Fund	220,728	156,991	200,267	143,242
Suppliers - Forfait	-	9,009	-	9,009

14.3. Suppliers – Forfait and FIDC - Credit Rights Investment Fund

RD Saúde has agreements with RD FIDC and Financial Institutions, through which the suppliers of goods and services can receive in advance their amounts receivable owed by RD Saúde. This operation is solely intended to facilitate the cash flow of suppliers without the Company having to advance their payments.

The Company's Management, based on NBC TG 03 (R3) - Statement of Cash Flows and NBC TG 40 (R2) - Financial Instruments: Disclosure, considered the qualitative aspects on the issue and concluded that there are no significant impacts since the economic substance of the transaction is maintained as an operating activity and there are no changes in the conditions originally agreed with suppliers, such as in the original maturities and amounts.

In the year ended December 31, 2024, certain suppliers assigned their rights to receive Company notes to RD FIDC, allowing suppliers to receive in advance their amounts receivable, accordingly, RD FIDC becomes creditor of the operation and RD Saúde settles the notes on the same date originally agreed with its supplier. RD Saúde receives a commission from the financial institutions for this intermediation and confirmation of the notes payable. This advance of supplier notes generated to the Company an intermediation revenue for the referral of suppliers of R$ 14,988 (R$ 10,843 in the year ended December 31, 2023). In this operation, the financial institution takes into consideration the credit risk of the buyer (in this case, the Company). There is no change in the pre-established terms and other conditions after the assignment of the receivables. In addition, there is no obligation that results in expenses for the Company.

At December 31, 2024, the balance payable negotiated by suppliers and accepted by RD Saúde amounted to R$ 220,728 (R$ 166,000 - Dec/23) in the Parent company and R$ 200,267 (R$ 152,251 - Dec/23) in the Consolidated. These amounts are classified as "Suppliers – FIDC" and the cash flows resulting from this operation are classified as operating activities in the Statement of Cash Flows.

(All amounts in thousands of reais unless otherwise stated)

15. Borrowings and debentures

(a) Breakdown

Borrowings items	Average annual long-term interest rate	Parent Company Dec/24	Parent Company Dec/23	Consolidated Dec/24	Consolidated Dec/23
Debentures					
3rd issue of debentures - CRIs	98.50% of CDI	256,380	256,155	256,380	256,155
4th issue of debentures	106.99% of CDI	301,168	300,921	301,168	300,921
5th issue of debentures	100.00% of CDI + 1.49% p.a.	525,196	528,154	525,196	528,154
6th issue of debentures - CRIs	100.00% of CDI + 0.70% p.a.	256,366	256,088	256,366	256,088
7th issue of debentures - CRIs	100.00% of CDI + 0.75% p.a.	541,459	539,372	541,459	539,372
8th issue of debentures - CRIs – 1st series	100.00% of CDI + 0.30% p.a.	360,182	360,057	360,182	360,057
8th issue of debentures - CRIs – 2nd series	100.00% of CDI + 0.65% p.a.	153,050	152,812	153,050	152,812
8th issue of debentures - CRIs – 3rd series	100.00% of CDI + 1.10% p.a.	199,533	198,820	199,533	198,820
9th issue of debentures	100.00% of CDI + 0.65% p.a.	611,014	-	611,014	-
Total debentures		**3,204,348**	**2,592,379**	**3,204,348**	**2,592,379**
Borrowings					
Direct loans - Law 4,131	100.00% of CDI + 1.30% p.a.	-	-	-	100,490
Direct loans - Law 4,131	100.00% of CDI + 1.37% p.a.	-	-	-	32,451
Direct loans - Law 4,131	100.00% of CDI + 1.42% p.a.	-	-	-	41,055
Direct loans - Law 4,131	100.00% of CDI + 1.45% p.a.	-	-	-	53,398
Direct loans - Law 4,131	100.00% of CDI + 2.61% p.a.	-	310,930	-	310,930
Direct loans - Law 4,131	100.00% of CDI + 1.35% p.a.	-	-	50,713	-
Other	100.00% of CDI + 2.00% p.a.	-	-	38,869	-
Total borrowings		**-**	**310,930**	**89,582**	**538,324**
Total		**3,204,348**	**2,903,309**	**3,293,930**	**3,130,703**
Current liabilities		547,528	377,207	637,110	604,601
Non-current liabilities		2,656,820	2,526,102	2,656,820	2,526,102

Voltar

(All amounts in thousands of reais unless otherwise stated)

The amounts above have the following payment flow forecast:

	Parent Company		Consolidated	
Payment forecast	**Dec/24**	**Dec/23**	**Dec/24**	**Dec/23**
2024	-	377,207	-	604,601
2025	547,528	467,805	637,110	467,805
2026	394,060	394,337	394,060	394,337
2027 and thereafter	2,262,760	1,663,960	2,262,760	1,663,960
Total	**3,204,348**	**2,903,309**	**3,293,930**	**3,130,703**

(b) Characteristics of the debentures

Debentures

Type of issue	Issue amount	Quantity outstanding	Issue	Maturity	Annual charges	Unit price
3rd issue – Single Series	R$ 250,000	250,000	3/15/2019	Mar/2026	98.50% of CDI	R$ 1
4th issue – Single Series	R$ 300,000	300,000	6/17/2019	Jun/2027	106.99% of CDI	R$ 1
5th issue – Single Series	R$ 500,000	500,000	1/25/2022	Jan/2029	100% of CDI + 1.49% p.a.	R$ 1
6th issue – Single Series	R$ 250,000	250,000	3/07/2022	Mar/2027	100% of CDI + 0.70% p.a.	R$ 1
7th issue – Single Series	R$ 550,000	550,000	6/26/2022	Jun/2029	100% of CDI + 0.75% p.a.	R$ 1
8thissue - 1st series	R$ 350,000	350,000	9/15/2023	Sept/2025	100% of CDI + 0.30% p.a.	R$ 1
8th issue - 2nd series	R$ 150,000	150,000	9/15/2023	Sept/2027	100% of CDI + 0.65% p.a.	R$ 1
8thissue - 3rd series	R$ 200,000	200,000	9/15/2023	Sept/2030	100% of CDI + 1.10% p.a.	R$ 1
9th issue – Single Series	R$ 600,000	600,000	4/22/2024	Apr/2031	100% of CDI + 0.65% p.a.	R$ 1

(*) Weighted average rate of series.

On February 1, 2019, the Company approved, through the Extraordinary Meeting of the Board of Directors, the 3rd issue of non-convertible, simple unsecured debentures, in a single series, in the total amount of R$ 250,000, with remuneration of 98.5% of CDI and payment term of seven years. Interest payments will be semi-annual, and principal will be amortized in two equal annual and consecutive installments, the last installment to be paid on March 13, 2026. The funds raised are being used for the construction, expansion, development and renovation of certain properties indicated by the Company. This operation is linked to the real estate receivables certificates issued by Vert Companhia Securitizadora, which were issued with guarantee in the "CRI" debentures, object of a public offering for distribution under CVM Instruction 400.

On June 17, 2019, the Company carried out the 4th issue of non-convertible, simple unsecured debentures in a single series for public distribution with restricted efforts (CVM 476), with settlement on July 12, 2019, in the amount of R$ 300,000, with remuneration of 106.99% of CDI and payment term of eight years. Interest payments will be semi-annual, and principal will be amortized in two equal annual and consecutive installments, the last installment to be paid on June 17, 2027. The funds were used to improve the working capital.

On January 25, 2022, the Company carried out the 5th issue of non-convertible, simple unsecured debentures in a single series for public distribution with restricted efforts (CVM 476), with settlement on February 16, 2022, in the amount of R$ 500,000, with remuneration of 100% of CDI, plus a surcharge of 1.49% per year, and payment term of seven years. Interest payments will be semi-annual, and principal will be amortized in two equal annual and consecutive installments, the last installment to be paid on January 25, 2029. The funds will be used to improve the working capital.

On March 7, 2022, the Company carried out the 6th issue of non-convertible, simple unsecured debentures in a single series for public distribution with restricted efforts (CVM 476), with settlement on March 17, 2022, in the amount of R$ 250,000, with remuneration of 100% of CDI, plus a surcharge of 0.70% per year, and payment term of five years. Interest payments will be semi-annual, and principal will be amortized in two equal annual and consecutive installments, the last installment to be paid on March 8, 2027. The funds raised will be used for the construction, expansion, development and renovation of certain properties indicated by the Company. This operation is linked to the real estate receivables certificates, which were issued with guarantee in the "CRI" debentures, object of a public offering for distribution under CVM Instruction 476.

On June 26, 2022, the Company carried out the 7th issue of non-convertible, simple unsecured debentures in a single series for public distribution with restricted efforts (CVM 476), with settlement on June 29, 2022, in the amount of R$ 550,000, with remuneration of 100% of the cumulative variation of the average daily rates of the DI, plus a surcharge of 0.75% per year and payment term of five years. Interest payments will be semi-annual, and principal will be amortized in two equal annual and consecutive installments, the last installment to be paid on June 25, 2029. The funds raised will be used for the construction, expansion, development and renovation of certain properties indicated by the Company. This operation is linked to the real estate receivables certificates, which were issued with guarantee in the "CRI" debentures, object of a public offering for distribution under CVM Instruction 476.

On September 15, 2023, the Company carried out the 8th issue of non-convertible, simple unsecured debentures, in three series, for public distribution with firm placement guarantee, pursuant to CVM Resolutions 160 and 60, as well as other applicable legal and regulatory provisions, with settlement on September 15, 2023, in the amounts of R$ 350,000 for the 1st series, R$ 150,000 for the 2nd series and R$ 200,000 for the 3rd series, with remuneration of 100% of the cumulative variation of the average daily rates of the DI, plus a surcharge of 0.30% p.a. for the 1st series, 0.65% p.a. for the 2nd series, and 1.10% p.a. for the 3rd series, with payment term of two, four and seven years, respectively. Interest payments will be semi-annual, and principal will be amortized for the 1st series on September 11, 2025, for the 2nd series on September 13, 2027, and for the 3rd series in two equal annual and consecutive installments, the last installment to be paid on September 12, 2030. The funds raised were used for real estate costs and expenses referring to the payment of rentals of certain properties indicated by the Company. This operation is linked to the real estate receivables certificates, which were issued with guarantee in the "CRI" debentures, object of a public offering for distribution under CVM Resolutions 160 and 60.

On April 22, 2024, the Company carried out the 9th issue of non-convertible, simple unsecured debentures in a single series for public distribution with restricted efforts (CVM 160), with settlement on May 3, 2024, in the amount of R$ 600,000, with remuneration of 100% of the cumulative variation of the average daily rates of the DI, plus a surcharge of 0.65% per year, and payment term of seven years. Interest payments will be semi-annual, and principal will be amortized in two equal annual and consecutive installments, the last installment to be paid on April 22, 2031. The funds were used to strengthen cash.

The costs incurred on the issues of the Company's debentures (2019 - 3rd and 4th issues, 2022 - 5th, 6th and 7th issues, 2023 - 8th, and 2024 - 9th issue), including fees, commissions and other costs are classified in the line item of the respective debentures, and will be recognized over the total period of the debt. At December 31, 2024, the amount to be recognized was R$ 26,025 (R$ 31,709 – Dec/2023), and is presented net in debentures balance.

The Company's debentures are conditioned to the compliance with the following covenants:

(i) Net Debt / EBTIDA: cannot exceed 3 times.
The calculation of net debt, the basis for determining the covenants calculation of Company's debentures, considers the balances of borrowings. As described in Note 25 (e), the lease obligations are being presented in a separate line item in the financial statements, and therefore, are not included in the net debt calculation.

Covenants are measured quarterly. The non-compliance with the covenants for two consecutive quarters can be considered as a default event and consequently result in early maturity.

The Group monitors clauses subject to compliance with financial and non-financial covenants, in order to ensure that they are being complied with. At December 31, 2024, the Company was in compliance with these covenants.

(c) Characteristics of borrowings

On March 26, 2021, the Company carried out loan operation – 4131, in the amount of R$ 300,000, with remuneration of 100% of the cumulative variation of the average daily rates of the CDI, plus a surcharge of 2.61% per year and payment term of three years. Interest payments were semi-annual and amortization of principal was carried out on the maturity date in March 2024. The funds were used to improve the working capital.

The transaction costs incurred in loan operation – 4131 are 0.30% referring to the amount of R$ 300,000, with a term of three years, including fees, commissions and other costs, and are classified in the line item of the respective borrowings, and will be recognized over the total period of the debt. At December 31, 2024, the amount to be recognized was R$ 0 (R$ 50 - Dec/23), and is presented net in the borrowings balance.

(d) Characteristics of borrowings - Subsidiaries

On June 7, 2023, the subsidiary 4Bio carried out loan operation Swap – 4131, in the amount of R$ 53,000, with remuneration of 100% of the cumulative variation of the average daily rates of the CDI, plus a surcharge of 1.45% per year and payment term of one year. Interest payments were quarterly and the principal was settled on the maturity date, in June 2024.

On July 14, 2023, the subsidiary 4Bio carried out loan operation Swap – 4131, in the amount of R$ 40,000, with remuneration of 100% of the cumulative variation of the average daily rates of the CDI, plus a surcharge of 1.42% per year and payment term of one year. Interest payments were quarterly and the principal was settled on the maturity date, in June 2024.

On September 14, 2023, the subsidiary 4Bio carried out loan operation – 4131, in the amount of R$ 100,000, with remuneration of 100% of the cumulative variation of the average daily rates of the CDI, plus a surcharge of 1.30% per year and payment term of one year. Interest payments were quarterly and the principal was settled on the maturity date, in September 2024.

On November 20, 2023, the subsidiary 4Bio carried out loan operation – 4131, in the amount of R$ 32,000, with remuneration of 100% of the cumulative variation of the average daily rates of the CDI, plus a surcharge of 1.37% per year and payment term of one year. Interest payments were quarterly and the principal was settled on the maturity date, in November 2024.

On February 15, 2024, the subsidiary 4Bio carried out loan operation Swap – 4131, in the amount of R$ 50,000, with remuneration of 100% of the cumulative variation of the average daily rates of the CDI, plus a surcharge of 1.35% per year and payment term of one year. Interest payments will be quarterly, and amortization of principal will be carried out on the maturity date. The funds were used to improve the working capital.

(All amounts in thousands of reais unless otherwise stated)

(e) Reconciliation of net debt

The analysis of and the changes in net debt are presented below:

	Parent Company		Consolidated	
Composition and changes in net debt	**Dec/24**	**Dec/23**	**Dec/24**	**Dec/23**
Short-term borrowings	547,528	377,208	637,110	604,601
Long-term borrowings	2,656,820	2,526,102	2,656,820	2,526,102
Total debt	**3,204,348**	**2,903,310**	**3,293,930**	**3,130,703**
(-) Cash and cash equivalents (Note 5)	(460,292)	(318,002)	(528,002)	(412,321)
Net debt	**2,744,056**	**2,585,308**	**2,765,928**	**2,718,382**

	Parent Company		
Changes in net debt	**Borrowings**	**Cash and cash equivalents**	**Net debt**
Net debt at January 1, 2023	2,239,606	(364,374)	1,875,232
Funding	686,567	-	686,567
Accrued interest	322,895	-	322,895
Payment of interest	(306,581)	-	(306,581)
Amortization of principal	(44,480)	-	(44,480)
Amortization of transaction costs	5,302	-	5,302
Decrease in cash and cash equivalents	-	46,372	46,372
Net debt at December 31, 2023	**2,903,309**	**(318,002)**	**2,585,307**
Funding	600,000	-	600,000
Accrued interest	344,501	-	344,501
Payment of interest	(349,196)	-	(349,196)
Amortization of principal	(300,000)	-	(300,000)
Transaction cost – net	5,734	-	5,734
Increase in cash and cash equivalents	-	(142,290)	(142,290)
Net debt at December 31, 2024	**3,204,348**	**(460,292)**	**2,744,056**

	Consolidated		
Changes in net debt	**Borrowings**	**Cash and cash equivalents**	**Net debt**
Net debt at January 1, 2023	2,317,905	(433,541)	1,884,364
Funding	1,058,865	-	1,058,865
Accrued interest	347,217	-	347,217
Payment of interest	(328,894)	-	(328,894)
Amortization of principal	(269,691)	-	(269,691)
Amortization of transaction costs	5,302	-	5,302
Increase in cash and cash equivalents	-	21,220	21,220
Net debt at December 31, 2023	**3,130,704**	**(412,321)**	**2,718,383**
Funding	688,869	-	688,869
Accrued interest	360,629	-	360,629
Charges on borrowings	6,238	-	6,238
Payment of interest	(373,244)	-	(373,244)
Amortization of principal	(525,000)	-	(525,000)
Transaction cost – net	5,734	-	5,734
Increase in cash and cash equivalents	-	(115,681)	(115,681)
Net debt at December 31, 2024	**3,293,930**	**(528,002)**	**2,765,928**

16. Leases

16.1. Accounting policy

On adoption of NBC TG 06 (R3) / IFRS 16 - Leases: the Group recognized lease liabilities involving leases that had already been classified as "operating leases" according to the principles of IAS 17 - Leases. These liabilities were measured at the present value of the remaining lease payments, discounted using the lessee's incremental borrowing rate on January 1, 2019.

For leases previously classified as finance leases, the Group recognized the carrying amount of the lease asset and liability immediately before the transition to the carrying amount of the right-of-use asset and lease liability on the date of initial application. The measurement principles of NBC TG 06 (R3) / IFRS 16 apply only after this date. The remeasurements of the lease liabilities were recognized as adjustments to the respective right-of-use assets immediately after the date of initial application.

The Group is qualified as a lessee after evaluating whether a contract is, or contains, a lease, according to the following assumptions:

(i) The lessor cannot have a substantive right to replace the asset with an alternative asset during the lease term;
(ii) The Group has substantially all the economic benefits of a contract's assets if it benefits from most of the benefits from the main product, by-product and other benefits that the asset may generate; and
(iii) The Group has the right to direct the use of the asset, managing how and for what purposes it will be used during the period of use or when these decisions are predetermined in the contract and the Group will operate the asset during the entire period of the contract, without the lessor having the right to amend these operating instructions.

The Group leases physical stores, distribution centers and real estate properties for its office space, vehicles and equipment. Operating real estate and distribution/administrative center leases have term of 5 to 20 years, residential real estate leases have term of 2.5 years, and lease agreements for vehicles have term of 3 years.

Since January 1, 2019, the Company has recognized lease agreements in its balance sheet as required by NBC TG 06 (R3) / IFRS 16 as right-of-use assets and lease liabilities. In compliance with CVM guidelines contained in CVM Circular Letter 2/2019, the Company adopts, since the year ended December 31, 2019, the use of the Nominal Discount Rate for lease agreements, disregarding the Real Rate applied at the beginning of effectiveness of that standard.

Information on the Group's leases are presented below.

(All amounts in thousands of reais unless otherwise stated)

As a lessee

Right-of-use assets

Breakdown of Parent Company and Consolidated right-of-use assets:

	Parent Company		Consolidated	
Right-of-use assets	**Dec/24**	**Dec/23**	**Dec/24**	**Dec/23**
Operating real estate	3,418,181	3,094,861	3,419,464	3,094,950
Residential real estate	27,357	18,889	27,622	19,514
Distribution centers and administrative properties	429,704	355,947	433,565	359,303
Vehicles	6,325	10,232	6,326	10,233
Total	**3,881,567**	**3,479,929**	**3,886,977**	**3,484,000**

The changes in the Parent Company and Consolidated right-of-use assets are presented below:

	Parent Company				
	Operating real estate	**Residential real estate**	**Distribution/ administrative centers**	**Vehicles**	**Total**
At 1/1/2023	**2,963,118**	**18,024**	**391,396**	**2,241**	**3,374,779**
New agreements	415,217	11,598	2,480	9,157	438,452
Remeasurements (i)	516,772	(5,111)	67,312	(564)	578,409
Termination of agreements	(3,509)	(776)	-	-	(4,285)
Depreciation	(796,737)	(4,846)	(105,241)	(602)	(907,426)
At 12/31/2023	**3,094,861**	**18,889**	**355,947**	**10,232**	**3,479,929**
New agreements	563,072	15,158	129,568	390	708,188
Remeasurements (i)	609,352	(1,628)	40,083	(1,533)	646,274
Termination of agreements	(15,312)	(2)	-	-	(15,314)
Depreciation	(833,792)	(5,060)	(95,894)	(2,764)	(937,510)
At 12/31/2024	**3,418,181**	**27,357**	**429,704**	**6,325**	**3,881,567**

	Consolidated				
	Operating real estate	**Residential real estate**	**Distribution/ administrative centers**	**Vehicles**	**Total**
At 1/1/2023	**2,963,409**	**18,688**	**394,113**	**2,242**	**3,378,452**
New agreements	415,217	11,598	2,481	9,156	438,452
Remeasurements (i)	516,761	(5,060)	69,850	(564)	580,987
Termination of agreements	(3,509)	(776)	-	-	(4,285)
Depreciation	(796,928)	(4,936)	(107,140)	(602)	(909,606)
At 12/31/2023	**3,094,950**	**19,514**	**359,304**	**10,232**	**3,484,000**
New agreements	564,355	15,158	130,969	390	710,872
Remeasurements (i)	609,352	(1,628)	41,859	(1,532)	648,051
Termination of agreements	(15,312)	(322)	(644)	-	(16,278)
Depreciation	(833,881)	(5,100)	(97,923)	(2,764)	(939,668)
At 12/31/2024	**3,419,464**	**27,622**	**433,565**	**6,326**	**3,886,977**

(i) The Company remeasures the right-of-use assets in order to reflect changes in future payments; changes in terms initially determined for the implementation of NBC TG 06 (R3) / IFRS 16 - Leases and contracts recognized as operating leases (NBC TG 06 (R3) / IAS 17 - Leases), initially determined as short-term contracts.

(All amounts in thousands of reais unless otherwise stated)

Lease liabilities

The changes in the Parent Company and Consolidated lease liabilities are as follows:

	Parent Company		Consolidated	
Leases	**Dec/24**	**Dec/23**	**Dec/24**	**Dec/23**
Operating real estate	3,832,931	3,486,567	3,834,212	3,486,663
Residential real estate	(22,315)	17,004	(21,794)	17,580
Distribution centers and administrative properties	610,271	418,723	614,013	422,231
Vehicles	(1,894)	10,287	(1,894)	10,287
Total	**4,418,993**	**3,932,581**	**4,424,537**	**3,936,761**

The changes in the Parent Company and Consolidated lease liabilities are as follows:

	Parent Company				
	Operating real estate	Residential real estate	Distribution/administrative centers	Vehicles	Total
At 1/1/2023	**3,258,706**	**(8,442)**	**487,897**	**(1,938)**	**3,736,223**
New agreements	415,217	11,598	2,480	9,157	438,452
Remeasurements (i)	516,772	(5,111)	67,312	(564)	578,409
Termination of agreements	(7,643)	(24)	-	18	(7,649)
Interest	300,199	2,416	30,310	1,046	333,971
Payments / compensations	(1,047,278)	(20,238)	(75,586)	(3,724)	(1,146,826)
At 12/31/2023	**3,486,567**	**17,004**	**418,723**	**10,287**	**3,932,581**
New agreements	562,992	15,264	129,568	390	708,214
Remeasurements (i)	609,353	(1,629)	40,082	(1,559)	646,247
Termination of agreements	(12,072)	65	(127)	(335)	(12,469)
Interest	367,106	3,670	27,940	1,365	400,081
Payments / compensations	(1,130,422)	(19,884)	(99,606)	(5,749)	(1,255,661)
At 12/31/2024	**3,883,524**	**14,490**	**516,580**	**4,399**	**4,418,993**

	Consolidated				
	Operating real estate	Residential real estate	Distribution/administrative centers	Vehicles	Total
At 1/1/2023	**3,258,976**	**(7,827)**	**490,797**	**(1,938)**	**3,740,008**
New agreements	415,217	11,598	2,480	9,157	438,452
Remeasurements (i)	516,772	(5,060)	69,850	(564)	580,998
Termination of agreements	(7,643)	(24)	-	18	(7,649)
Interest	300,199	2,427	30,507	1,046	334,179
Payments / compensations	(1,047,451)	(20,339)	(77,713)	(3,724)	(1,149,227)
At 12/31/2023	**3,436,070**	**(19,225)**	**515,921**	**3,995**	**3,936,761**
New agreements	564,275	15,264	130,975	390	710,904
Remeasurements (i)	609,353	(1,629)	41,858	(1,559)	648,023
Termination of agreements	(12,072)	65	(127)	(335)	(12,469)
Interest	367,110	3,676	28,210	1,365	400,361
Payments / compensations	(1,130,524)	(19,945)	(102,824)	(5,750)	(1,259,043)
At 12/31/2024	**3,834,212**	**(21,794)**	**614,013**	**(1,894)**	**4,424,537**

(i) The Company remeasures the lease liabilities in order to reflect changes in future payments; changes in terms initially determined for the implementation of NBC TG 06 (R3) / IFRS 16 - Leases and contracts recognized as operating leases (NBC TG 06 (R3) / IAS 17 - Leases).

The maturities of lease liabilities are classified according to the following schedule:

	Parent Company		Consolidated	
Analysis of maturities - Lease liabilities	**Dec/24**	**Dec/23**	**Dec/24**	**Dec/23**
Less than 1 year	949,350	856,427	951,044	858,467
Current	**949,350**	**856,427**	**951,044**	**858,467**
1 to 5 years	2,659,185	2,453,166	2,663,035	2,455,306
Over 5 years	810,458	622,988	810,458	622,988
Non-current	**3,469,643**	**3,076,154**	**3,473,493**	**3,078,294**
Total	**4,418,993**	**3,932,581**	**4,424,537**	**3,936,761**

(All amounts in thousands of reais unless otherwise stated)

Future payments to be made to the lessor may give the Group the right to be credited with PIS and COFINS. Therefore, the recorded amount of the right-of-use asset against the lease liability already includes potential future credit.

The potential right to PIS and COFINS recoverable embedded in future lease payments is presented below:

Future considerations	Parent Company / Consolidated	Potential PIS / COFINS (9.25%)
Less than 1 year	773,544	71,553
1 to 2 years	683,026	63,180
2 to 3 years	553,031	51,155
3 to 4 years	419,532	38,807
4 to 5 years	308,961	28,579
Over 5 years	748,558	69,241
Total	**3,486,652**	**322,515**

The right to use PIS and COFINS credits comprises only contracts whose lessor is a legal entity. The Company has lease contracts for both lessors, corporate and individual.

In compliance with CVM Circular Letter 02/2019 and NBC TG 06 (R3) / IFRS 16, justified by the fact that the Group has not applied the methodology of nominal flows due to the prohibition imposed by NBC TG 06 (R3) of future inflation projection and in order to provide additional information to the users of the Group's financial statements, the analysis of contract maturities and installments not yet discounted at December 31, 2024 is presented below:

	Parent Company			Consolidated		
Year	Amounts of installments not yet discounted	Estimated interest (future) (i)	Net present value	Amounts of installments not yet discounted	Estimated interest (future) (i)	Net present value
2025	1,303,887	(349,035)	954,852	1,305,581	(349,035)	956,546
2026	1,109,073	(279,618)	829,455	1,109,073	(279,618)	829,455
2027	889,186	(219,039)	670,147	889,186	(219,039)	670,147
2028	693,230	(168,720)	524,510	697,079	(168,720)	528,359
2029	527,581	(127,636)	399,945	527,581	(127,636)	399,945
2030 and thereafter	1,289,991	(249,907)	1,040,084	1,289,992	(249,907)	1,040,085
Total	**5,812,948**	**(1,393,955)**	**4,418,993**	**5,818,492**	**(1,393,955)**	**4,424,537**

(i) The present value of the leases payable was calculated considering the projection of future fixed payments, discounted at the rate of 11.21% p.a. (13.73% p.a. – Dec/23), which was built from the basic interest rate released by the Central Bank of Brazil (BACEN).

Amount recognized in the statement of income

	Parent Company		Consolidated	
Amount recognized in the statement of income	Dec/24	Dec/23	Dec/24	Dec/23
Amortization of right-of-use assets	937,510	907,426	935,352	905,246
Interest on lease liabilities	400,081	330,574	400,361	330,782
Adjustment for lease write-off (contracts terminated)	(13,180)	(1,023)	(13,180)	(1,023)
Variable payments not included in the measurement of lease liabilities	50,826	36,334	51,123	36,893
Revenue on subleases of right-of-use assets	3,937	2,815	3,937	2,815
Expenses related to short-term and/or low-value leases	30,585	14,986	30,585	14,986
Discounts on property rental	-	(73)	-	(73)

(All amounts in thousands of reais unless otherwise stated)

(i) Payment of variable leases based on sales

Some operating real estate leases contain variable lease payments based on a percentage of 2% to 12% of the sales made during the period in the leased operating real estate. These payment conditions are common for stores in the country where the Group operates. Variable lease payments for the year ended December 31, 2024 amounted to R$ 5,386 (R$ 3,292 in Dec/23) for Parent Company and Consolidated accounts.

(ii) Leases fitting into exceptions and practical expedients

The lease agreements identified and that fall within the scope of exemption mainly refer to lease of printers, forklifts, scales, power generators, electron aligners and photovoltaic plates.

The Group also leases equipment with contracts of up to one year. These leases are short-term and/or low-value leases. The Group opted not to recognize the right-of-use assets and the lease liabilities of such items.

As a lessor

The Group subleases some of the properties to third parties. The Group has classified these leases as operating leases because they do not transfer substantially all the risks and rewards of ownership of assets.

The table below presents an analysis of maturities of lease payments, showing undiscounted lease payments to be received after the reporting date:

	Parent Company and Consolidated	
Undiscounted lease payments	**Dec/24**	**Dec/23**
Less than 1 year	1,944	2,100
1 to 2 years	1,317	1,463
2 to 3 years	1,015	889
3 to 4 years	703	775
4 to 5 years	550	441
Over 5 years	596	987
Total	**6,125**	**6,655**

(All amounts in thousands of reais unless otherwise stated)

17. Provision for contingencies and judicial deposits

17.1. Accounting policy

Provision

Provisions are recognized when the Group has a present legal or constructive obligation as a result of past events and is probable that a transfer of economic benefits will be required to settle the obligation; and the amount can be reliably estimated. Provision for legal proceedings is recorded reflecting the best estimates of the risk involved, in amounts deemed sufficient to cover probable losses. The proceedings rated as involving possible losses are disclosed in explanatory notes and those rated as remote losses are not provisioned or disclosed.

The Company and its subsidiaries are subject to legal claims (tax, civil and labor) arising in the normal course of business. Management, supported by the opinion of its legal advisors and, where applicable, by specific opinions issued by experts, assesses the probable final outcomes of ongoing litigation and determines whether or not setting up of provision for contingencies is necessary. In the case of labor contingencies, the evolution of the lawsuits and the history of losses are determining factors to reflect the best estimate.

Judicial deposits

The Company makes judicial deposits to guarantee the enforcement of judicial decisions, as required by the courts and/or made due to Management's strategic decision to protect its cash. In the cases in which the provision has a corresponding judicial deposit and the Company has the intention to settle the liability and realize the asset simultaneously, the amounts are offset. Judicial deposits are monetarily adjusted on the total amount, the gains or losses are recognized in the Company's statement of income when the lawsuit is settled.

17.2. Breakdown of balances and changes in provisions

At December 31, 2024, the Group had the following provisions and corresponding judicial deposits relating to legal proceedings:

	Parent Company		Consolidated	
Judicial deposit items	**Dec/24**	**Dec/23**	**Dec/24**	**Dec/23**
Labor and social security	123,559	105,146	123,559	105,146
Tax [(i)]	26,874	49,606	222,253	205,285
Civil	18,076	11,994	18,076	12,014
Subtotal	**168,509**	**166,746**	**363,888**	**322,445**
(-) Corresponding judicial deposits	-	(8,987)	-	(8,987)
Total	**168,509**	**157,759**	**363,888**	**313,458**
Current liabilities	81,829	57,224	81,829	57,224
Non-current liabilities	86,680	100,535	282,059	256,234

(i) One of the Company's subsidiaries is a party to lawsuits challenging the payment of the differences in ICMS rates in certain states, recording judicial deposits for the amounts in dispute. In this context, up to the first quarter of 2022, the subsidiary adopted the practice of recording a provision for the judicial deposits. Considering the lawsuits with final and unappealable decisions favorable to the subsidiary, occurred during the first quarter of 2022, and the withdrawal of the deposits, it was decided, after the assessment of the external advisors, that the provision for the deposited amounts would be reversed in March 2022. After the decision of the Federal Supreme Court (STF) on November 29, 2023, the subsidiary started to record a provision referring to the lawsuits challenging the payment of the ICMS- DIFAL in certain states, considering the judicial deposits made between April 2022 and December 2023.

(All amounts in thousands of reais unless otherwise stated)

Changes in the provision are as follows:

Changes in the contingencies	Parent Company	Consolidated
At January 1, 2023	**116,125**	**116,282**
Additions of new lawsuits and review of estimate	123,312	278,697
Write-offs for payments	(62,419)	(62,419)
Constitution/(Reversals) due to changes in lawsuits	(19,182)	(19,182)
Monetary adjustment	8,910	9,067
At December 31, 2023	**166,746**	**322,445**
Additions of new lawsuits and review of estimate	125,630	130,456
Write-offs for payments	(82,906)	(82,906)
Constitution/(Reversals) due to changes in lawsuits	(50,755)	(51,507)
Monetary adjustment	9,794	20,317
At December 31, 2024	**168,509**	**338,805**

The provision for legal claims took into consideration the best estimate of the amounts involved, for the cases in which the likelihood of loss is estimated as probable, remaining a portion of these claims guaranteed by pledged assets.

Possible losses

At December 31, 2024 and 2023, the Group has tax lawsuits related to fines applied by the relevant administrative authorities, tax rate difference in interstate transfers and tax enforcements, as well as civil lawsuits due to indemnity claims for losses and pain and suffering arising from consumer relations, and sundry labor claims, involving possible loss as assessed by Management and its legal advisors in the amount of R$ 361,707 for the Parent Company and R$ 578,498 for the Consolidated (R$ 160,164 and R$ 375,681, respectively, in Dec/2023), of which R$ 326,845 for the Parent Company and R$ 543,636 for the Consolidated refer to tax lawsuits (R$ 137,133 for the Parent Company and R$ 375,681 for the Consolidated – Dec/2023), the total of R$ 16,912 refers to labor claims for the Parent Company and Consolidated (R$ 10,653 – Dec/2023) and the amount of R$ 17,950 for both the Parent Company and Consolidated corresponds to civil lawsuits (R$ 12,398 – Dec/2023).

Judicial deposits

At December 31, 2024, the Group had the following judicial deposit amounts, for which no corresponding provision had been set up:

	Parent Company		Consolidated	
Analysis of judicial deposits	**Dec/24**	**Dec/23**	**Dec/24**	**Dec/23**
Labor and social security	5,922	2,846	6,045	2,846
Tax	19,015	12,312	242,038	221,575
Civil	5,698	4,025	5,698	4,025
Total	**30,635**	**19,183**	**253,781**	**228,446**

Labor contingencies

Most labor claims relate to lawsuits filed by former employees questioning the payment of unpaid overtime and health hazard premium. The Group is also involved in proceedings arising from Raia S.A., as well as from Drogaria Onofre Ltda., which were filed by former employees of service providers claiming to have employment relationships directly with the Group, or in which the Group received a joint enforcement order for the payment of the labor rights claimed. There are also proceedings filed by professional unions for the payment of union dues, under the dispute regarding the legitimacy of the territorial base.

Tax contingencies

These represent administrative fines, tax rate differences on interstate transfers and tax collection proceedings.

Civil contingencies

The Group is a defendant in lawsuits regarding usual and unique matters arising in the course of its business, most of which seek indemnification for property damage and pain and suffering from consumption relations.

Guarantees for lawsuits

The items of fixed assets were given as guarantees for tax, social security and labor proceedings:

	Parent Company / Consolidated	
Guarantees for lawsuits	**Dec/24**	**Dec/23**
Furniture and facilities	-	2
Machinery and equipment	85	85
Total guarantees for lawsuits	**85**	**87**

18.Income tax and social contribution

18.1. Accounting policy

Current and deferred income tax and social contribution are calculated according to the criteria set forth by tax legislation currently in effect, at the statutory rates of 25% and 9%, respectively.

The provision for income tax and social contribution is based on the taxable profit for the year, which differs from profit as reported in the statement of income because it is subject to adjustments that permanently affect the calculation base, such as the exclusion of non-taxable revenues and addition of non-deductible expenses.

Deferred income tax and social contribution are recognized on the projections of future results prepared and based on internal assumptions and future economic scenarios, which will be taxed in periods subsequent to the recognition in the Company's statement of income and, therefore, may be subject to changes. This assumption includes balances of income tax and social contribution losses, when applicable.

The carrying amount of deferred tax assets is reviewed at each balance sheet date and adjusted in case the study indicates the expectation of its realization has changed.

Deferred taxes are recognized based on the transaction that triggered it, in the statement of income or directly in equity.

(All amounts in thousands of reais unless otherwise stated)

18.2. Breakdown of current income tax and social contribution and effective rate

	Parent Company		Consolidated	
Income tax and social contribution paid items	**Dec/24**	**Dec/23**	**Dec/24**	**Dec/23**
Profit before income tax and social contribution	1,468,902	1,226,020	1,418,994	1,216,693
Interest on capital and additional interest on capital proposed	(389,500)	(360,200)	(389,500)	(360,200)
Taxable profit	**1,079,402**	**865,820**	**1,029,494**	**856,493**
Combined tax rate (25% for income tax and 9% for social contribution)	34,00%	34,00%	34,00%	34,00%
Theoretical tax expense	**(366,997)**	**(294,379)**	**(350,028)**	**(291,208)**
Permanent additions	(14,182)	(16,467)	6,188	(32,159)
Equity in the results of subsidiaries	23,066	3,705	1,113	(2,031)
Investment grant	-	100,113	-	141,394
Income tax and social contribution losses	-	-	-	21,241
Provisions with no deferred charges	(749)	-	(749)	-
Tax Incentives – Technological Innovation (i)	74,713	14,604	74,713	14,604
Tax Incentives – Other Incentives	26,560	19,459	26,560	19,733
Other (revaluation reserve + income tax surcharge exemption limit)	(11,449)	1,918	34,582	(1,124)
Result of current income tax and social contribution	**(306,117)**	**(291,481)**	**(328,232)**	**(314,521)**
Result of deferred income tax and social contribution	**37,079**	**120,434**	**120,611**	**184,971**
Income tax and social contribution expense	**(269,038)**	**(171,047)**	**(207,621)**	**(129,550)**
Effective tax rate	**18.32%**	**13.95%**	**14.63%**	**10.65%**

(i) The amount of R$74,713 refers to the tax incentive of "*Lei do Bem*", of which R$17,040 corresponds to 2023.

18.3. Deferred income tax and social contribution are comprised as follows:

Deferred income tax and social contribution assets amounting to R$ 444,111 in Dec/24 (R$ 401,942 – Dec/23) for the Parent Company and R$ 602,154 in Dec/24 (R$ 476,645 – Dec/23) for the Consolidated accounts arose from temporarily non-deductible expenses that may be carried forward indefinitely, with estimated realization as disclosed in item (c) below.

Deferred income tax and social contribution liabilities amounting to R$ 302,834 in Dec/24 (R$ 297,808 – Dec/23) for the Parent Company and R$ 303,749 in Dec/24 (R$ 298,915 – Dec/23) for the Consolidated accounts relate to tax charges on the remaining balances of: (i) the revaluation reserve; (ii) PPA (Purchase Price Allocation); and (iii) gain on bargain purchase.

(All amounts in thousands of reais unless otherwise stated)

In the years ended December 31, 2024 and 2023, deferred income and social contribution were as follows:

	Balance sheet				Statement of income			
	Parent Company		Consolidated		Parent Company		Consolidated	
Temporary differences	**Dec/24**	**Dec/23**	**Dec/24**	**Dec/23**	**Dec/24**	**Dec/23**	**Dec/24**	**Dec/23**
Revaluation at fair value of land and buildings	(6,493)	(6,558)	(7,408)	(7,665)	-	-	-	-
Amortization of the goodwill on future profitability	(243,007)	(238,263)	(243,007)	(238,263)	4,744	17,930	4,744	17,930
Non-deductible intangible assets	(53,334)	(37,909)	(53,334)	(37,909)	15,425	(21,359)	15,425	(21,359)
Gain on bargain purchase – acquisition of Onofre	-	(15,078)	-	(15,078)	(15,078)	(22,617)	(15,078)	(22,617)
Tax losses to be offset against future taxable profits	-	-	93,992	14,665	-	-	(79,327)	(14,665)
Adjustment to present value	12,890	(13,690)	13,325	(13,162)	(26,580)	(2,370)	(26,487)	(2,201)
Adjustment to fair value	-	27,149	-	27,149	27,149	(11,385)	27,149	(11,385)
Provision for inventory losses	32,284	26,095	32,284	26,095	(6,189)	(2,483)	(6,189)	(2,483)
Provision for sundry obligations	92,344	85,560	95,384	85,597	(6,784)	(17,447)	(9,787)	(17,266)
Provision for employee profit sharing	38,388	38,325	41,118	41,368	(63)	(2,968)	249	(3,639)
Provision for contingencies	51,541	52,135	106,745	106,067	594	(16,086)	(678)	(64,543)
Expected credit losses	1,430	1,701	7,380	4,374	272	(391)	(3,005)	(1,695)
Lease (depreciation x consideration)	180,305	153,608	177,086	153,433	(26,787)	(33,837)	(23,653)	(33,628)
Other adjustments	34,840	31,059	34,840	31,059	(3,782)	(7,421)	(3,974)	(7,420)
Deferred income tax and social contribution expense	-	-	-	-	**(37,079)**	**(120,434)**	**(120,611)**	**(184,971)**
Deferred tax assets, net	**141,188**	**104,134**	**298,405**	**177,730**				
Deferred tax liabilities, net	**-**	**-**	**-**	**-**				
Reflected in the balance sheet as follows:								
Deferred tax assets	444,112	401,942	602,154	476,645				
Deferred tax liabilities	(302,834)	(297,808)	(303,749)	(298,915)				
Deferred tax assets, net - Parent Company	**141,278**	**104,134**	**141,278**	**104,134**				
Deferred tax liabilities, net	**-**	**-**	**-**	**-**				
Deferred tax assets – Subsidiaries	**-**	**-**	**157,127**	**73,596**				
Reconciliation of deferred tax assets (liabilities), net								
Balance at the beginning of the year	104,134	(16,360)	177,730	(7,303)				
Expense recognized in the statement of income	37,079	120,434	120,611	184,971				
Realization of deferred tax recognized in equity	65	60	64	62				
Balance at the end of the year	**141,278**	**104,134**	**298,405**	**177,730**				

(All amounts in thousands of reais unless otherwise stated)

18.4. Estimated recovery of income tax and social contribution credits

The projections of future taxable profits are based on estimates relating to the Group's performance, the behavior of the market in which the Group operates and certain economic aspects, among other factors. Actual amounts may differ from these estimates. According to projections, the tax credit will be recovered according to the following schedule:

	Parent Company		Consolidated	
Recovery forecast	**Dec/24**	**Dec/23**	**Dec/24**	**Dec/23**
2024	-	251,375	-	296,392
2025	285,074	44,621	362,468	74,112
2026	47,547	47,567	68,596	47,567
2027	59,513	43,305	82,849	43,305
2028	43,026	15,074	67,582	15,269
2029 and thereafter	8,952	-	20,659	-
Total	**444,112**	**401,942**	**602,154**	**476,645**
Deferred tax assets on temporary differences, recorded net in liabilities	444,112	401,942	508,162	461,980
Deferred tax assets on tax losses in subsidiaries	-	-	93,992	14,665

18.5. Uncertainties over the IRPJ and CSLL tax treatment

The Company has four discussions in the administrative stage with the Brazilian Federal Revenue referring to the disallowance for tax amortization of goodwill arising from acquisitions of companies in the amount of R$ 38,758, which, according to internal and external assessment of legal advisors, will probably be accepted in decisions of higher courts (probability of acceptance higher than 50%); for this reason, the Company did not record any IRPJ and CSLL liabilities in connection with these proceedings.

19. Earnings per share

Basic earnings per share are calculated by dividing the profit attributable to equity holders of the Company by the weighted average number of common shares outstanding during the year. Diluted earnings per share are calculated by adjusting the weighted average number of common shares outstanding to assume conversion of all potential common diluted shares.

The following table presents profit and stock information used for calculating basic and diluted earnings per share:

	Parent Company / Consolidated	
Earnings per share items	**Dec/24**	**Dec/23**
Basic		
Profit for the year	1,199,864	1,054,973
Weighted average number of common shares	1,649,227	1,695,194
Basic earnings per share - R$	**0.72753**	**0.62233**
Diluted		
Profit for the year	1,199,864	1,054,973
Weighted average number of common shares adjusted for dilution effect	1,654,988	1,659,712
Diluted earnings per share - R$	**0.72500**	**0.63564**

(All amounts in thousands of reais unless otherwise stated)

20. Equity

(a) Issued capital

At December 31, 2024, the fully paid-up capital amounted to R$ 4,000,000 (R$ 4,000,000 – Dec/23), represented by 1,718,007,200 book-entry registered common shares, with no par value, of which 1,290,335,615 were outstanding common shares (1,278,007,707 common shares – Dec/23).

Pursuant to the Company's bylaws, it is authorized to increase its capital up to the limit of 2,000,000,000 common shares, subject to the approval of the Board of Directors.

At December 31, 2024, the Company's ownership structure was as follows:

	Number of shares		Interest (%)	
Ownership interest	**Dec/24**	**Dec/23**	**Dec/24**	**Dec/23**
Controlling shareholders	421,659,013	436,381,651	24.54	25.40
Shares outstanding	1,290,335,615	1,278,000,707	75.11	74.39
Treasury shares	6,012,572	3,624,842	0.35	0.21
Total	**1,718,007,200**	**1,718,007,200**	**100.00**	**100.00**

The ownership interest of the controlling shareholders is represented by the families Pipponzi, Pires Oliveira Dias and Galvão.

The change in the number of outstanding shares of the Company is as follows:

Changes	**Shares outstanding**
At January 1, 2023	1,209,031,054
(Purchase)/sale of restricted shares, net	68,969,653
At December 31, 2023	**1,278,000,707**
(Purchase)/sale of restricted shares, net	12,334,908
At December 31, 2024	**1,290,335,615**

At December 31, 2024, the Company's common shares were quoted at R$ 22.00 (closing quote) (R$ 29.40 – Dec/23).

(b) Revenue reserves

The legal reserve is set up at 5% of profit for the year, pursuant to Law 6,404/76, until it reaches 20% of the capital. In the year in which the legal reserve balance, plus the capital reserve amount, exceeds 30% of the capital, the allocation of part of the profit for the year to the legal reserve is not required.

The statutory reserve is established in the Company's bylaws, limited to 65% of the profit for the year, to set up the "Statutory Revenue Reserve", which has the purpose and objective of improving the Company's working capital, observing that its balance, except the Contingency Reserve and the Unrealized Revenue Reserve, cannot exceed 100% of the capital. Once this ceiling is reached, the General Meeting shall resolve, in accordance with article 199 of the Brazilian Corporation Law, on the excess, and shall invest it in the payment or increase of capital or in the distribution of dividends.

The tax incentive reserve refers to ICMS tax benefits obtained in the states of Bahia, Goiás and Pernambuco, as regulated by complementary Law 160/17, ICMS CONFAZ 190/17 agreement and amendment to Law 12,973/2014. Set up in accordance with the provisions of article 195-A of the Brazilian Corporate Law (as amended by Law 11,638/07). This reserve receives the portion of government subsidy recognized in profit or loss, as a deduction from sales taxes and allocated to it from the retained earnings account, accordingly, they are not included in the calculation basis of the minimum mandatory dividend. By means of Law 14,789/2023, Article 30 of Law 12,973/2014 was revoked, relieving taxpayers from the requirement to set up a tax incentive reserve as of January 1, 2024.

(All amounts in thousands of reais unless otherwise stated)

(c) Treasury shares

The changes in treasury shares in the year ended December 31, 2024 are summarized below:

	Parent Company	
Changes in treasury shares	**Number of shares**	**Amount of shares**
At January 1, 2023	**4,179,812**	**80,605**
Shares delivered to executives related to the 3rd tranche of the 2019 grant, 2nd tranche of the 2020 grant and 1st tranche of the 2021 grant	(678,189)	(13,078)
Shares delivered to executives related to the 1st tranche of 2021, 2nd tranche of 2020 and 3rd tranche of 2019 of the subsidiaries	(16,198)	(312)
Bonus shares	139,417	-
At December 31, 2023	**3,624,842**	**67,215**
Shares delivered to executives related to the 3rd tranche of the 2020 grant, 2nd tranche of the 2021 grant and 1st tranche of the 2022 grant	(708,801)	(14,858)
Shares delivered to executives related to the 1st tranche of 2022, 2nd tranche of 2021 and 3rd tranche of 2020 of the subsidiaries	(35,150)	(652)
Acquisition of shares issued by the Company	3,131,681	73,286
At December 31, 2024	**6,012,572**	**124,991**

At December 31, 2024, the market value of the treasury shares, having as reference the quotation of R$ 22.00 per share (R$ 29.40 - Dec/23), corresponds to R$ 132,277 (R$ 106,570 - Dec/23).

(d) Shareholders' remuneration

According to the Company's bylaws, shareholders are entitled to minimum dividend corresponding to 25% of the adjusted annual profit, calculated under the terms of the Brazilian Corporate Law.

The distributions of dividends and interest on capital to the Company's shareholders are recognized as a liability in the financial statements at year end. The tax benefit of interest on capital is recognized in the statement of income.

(All amounts in thousands of reais unless otherwise stated)

The dividend proposed, including interest on capital, is calculated as follows:

	Parent Company	
Changes in shareholders' remuneration	**Dec/24**	**Dec/23**
Profit for the year	1,199,864	1,054,973
Legal reserve	(59,993)	(52,749)
Realization of the revaluation reserve in the year	125	142
Investment grant reserve (Note 18b)	-	(294,450)
Dividend calculation basis (a)	**1,139,996**	**707,916**
Minimum mandatory dividends, according to statutory provision (25%)	284,999	176,979
Proposed dividends	210,000	167,300
Interest on capital and additional interest on capital proposed	389,500	360,200
Income tax withheld on interest on capital	**599,500**	(49,923)
	(54,306)	**527.500**
Remuneration net of withheld income tax (b)	**545,194**	477,577
% distributed on the dividend calculation basis (b ÷ a)	47.82%	67.46%
Amount in excess of the mandatory minimum dividend	**260,195**	**300,598**
Early payment of dividends approved at the BDM of 12/15/2023	-	(83,000)
Early payment of dividends approved at the BDM of 04/17/2024	(84,300)	-
Early payment of dividends approved at the BDM of 09/30/2024	(106,000)	-
Balance of dividends payable	**69,895**	**217,598**

The Company recognized interest on capital of R$ 389,500 (R$ 360,200 - 2023), observing both the limit of the Long-Term Interest Rate (TJLP) variation in 2024 and 2023 and the expense deductibility limits for income tax and social contribution calculation, pursuant to Law 9,249/95.

At December 31, 2024, the amount of R$ 260,195 (R$ 300,598 - 2023) in excess of the minimum mandatory dividend established in the Company's bylaws was recorded in equity as proposed additional dividend.

Changes in the dividend and interest on capital obligations were as follows:

	Parent Company	
Changes in dividend and interest on capital obligations	**Dec/24**	**Dec/23**
At January 1, 2023	23,508	62,417
Additions	692,882	497,105
Payment	(474,573)	(535,501)
Unclaimed	(341)	(513)
At December 31, 2024	**241,476**	**23,508**

(e) Restricted share plan

Long-Term Incentive Program

Since March 2014, the Company offers its officers the Long-Term Incentive Program with Restricted Shares (the "Restricted Share Plan"), which aims to offer an opportunity to receive variable compensation provided that the officer remains for a predetermined period in the Company.

The maximum number of shares that may be delivered as a result of the exercise of the Plan is limited to 3% of the Company's Capital during the entire term of the Plan. The reference price per restricted share, for the purpose of determining the target amount that will be granted to each Beneficiary, will be equivalent to the average share price on B3 (weighted by the volume of trades) in the last thirty trading sessions preceding the grant.

(All amounts in thousands of reais unless otherwise stated)

As stated in the Restricted Share Plan, a portion of their annual variable compensation (profit-sharing) will be paid to the officer in cash and the remaining balance shall be paid only in Company shares ("incentive stock").

If the officer decides to use a portion or the total amount of the variable compensation paid in cash to buy Company shares ("own shares") on the stock exchange, the Company will offer the officer an equal number of shares purchased on the stock exchange.

At its discretion, the Company may grant to this officer more Company shares, using as reference the number of own shares acquired by the officer on the stock exchange.

The shares offered to the officer through the Restricted Share Plan may not be sold, assigned or transferred to third parties for a period of four years from the date of the grant. Every year, from the second, third and fourth anniversary of the grant date, the officers will acquire the right to receive a third of their restricted stock. The portion not exercised within the established terms and conditions will be automatically considered extinguished 7 years after the respective grant date.

Performance shares

At a meeting of the Board of Directors on October 22, 2020, the granting of restricted shares was approved under the terms of the Restricted Share Granting Plan - Performance Shares ("Plan"), approved at the Extraordinary General Meeting of the Company held on September 15, 2020.

The purpose of the Plan is: (a) to foster the expansion, success and fulfillment of the corporate purposes of the Company and the companies under its control; (b) to align the interests of Beneficiaries with the interests of shareholders; and (c) to encourage Beneficiaries to stay in the Company or companies under its control. The Plan will be managed by the Board of Directors, and may have an advisory committee created or appointed by the Board of Directors to advise it in this respect. Beneficiaries will be chosen and elected by the Board of Directors at each new grant.

The maximum number of shares that may be delivered as a result of exercising the Plan is limited to 2% of the Company's Capital on the date of approval of the Plan. The reference price per restricted share, for the purpose of determining the target amount that will be granted to each Beneficiary will be equivalent to the average share price on B3 (weighted by the volume of trades) in the ninety trading sessions prior to January 1 of the year in which the grant occurs.

The definitive transfer of the Restricted Shares will be subject to the fulfillment of a four-year grace period from the grant date and, at the end of the grace period, the participant must be linked to the Company so that the grants are not canceled. Restricted Shares that have not yet completed the grace period will become due and will be transferred to the holders, their estate or heirs in the event of death, permanent disability or retirement. The Plan provides that the liquidation must occur through the transfer of shares, however, in the event that the Company does not have treasury shares at the time of liquidation and / or upon inability to acquire shares on the market, the Board of Directors may choose to settle the delivery of the Restricted Shares in cash.

Changes in restricted shares

The changes in restricted shares are summarized below:

	Dec/24		Dec/23	
Changes in restricted shares	**Shares**	**Amount**	**Shares**	**Amount**
Opening balance at January 1	6,295,098	69,577	4,108,984	49,048
Granted shares for the period / year	2,283,149	37,507	2,741,084	33,528
Value of the shares at the delivery date	(743,951)	(16,847)	(554,970)	(12,999)
Closing balance	**7,834,296**	**90,237**	**6,295,098**	**69,577**

(All amounts in thousands of reais unless otherwise stated)

Position of the restricted share plan

Below is a breakdown of the assumptions that govern each grant plan:

Grants	Grant date	Number of shares granted(i)	Date on which they will become exercisable	Period of restriction to share transfer	Fair value of shares on grant date(i)
Long-Term Incentive Program					
2021 - 3rd tranche	3/01/2021	271,184	2/28/2025	2/28/2025	R$ 22.72
2022 - 2nd tranche	3/01/2022	411,805	2/28/2025	2/28/2025	R$ 23.90
2022 - 3rd tranche	3/01/2022	411,805	2/28/2026	2/28/2026	R$ 23.90
2023 - 1st tranche	3/01/2023	623,457	2/28/2025	2/28/2025	R$ 23.90
2023 - 2nd tranche	3/01/2023	623,457	2/28/2026	2/28/2026	R$ 23.90
2023 - 3rd tranche	3/01/2023	623,457	2/28/2027	2/28/2027	R$ 23.90
2024 - 1st tranche	3/01/2024	563,148	2/28/2026	2/28/2026	R$ 26.76
2024 - 2nd tranche	3/01/2024	563,148	2/28/2027	2/28/2027	R$ 26.76
2024 - 3rd tranche	3/01/2024	563,148	2/28/2028	2/28/2028	R$ 26.76
Performance shares					
2021 - 1st tranche	1/01/2021	302,990	2/01/2025	1/01/2026	R$ 33.99
2022 - 1st tranche	1/01/2022	381,554	2/01/2026	1/01/2027	R$ 31.18
2023 - 1st tranche	1/01/2023	435,443	2/01/2027	1/01/2028	R$ 31.18
2024 - 1st tranche	1/01/2024	450,275	2/01/2028	1/01/2029	R$ 31.18

(i) After the application of the stock split effect, approved at the EGM held on September 15, 2020 and, on April 10, 2023 as a bonus, 1 (one) new share for every 25 (twenty-five) shares issued by the Company that were outstanding.

21. Net sales revenue

21.1. Accounting policy

TG 47 / IFRS 15 - Revenue from Contracts with Customers establishes a comprehensive framework for determining whether, when and for how much revenue is recognized from the identification of performance obligations, the transfer of control of the product or service to the customer and the determination of the selling price. This standard establishes a model that aims to identify whether the criteria for revenue recognition have been satisfied and comprise the following aspects:

(i) Identification of a contract with a customer;
(ii) Determination of the performance obligations;
(iii) Determination of the transaction price;
(iv) Allocation of the transaction price; and
(v) Recognition of revenue at a point in time or over time, in accordance with the satisfaction of the performance obligations.

Considering these aspects, revenues are recognized at the amount that reflects the Group's expectation of receiving in return for products and services offered to customers. Gross revenue is presented deducting rebates and discounts, in addition to the elimination of revenue between related parties and the adjustment to present value, as mentioned in Note 6.1

Sales of goods (medicines, perfumery and OTC products)

The Group's revenues derive mainly from the sale of medicines, perfumery products and a series of self-service products (OTC - Over the Counter - drugs, food products, etc.) to final consumers, carried out both through physical pharmacies and e-commerce. Being a Group that operates in the retail industry of medicines, where the consumer self-service of the goods at our stores where prices and discounts are informed by consulting the Company's employees or obtained in places where the products are exposed and considering that the transfer of control processes take place when delivering directly to the final consumer at the points of sales, it was concluded that there is a single performance obligation and, therefore, there is no complexity involved in defining performance obligations and transferring control of products and services to consumers.

(All amounts in thousands of reais unless otherwise stated)

Additionally, the other transactions of the Company subject to the assessment under NBC TG 47 / IFRS 15 are represented by variable consideration related to commercial agreements through which products can be sold together with other products or with discounts, which are substantially negotiations promoted by suppliers at the Group's points of sale. The sales revenue recognized in the financial statements comprises the fair value of the transactions carried out that, according to the nature of the negotiations, consider amounts of sales and receipts from consumers supplemented by receipts from suppliers.

Revenue is presented in the financial statements net of trade discounts and returns.

Taxes on sales

Primarily comprise ICMS at rates predominantly between 17% and 18%, for goods not subject to the tax substitute (ST) regime, service tax at 5%, and PIS (1.65%) and COFINS (7.60%) for goods not subject to the one-time taxation regime (Law 10,147/00).

Returns and cancellations

For contracts that permit a customer to return an item, in accordance with NBC TG 47 / IFRS 15, revenue is recognized to the extent that it is probable that a significant reversal will not occur. The amount of revenue recognized is accounted for based on the total amount of the transaction and presented net of indirect taxes, returns and cancellations.

21.2. Balance breakdown

	Parent Company		Consolidated	
Breakdown of net revenue	**Dec/24**	**Dec/23**	**Dec/24**	**Dec/23**
Sales revenue	38,077,796	33,369,892	41,547,697	36,133,251
Service revenue	68,596	106,383	234,276	216,195
Gross sales revenue	**38,146,392**	**33,476,275**	**41,781,973**	**36,349,446**
Taxes on sales	(1,867,697)	(1,551,175)	(2,168,128)	(1,706,374)
Returns, rebates and other	(634,365)	(579,110)	(742,323)	(669,282)
Net sales revenue	**35,644,330**	**31,345,990**	**38,871,522**	**33,973,790**

22. Information on the nature of expenses recognized in the statement of income

The Group presented its statement of income using a classification based on the function of expenses. Information on the nature of these expenses is recorded in the statement of income as follows:

	Parent Company		Consolidated	
Nature of expenses	**Dec/24**	**Dec/23**	**Dec/24**	**Dec/23**
Costs of inventories sold (Note 8)	(24,393,311)	(21,412,578)	(27,254,259)	(23,714,554)
Personnel expenses	(4,440,500)	(3,980,660)	(4,659,666)	(4,166,367)
Occupancy expenses [(i)]	(431,540)	(398,332)	(438,583)	(402,107)
Depreciation and amortization [(ii)]	(1,783,685)	(1,647,067)	(1,801,624)	(1,661,346)
Service provider expenses	(497,027)	(495,650)	(505,263)	(509,143)
Expenses on card operator fees	(572,956)	(490,415)	(583,828)	(496,109)
Other	(1,192,591)	(956,287)	(1,269,965)	(1,009,601)
Total	**(33,311,610)**	**(29,380,989)**	**(36,513,188)**	**(31,959,227)**

Classified in the statement of income as:

Function of expenses	**Dez/24**	**Dez/23**	**Dez/24**	**Dec/23**
Costs of sales and services	(24,390,727)	(21,416,143)	(27,314,741)	(23,766,426)
Selling	(7,479,652)	(6,567,441)	(7,627,819)	(6,689,275)
General and administrative	(1,441,231)	(1,397,405)	(1,570,628)	(1,503,526)
Total	**(33,311,610)**	**(29,380,989)**	**(36,513,188)**	**(31,959,227)**

(All amounts in thousands of reais unless otherwise stated)

(i) These refer to expenses on property rental, condominium fees, electricity, water, communication and municipal real estate tax (IPTU).

(ii) Depreciation and amortization in 2024 totaled R$ 1,783,685 (R$ 1,647,067 - 2023) for the Parent Company, of which R$ 1,533,413 (R$ 1,450,004 - 2023) refer to the Sales area and R$ 250,272 (R$ 197,063 - 2023) to the Administrative area, and totaled R$ 1,800,624 (R$ 1,661,346 - 2023) for the Consolidated accounts, of which R$ 1,535,364 (R$ 1,452,183 - 2023) refer to the Sales area and R$ 266,001 (R$ 209,162 - 2023) to the Administrative area. These amounts are presented net of PIS and COFINS credits on the lease right-of-use, which resulted in an expense reduction in the amount of R$ 51,066(R$ 47,981 - 2023).

In the first quarter of 2024, the Company's Management completed the process of reviewing the allocation of its operating expenses, aiming to ensure a greater correlation with the operating activities. Any reclassifications that are necessary in previous periods would not affect the result, being merely a redistribution between Service Revenue, General and Administrative Expenses and Selling Expenses. Management assessed the impact and understood that due to the immateriality of the amounts involved, it is not necessary to restate the financial statements for the year ended December 31, 2023, therefore the comparative amounts included in these financial statements are presented as originally disclosed. The main changes refer to the allocation of delivery fees charged to customers in digital sales and their corresponding deductions, which are no longer part of gross revenue and are now allocated to selling expenses, a line item in which expenses related to these deliveries are included, and the reclassification of certain general and administrative expenses to selling expenses, such as (i) marketing expenses related to the Raia and Drogasil brands and Company brands; (ii) expenses with software licensing and cloud computing that directly support sales, especially in the case of digital channels; and (iii) other sundry reclassifications.

23. Other operating income or expenses, net

In 2024, other operating income / (expenses) totaled R$ 11,714 (R$ 129,637 - 2023) for the Parent Company and R$ (7,297) (R$ 78,435 - 2023) for the Consolidated accounts. These amounts comprise non-recurring expenses and revenues, as presented below:

	Parent Company		**Consolidated**	
Nature of income / (expenses)	**Dec/24**	**Dec/23**	**Dec/24**	**Dec/23**
Refund of ICMS-ST on the margin not adopted in prior periods	89,909	41,461	100,317	41,461
Recovery of taxes, 1/3 vacation pay	29,277	-	29,277	-
Recognition of INSS credits from prior periods	386	5,156	386	5,156
Credits from prior years - PIS and COFINS from 2018 to 2023	247	125,068	15	131,562
Provision for ICMS-DIFAL (Note 17)	-	-	(1,115)	(60,955)
Write-off of fixed assets and intangible assets due to the pharmacies closure	(9,717)	861	(9,717)	861
Write-off of surplus value and goodwill for expected profitability	-	(30,111)	-	(30,111)
Uninsured losses	(5,778)	-	(5,778)	-
Donations	(159)	(468)	(145)	(495)
Social investment	(11,286)	(9,275)	(11,286)	(9,275)
Corporate restructuring	(5,000)	-	(25,534)	-
Expenses from prior years, mainly related to PVA - Inventories	(70,013)	-	(73,605)	-
Other expenses	(6,152)	(3,055)	(10,112)	231
Total	**11,714**	**129,637**	**(7,297)**	**78,435**

(All amounts in thousands of reais unless otherwise stated)

24. Finance income (costs)

	Parent Company		Consolidated	
Finance income	**Dec/24**	**Dec/23**	**Dec/24**	**Dec/23**
Present value adjustment	272,257	282,671	327,796	328,552
Short-term investment yields	10,777	16,557	36,043	52,780
Monetary variations	42,175	28,539	64,698	30,329
Discounts obtained	5,799	2,565	6,657	2,604
Interest on intercompany loans	24	33	24	43
Other income	-	-	9,371	14,427
Total finance income	**331,032**	**330,365**	**444,589**	**428,735**
Finance costs	**Dec/24**	**Dec/23**	**Dec/24**	**Dec/23**
Present value adjustment	(473,684)	(479,618)	(520,695)	(521,053)
Interest on leases[(i)]	(378,544)	(313,125)	(378,565)	(312,917)
Charges on debentures and promissory notes	(334,665)	(276,729)	(334,665)	(276,729)
Interest, charges and bank fees	(34,853)	(46,712)	(41,857)	(60,763)
Charges on borrowings	(9,836)	(46,166)	(26,488)	(46,166)
Interest on payables to subsidiary's shareholder	(31,151)	(33,486)	(31,151)	(41,212)
Monetary variations	-	(380)	(33,973)	(26,538)
Amortization of transaction costs	(9,372)	(6,915)	(9,372)	(6,915)
Discounts granted	-	-	(935)	(238)
Total finance costs	**(1,272,105)**	**(1,203,131)**	**(1,377,701)**	**(1,292,531)**
Finance income (costs)	**(941,073)**	**(872,766)**	**(933,112)**	**(863,796)**

(i) Interest on leases is shown net of PIS and COFINS.

25. Financial instruments and risk management policy

25.1. Accounting policy

The Group classifies its financial assets into the following measurement categories:

- Measured at fair value (either through other comprehensive income or through profit or loss)
- Measured at amortized cost

The classification depends on the Group's business model for managing the financial assets and the contractual terms of the cash flows.

The Group classifies the following assets at fair value through profit or loss:

- Debt investments that do not qualify for measurement at either amortized cost or at fair value through comprehensive income (FVOCI)
- Equity investments for which the entity did not elect to recognize gains and losses through other comprehensive income

For financial assets measured at fair value, gains and losses will be recognized in profit or loss or in other comprehensive income. For debt investments, this will depend on the business model in which the investment is held. For equity investments that are not held for trading, this will depend on whether the Group has or not an irrevocable option, on initial recognition, of accounting for the equity investment at fair value through other comprehensive income.

The Group reclassifies debt investments and only when the business model for managing such assets is changed.

Recognition and derecognition

Regular way purchases and sales of financial assets are recognized on trade- date, the date on which the Group commits to purchase or sell the asset. Financial assets are derecognized when the rights to receive cash flows from the financial assets have expired or have been transferred and the Group has substantially transferred all the risks and rewards of ownership.

Measurement

At initial recognition, the Group measures a financial asset at fair value plus, in the case of a financial asset not at fair value through profit or loss (FVPL), transaction costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial assets carried at FVPL are expensed in profit or loss.

Impairment loss

Expected credit losses from customers are measured using weighted estimates of probable credit losses based on historical losses and projections of related assumptions. Credit losses are measured at present value based on all cash shortfalls. Expected credit losses are discounted at the effective interest rate of the financial asset.

The Group assesses at each balance sheet date whether there is objective evidence that a financial asset or group of financial assets is impaired. A financial asset or a group of financial assets is impaired and impairment losses are incurred only if there is objective evidence of impairment as a result of one or more events that occurred after the initial recognition of the asset (a "loss event") and that loss event (or events) has an impact on the estimated future cash flows of the financial asset or group of financial assets that can be reliably estimated.

Under NBC TG 48 / IFRS 9 - Financial instruments, expected credit losses are measured in one of the following bases:

- 12-month expected credit loss: these are credit losses that result from possible default events within twelve months after the end of the reporting period
- Lifetime expected credit losses: these are credit losses that result from all possible default events over the expected life of a financial instrument.

(All amounts in thousands of reais unless otherwise stated)

Offsetting financial instruments

Financial assets and liabilities are offset and the net amount reported in the balance sheet where currently there is a legally enforceable right to offset the recognized amounts, and there is an intention to settle on a net basis or realize the asset and settle the liability simultaneously. The legally enforceable right should not be contingent on future events and should be applicable in the normal course of business and in the case of default, insolvency or bankruptcy of the company or the counterpart.

Fair value hierarchy

The Group classifies and discloses the fair value of financial instruments based on measurement techniques:

- Level 1: prices (unadjusted) quoted in active markets for identical assets or liabilities.
- Level 2: other techniques for which all inputs that have a significant effect on the recorded fair value are observable, either directly or indirectly.
- Level 3: techniques that use data that have a significant effect on the recorded fair value that are not based on observable market data.

25.2. Financial instruments by category

	Parent Company		Consolidated	
Financial instruments items	**Dec/24**	**Dec/23**	**Dec/24**	**Dec/23**
Assets				
At amortized cost				
Cash and cash equivalents (Note 5)	460,292	318,002	528,002	412,321
Financial investments (Note 6)	27,774	26,506	15,706	-
Trade receivables (Note 7)	1,919,599	2,515,546	2,666,758	3,084,940
Other receivables	460,282	392,296	499,647	425,390
Judicial deposits (Note 17)	30,635	19,183	253,781	228,446
Total assets	**2,898,582**	**3,271,533**	**3,963,894**	**4,151,097**
Liabilities				
Liabilities at fair value through profit or loss				
Payables to subsidiary's shareholder	13,573	98,197	13,573	98,197
Subtotal	**13,573**	**98,197**	**13,573**	**98,197**
Other liabilities				
Suppliers and Suppliers - Forfait (Note 14)	5,307,632	4,659,044	5,816,222	5,091,454
Borrowings (Note 15)	3,204,348	2,903,309	3,293,930	3,130,703
Other payables	439,701	492,919	516,227	554,846
Leases payable (Note 16)	4,418,993	3,932,581	4,424,537	3,936,761
Subtotal	**13,370,674**	**11,987,853**	**14,050,916**	**12,713,764**
Total liabilities	**13,384,247**	**12,086,050**	**14,064,489**	**12,811,961**

25.3. Financial risk management

The Group's activities expose it to a variety of financial risks: market risk, credit risk and liquidity risk. The Group's risk management program focuses on the unpredictability of financial and operational markets and seeks to minimize potential adverse effects on the Group's financial performance.

The Board of Directors provides principles for overall risk management, as well as written policies covering specific areas, such as interest rate risk, credit risk, use of non-derivative financial instruments and investment of surplus cash.

(All amounts in thousands of reais unless otherwise stated)

(a) Market risk

Foreign exchange risk

All of the asset and liability operations of the Group are denominated in Brazilian reais (R$); therefore, the Company is not exposed to foreign exchange risk.

Derivative financial instruments

The Group does not operate with derivative instruments, except in specific situations. At December 31, 2024, the Group did not have any derivative transactions.

Interest rate risk

The Company's borrowings are pegged to the CDI plus bank spread. Financial investments are entered into based on the CDI variations, which does not result in higher interest rate risk since these variations are not significant. Management understands that there is a low risk of significant changes in profit or loss or in cash flows.

(b) Credit risk

Credit risk arises from financial assets, i.e. cash and cash equivalents, short-term investments and trade receivables. Cash and cash equivalents and short-term investments are maintained with sound financial institutions.

The risk ratings of the cash equivalents are in accordance with the main risk rating agencies, according to the table below:

	Parent Company		Consolidated	
Risk rating	**Dec/24**	**Dec/23**	**Dec/24**	**Dec/23**
Rating - National scale				
brAAA	157,187	48,473	206,520	133,104
brAA+	5,940	2,186	5,940	2,186
brA	166	286	166	289
(*) n/a - Cash and automatic investments	296,999	267,057	315,376	274,573
(*) n/a - Investment funds	-	-	-	2,169
Total - National scale	**460,292**	**318,002**	**528,002**	**412,321**

(*) Not applicable, since there is no risk rating for cash, automatic investments and investment funds.

The granting of credit on sales of goods follows a policy that aims at minimizing defaults. For the year ended December 31, 2024, credit sales represented 68% (65% in 2023) for the Parent Company and 70% (67% in 2023) for the Consolidated accounts, of which 80% (84% in 2023) for the Parent Company and 72% (76% in 2023) for the Consolidated accounts related to credit card sales which, based on the history of losses, posed an extremely low risk. The remaining 20% (16% in 2023) for the Parent Company and 28% (24% in 2023) for the Consolidated accounts refer to credits from Medicine Benefit Programs (PBMs) and special plans that pose a low risk, due to customer selectivity.

(c) Liquidity risk

The Group's management continuously monitors forecasts of the Company's liquidity requirements, in order to ensure that it has sufficient cash to meet operational needs. The Group invests its surplus cash in financial assets with appropriate maturities to provide the liquidity necessary to honor its obligations.

(d) Sensitivity analysis

The Company prepares a sensitivity analysis of financial instruments indexed to interest rates to which the Company is exposed.

According to the assessment made by Management, the most probable scenario is based on an increase of 3.0% in the interest rate. Two further scenarios are presented in order to show a 25% and 50% deterioration in the risk variables considered (scenarios II and III).

(All amounts in thousands of reais unless otherwise stated)

		Parent Company		
		Effect on profit or loss and equity		
Operation	**Notional amount**	**Scenario I (probable)**	**Scenario II - 25%**	**Scenario III - 50%**
Short-term investments - CDI	278,648	8,359	10,449	12,539
Revenue	-	**8,359**	**10,449**	**12,539**
Borrowings - CDI	3,204,348	(96,130)	(120,163)	(144,196)
Expense		**(96,130)**	**(120,163)**	**(144,196)**
Effect on profit or loss		**(87,771)**	**(109,714)**	**(131,657)**

		Consolidated		
		Effect on profit or loss and equity		
Operation	**Notional amount**	**Scenario I (probable)**	**Scenario II - 25%**	**Scenario III - 50%**
Short-term investments - CDI	297,018	8,911	11,138	13,366
Revenue		**8,911**	**11,138**	**13,366**
Borrowings - CDI	3,293,930	(98,818)	(123,522)	(148,227)
Expense		**(98,818)**	**(123,522)**	**(148,227)**
Effect on profit or loss		**(89,907)**	**(112,384)**	**(134,861)**

(e) Capital management

The Group's objective relating to capital management is to maintain the Group's investment capacity, thus allowing it to grow its business and provide proper returns for shareholders.

The Group has adopted a policy of not leveraging its capital structure with borrowings, except for long-term credit facilities of debentures at interest rates that are commensurate with the Group's profit levels.

Accordingly, this ratio corresponds to the net debt expressed as a percentage of total capital. The net debt, in turn, corresponds to total borrowings less cash and cash equivalents. The total capital is calculated through the sum of the equity, as shown in the individual and consolidated balance sheet, and the net debt, as presented below:

	Parent Company		Consolidated	
Capital management items	**Dec/24**	**Dec/23**	**Dec/24**	**Dec/23**
Short- and long-term borrowings	3,204,348	2,903,309	3,293,930	3,130,703
(-) Cash and cash equivalents	(460,292)	(318,002)	(528,002)	(412,321)
Net debt	**2,744,056**	**2,585,307**	**2,765,928**	**2,718,382**
Equity attributable to the shareholders of the parent	6,433,460	5,956,001	6,433,460	5,956,001
Noncontrolling interests	-	-	13,427	72,300
Total equity	**6,433,460**	**5,956,001**	**6,446,887**	6,028,301
Total capital	**9,177,516**	**8,541,308**	**9,212,815**	**8,746,683**
Gearing ratio (%)	**29.90%**	**30.27%**	**30.02%**	**31.08%**

At December 31, 2024, the balance of lease liabilities in the Parent Company and Consolidated accounts corresponded to R$ 4,418,993 and R$ 4,424,537 respectively. Considering the lease liability in the capital management calculation, the gearing ratio of the Company and the Group would be 52.68% in the Parent Company and 52.73% in the Consolidated accounts. Considering the balance of lease liabilities at the balance sheet dates in the capital management calculation, the gearing ratio of the Company and the Group would be as follows:

(All amounts in thousands of reais unless otherwise stated)

	Parent Company		Consolidated	
Adjusted net debt with lease liabilities	**Dec/24**	**Dec/23**	**Dec/24**	**Dec/23**
Net debt	2,744,056	2,585,307	2,765,928	2,718,382
Lease liabilities	4,418,993	3,932,581	4,424,537	3,936,761
Adjusted net debt	**7,163,049**	**6,517,888**	**7,190,465**	**6,655,143**
Total equity	6,433,460	5,956,001	6,446,887	6,028,301
Total adjusted capital	**13,596,509**	**12,473,889**	**13,637,352**	**12,683,444**
Adjusted gearing ratio (%)	**52.68%**	**52.25%**	**52.73%**	**52.47%**

(f) Fair value estimation

The carrying values of financial investments in the balance sheet are equivalent to their fair values since the remuneration rates are based on the CDI variation. The carrying values of trade receivables and payables are measured at amortized cost and are recorded at their original amount, less the provision for impairment and present value adjustment, when applicable. The carrying values are assumed to approximate their fair values, taking into consideration the realization of these balances and settlement terms not exceeding 58 days.

Borrowings are classified as financial liabilities not measured at fair value and are carried at amortized cost and according to contractual conditions. The fair values of the borrowings are equivalent to their carrying values since they refer to financial instruments with rates that approximate market rates. The estimated fair values are:

	Parent Company				Consolidated			
	Carrying amount		Fair value		Carrying amount		Fair value	
Fair value estimation	**Dec/24**	**Dec/23**	**Dec/24**	**Dec/23**	**Dec/24**	**Dec/23**	**Dec/24**	**Dec/23**
Debentures	3,204,348	2,592,379	3,204,348	2,592,379	3,204,348	2,592,379	3,204,348	2,592,379
Other	-	310,930	-	310,930	89,582	538,324	89,582	538,324
Total	**3,204,348**	**2,903,309**	**3,204,348**	**2,903,309**	**3,293,930**	**3,130,703**	**3,293,930**	**3,130,703**

For disclosure purposes, the fair value of financial liabilities is estimated by discounting future contractual cash flows at the market interest rate that is available to the Group for similar financial instruments. The effective interest rates at the balance sheet dates are usual market rates and their fair value does not significantly differ from the balances in the accounting records.

At December 31, 2024, the Group had no material assets and liabilities measured at fair value at Level 1 and Level 2 in the fair value hierarchy. The following table presents the changes in Level 3 instruments for the year ended December 31, 2024:

	Parent Company/Consolidated	
	Payables to subsidiary's shareholder	
Changes in payables to subsidiary's shareholder	**Dec/24**	**Dec/23**
Balance at January 1	98,197	64,710
(-) Payment for the exercise of the 2nd Call Option of shares	(117,817)	-
Expenses recognized in the statement of income	33,193	33,487
Closing balance	13,573	98,197
Total expenses for the year recognized in the statement of income	**33,193**	**33,487**
Changes in unrealized expenses for the year included in the statement of income	**2,041**	**33,487**

(All amounts in thousands of reais unless otherwise stated)

26. Transactions with related parties

Transactions with related parties consist of transactions with the Company's shareholders and persons connected to them:

		Parent Company		Consolidated		Parent Company		Consolidated	
		Assets				Transacted amount			
Related parties	**Relationship**	**Dec/24**	**Dec/23**	**Dec/24**	**Dec/23**	**Dec/24**	**Dec/23**	**Dec/24**	**Dec/23**
Current assets									
Receivables									
Special plans (i)									
4Bio Medicamentos Ltda.	Subsidiary	38	87	-	-	585	133	-	-
Regimar Comercial S.A.	Shareholder/Family	22	16	22	16	130	33	130	33
Impulso	Subsidiary	5	5	-	-	72	7	-	-
RD Ads	Subsidiary	-	6	-	-	-	10	-	-
Amplisoftware Tecnologia Ltda.	Subsidiary	1	1	-	-	-	-	-	-
Labi Exames S.A.	Associate	1	2	1	2	-	-	-	-
Heliomar Ltda.	Shareholder/Board Member	2	2	2	2	14	4	14	4
Healthbit Performasys Tecnologia	Subsidiary	30	1	-	-	-	-	-	-
Advances to suppliers									
Cfly Consultoria e Gestão Empresarial Ltda. (ii)	Shareholder/Family	-	-	-	-	3,552	-	3,552	-
Ribeiro Filho, Pires Oliveira Dias e Freire Advogados (iii)	Shareholder/Family	17	120	17	120	1,040	-	1,040	-
Other receivables									
Rodrigo Wright Pipponzi (Editora Mol Ltda.) (vi)	Shareholder/Family	-	-	-	-	615	-	615	-
Subtotal (a)		**116**	**240**	**42**	**140**	**6,008**	**187**	**5,351**	**37**
Other receivables									
Stix Fidelidade e Inteligência S.A. (vii)	Associate	41,887	45,453	41,887	45,453	30,173	42,439	30,173	42,439
Impulso (xii)	Subsidiary	5,886	-	-	-	5,514	-	-	-
ZTO Tecn. e Ser. de Infor.(xviii)	Subsidiary	14	-	-	-	72	-	-	
4Bio Medicamentos S.A. (iv)	Subsidiary	1,373	791	-	-	86	411	-	-
Subtotal		**49,160**	**46,244**	**41,887**	**45,453**	**35,845**	**42,850**	**30,173**	**42,439**
Total current assets		**49,160**	**46,244**	**41,887**	**45,453**	**35,845**	**42,850**	**30,173**	**42,439**
Non-current assets									
Loans									
ZTO Tecn. e Ser. de Infor.(viii)	Subsidiary	-	213	-	-	546	60	-	-
SafePill Com. Varejista de Med. Manip. Ltda (x)	Subsidiary	-	-	-	-	-	67	-	-
Full Nine Digital Consultoria (Conecta Lá) (ix)	Associate (up to November 2023)	-	-	-	-	-	62	-	62
Total non-current assets		**-**	**213**	**-**	**-**	**546**	**189**	**-**	**62**
Total receivables from related parties		**49,276**	**46,697**	**41,929**	**45,593**	**42,327**	**43,226**	**35,524**	**42,538**

(All amounts in thousands of reais unless otherwise stated)

Related parties	Relationship	Parent Company (Liabilities)		Consolidated (Liabilities)		Parent Company (Transacted amount)		Consolidated (Transacted amount)	
		Dec/24	Dec/23	Dec/24	Dec/23	Dec/24	Dec/23	Dec/24	Dec/23
Current liabilities									
Service providers									
Stix Fidelidade e Inteligência S.A. (vii)	Associate	17,976	16,567	17,976	16,567	100,754	77,844	100,754	77,844
Cfly Consultoria e Gestão Empresarial Ltda. (ii)	Family	1,138	-	1,138	-	5,137	32	5,137	32
Subtotal		**19,114**	**16,567**	**17,114**	**16,567**	**105,891**	**77,876**	**105,891**	**77,876**
Payables									
Rentals (v)									
Heliomar Ltda.	Shareholder/Board Member	-	35	-	35	349	366	349	366
Antonio Carlos Pipponzi	Shareholder/Board Member	10	10	10	10	98	139	98	139
Rosalia Pipponzi Raia	Shareholder/Board Member	10	10	10	10	98	139	98	139
Cristiana Almeida Pipponzi	Shareholder/Board Member	4	4	4	4	33	46	33	46
André Almeida Pipponzi	Shareholder/Board Member	4	4	4	4	33	46	33	46
Marta Almeida Pipponzi	Shareholder/Board Member	4	4	4	4	33	46	33	46
Subtotal (a)		**32**	**67**	**32**	**67**	**644**	**782**	**644**	**782**
Service providers									
Impulso (xii)	Subsidiary	303	-	-	-	4,484	-	-	-
Amplisoftware Tecnologia Ltda. (xi)	Subsidiary	584	175	-	-	7,279	4,256	-	-
Healthbit Performasys Tecnologia (xviii)	Subsidiary	376	320	-	-	2,841	2,927	-	-
Ribeiro Filho, Pires Oliveira Dias e Freire Advogados (iii)	Shareholder/Family	757	284	757	284	4,312	4,644	4,312	4,644
RD Ads (xii)	Subsidiary	-	760	-	-	-	4,076	-	-
Healthbit Serviços Médicos Ltda. (xviii)	Subsidiary	55	152	-	-	1,555	1,280	-	-
Labi Exames S.A. (xiii)	Associate	-	-	-	-	151	5	151	5
Rodrigo Wright Pipponzi (Editora Mol Ltda.) (vi)	Shareholder/Family	-	-	-	-	23,227	22,770	23,227	22,770
CI&T IOT Comercio de HardWare e Software Ltda and CI&T Softwares S.A) (xv)	Shareholder/Board Member between April/21 and April/23	-	-	-	-	-	6,268	-	6,268
Sensedia S.A. (xvi)	Shareholder/Board Member between April/21 and April/23	-	-	-	-	-	1,300	-	1,300
4Bio Medicamentos Ltda. (XIX)	Subsidiary	7	6	-	-	61	26	-	-
Subtotal (a)		**2,082**	**1,697**	**757**	**284**	**43,910**	**47,552**	**27,690**	**34,987**
Total current liabilities		**19,114**	**16,567**	**19,114**	**16,567**	**105,891**	**77,876**	**105,891**	**77,876**
Total payables to related parties		**21,228**	**18,331**	**19,903**	**16,918**	**150,445**	**126,210**	**134,225**	**113,645**

(a) *The balances of receivables and payables with related parties, arising from commercial transactions between the Company and its Related Parties, are allocated by function, with transactions with the same characteristics carried out with third parties.*

Transactions with related parties, basically purchases and sales of products, were carried out at prices, terms and conditions usual in the market.

(i) Sales made by agreements whose transactions are carried out under commercial conditions equivalent to those adopted with other companies.

(ii) Services of aircraft operation owned by Raia Drogasil S.A., which will pay the operator a monthly remuneration for the services of operational advisory, compliance, finance, maintenance coordination and maintenance technical control.

(iii) Transaction related to legal advisory.

(iv) Other receivables comprise commissions on Raia Drogasil S.A. referrals (R$ 1,373), recognized in “other receivables”.

(v) Transactions related to rental of commercial properties for the implementation of pharmacies.

(vi) The balances and transactions relate to service agreements for the development, creation and production of marketing materials for the institutional sales area, and the design of the Company's internal magazine.

(vii) Transactions related to trade receivables and suppliers referring to the Stix points program.

(viii) Loan transaction with subsidiary ZTO Tecnologia e Servicos de Informação na Internet Ltda - Manipulaê in the amount of R$ 180, which is updated by CDI + 1.45% p.a.

(ix) Loan transaction carried out between Raia Drogasil S.A. (lender) and Full Nine Digital Consultoria - Conecta Lá (borrower) in the amounts of R$ 700 and R$ 400, with monetary adjustment based on CDI + 3.50% p.a. The transaction was fully settled in November 2023.

(x) Loan transactions between Raia Drogasil S.A. and SafePill Comercio Varejista de Med. Manip. Ltda in the amount of R$ 400 in August 2022, with remuneration linked to CDI + 3.26% p.a. and maturity in August 2024.

(xi) The balances and transactions refer to the provision of services related to implementation of electronic medical records for physicians and systems in pharmacies so that customers are able to schedule exams and consultations in pharmacies.

(xii) Represents the reimbursement of the sharing of costs or expenses, such as consulting services and software licensing.

(xiii) Provision of services related to tests.

(xiv) The balances and transactions refer to agreements for provision of services related to health content production.

(xv) Transactions related to information technology consulting services, namely a contract entered into in March 2020 with CI&T Comércio de Hardware e Software Ltda. and another in November 2020 with CI&T Softwares S.A., aimed at consultancy for digital transformation and squads.

(xvi) The balances and transactions refer to agreements for provision of services related to digital transformation implementation.

(xvii) Balance referring to corporate restructuring.

(xviii) Provision of services related to healthcare programs.

(xix) Balance relating to commission intermediations.

(All amounts in thousands of reais unless otherwise stated)

We also inform that there are no additional transactions other than the amounts presented above and that the category of the related parties corresponds to the entity's key management personnel.

(b) Key management compensation

Key management includes the Officers, Directors and members of the Supervisory Board. The compensation paid or payable for services rendered is as follows:

	Parent Company		Consolidated	
Compensation items	**Dec/24**	**Dec/23**	**Dec/24**	**Dec/23**
Share-based payment	30,367	30,217	30,367	30,217
Bonuses and social charges	21,103	16,049	21,103	16,049
Subtotal bonuses and social charges	**51,470**	**46,266**	**51,470**	**46,266**
Fees and social charges	30,182	28,919	30,182	28,919
Fringe benefits	474	423	474	423
Total	**82,126**	**75,608**	**82,126**	**75,608**

The Company applied the requirements of NBC TG 05 (R3) - Related-Party Disclosures and also considered the guidance in CVM Circular Letter SNC/SEP 01/2021, observing qualitative aspects of related-party transaction, and concluded that there are no material impacts that require disclosure of additional information in the financial statements.

27.Insurance coverage

The Group has adopted a policy of taking out insurance coverage at amounts deemed sufficient to cover any losses on assets or civil liability attributed to it taking into consideration the nature of its activities and the guidance of its insurance consultants.

Insurance coverage amounts to R$ 1,155,255, considering Operational Risks, Civil Liability, D&O, Cyber Risk, Transportation, Fleet, Aircraft and Environmental policies.

28.Non-cash transactions

At December 31, 2024, the Group's main non-transactions were:

a) the monetary adjustment of the financial liability arising from payables to subsidiary's shareholder (Note 25.2 (f));
b) During the second quarter of 2024, a 15% interest in subsidiary 4Bio was acquired, without change in control (Note 10.1). Due to this change in the percentage of interest, an adjustment of R$ 59,708 was recognized in the Parent Company's equity;
c) part of the compensation of key management personnel associated with the restricted share plan (Note 26 (b));
d) the installment purchase of fixed assets items in the amount of R$ 26,979 (R$ 10,853 - Dec23).
e) Recognition of lease liability with a balancing item in right-of-use assets, with additions of new agreements in the amount of R$ 708,214 (R$ 438,452 - Dec/23) for the Parent Company and R$ 710,899 (R$ 438,452 – Dec/23) for the Consolidated accounts, remeasurements of R$ 646,247 (R$ 578,409 - Dec/23) for the Parent Company and R$ 648,023 (R$ 580,987 – Dec/23) for the Consolidated accounts, and termination of agreements in the amount of (R$ 15,314) ((R$ 4,285) - Dec/23) for the Parent Company and (R$ 15,973) ((R$ 4,285 -Dec/23) for the Consolidated accounts.

29.Events after the reporting period

On February 18, 2025, the subsidiary 4Bio carried out a loan operation in foreign currency - working capital, in the amount of R$ 90,000, with remuneration of 100% of the cumulative variation of the average daily rates of the CDI, plus a surcharge of 0.86% per year and payment term of six months. The loan amount will be fully paid on the maturity date. The funds were used to improve the working capital. The subsidiary has an interest rate swap contract, which is being used as a hedge of the exposure to the changes in the fair value of the secured loan of 0.86%.

Building a better
working world

São Paulo Corporate Towers
Av. Presidente Juscelino Kubitschek, 1.909
Vila Nova Conceição
04543-011 - São Paulo – SP - Brasil

T: +55 11 2573-3000
ey.com.br

A free translation from Portuguese into English of Independent Auditor's Report on Individual and Consolidated Financial Statements prepared in Brazilian currency in accordance with the accounting practices adopted in Brazil and with the International Financial Reporting Standards (IFRS)

Independent auditor's report on individual and consolidated financial statements

To the
Board of Directors and Shareholders
Raia Drogasil S.A.
São Paulo - SP

Opinion

We have audited the accompanying individual and consolidated financial statements of Raia Drogasil S.A. ("Company"), identified as Individual and Consolidated, respectively, which comprise the statement of financial position as at December 31, 2024 and the statements of profit or loss, of comprehensive income (loss), of changes in equity and of cash flows for the year then ended, as well as the corresponding explanatory notes, including material accounting policies and other instructive information.

In our opinion, the accompanying financial statements present fairly, in all material respects, the individual and consolidated financial position of Raia Drogasil S.A. as at December 31, 2024, and its individual and consolidated financial performance and individual and consolidated cash flows for the year then ended in accordance with the accounting practices adopted in Brazil and with the International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB) (currently referred to by the IFRS Foundation as "IFRS accounting standards").

Basis for opinion

We conducted our audit in accordance with Brazilian and international standards on auditing. Our responsibilities under those standards are further described in the 'Auditors' responsibilities for the audit of the individual and consolidated financial statements' section of our report. We are independent of the Company and its subsidiaries and comply with the relevant ethical principles set forth in the Code of Professional Ethics for Accountants, the professional standards issued by Brazil's National Association of State Boards of Accountancy ("CFC") and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key audit matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current year. These matters were addressed in the context of our audit of the overall individual and consolidated financial statements, and in forming our opinion on the individual and consolidated financial statements. Therefore, we did not express a separate opinion on these matters. For each of the matters below, a description of how our audit has addressed

São Paulo Corporate Towers
Av. Presidente Juscelino Kubitschek, 1.909
Vila Nova Conceição
04543-011 - São Paulo – SP - Brasil

T: +55 11 2573-3000
ey.com.br

them, including any comments on the results of our procedures is presented in the context of the financial statements taken as a whole.

We have fulfilled the responsibilities described in the "Auditor's responsibilities for the audit of individual and consolidated financial statements" section, including in relation to these matters. Accordingly, our audit included the performance of procedures designed to respond to our assessment of the risks of material misstatement of the financial statements. The results of our procedures, including the procedures performed to address the matters below, provide the basis for our audit opinion on the accompanying financial statements.

Technology environment

Due to the volume of transactions and the fact that the operations of the Company and its subsidiaries are highly dependent on the proper operation of the technology structure and its systems, added to the nature of their business and their geographic dispersion, we consider the technology environment to be a key audit matter.

How our audit conducted this matter

Our audit procedures included, among others, the assessment of the design of general IT controls ("ITGCs") implemented by the Company for the systems we considered relevant for the generation of information that directly impact their financial statements. The assessment of ITGCs included audit procedures to assess controls over logical access, change management, information technology operation management, report processing and other aspects of technology.

With regard to the audit of logical accesses, we analyze the process of authorization and granting of new users, the timely revocation of access to employees transferred or separated and the periodic review of users. In addition, we evaluated password policies, security settings and access to technology resources.

With respect to the change management process, we assessed whether the changes in the systems have been duly authorized and approved by the Company's management, as well as the existence of segregation of duties in the process. We also analyzed the operations management process, focusing on policies for safeguarding information and the timely handling of incidents.

Lastly, we evaluated the process of generating and extracting reports that support the accounting balances and performed adherence tests on the information generated by the Company's systems.

We involved our IT professionals to assist us in performing these procedures.

We identified deficiencies in change management controls related to segregation of duties, access management related to transfer of access, administrative users and review of access profiles, as well as opportunities for improvements in the third-party management process.

EY
Building a better working world

São Paulo Corporate Towers
Av. Presidente Juscelino Kubitschek, 1.909
Vila Nova Conceição
04543-011 - São Paulo – SP - Brasil

T: +55 11 2573-3000
ey.com.br

Deficiencies in the design and operation of ITGCs have altered our assessment of the nature, timing and extent of our planned substantive procedures to obtain sufficient and appropriate audit evidence

for December 31, 2024 financial statements. Taking this into consideration, the result of the audit procedures performed provided us with adequate and sufficient audit evidence to be acceptable in the context of the financial statements taken as a whole.

Commercial agreements on the purchase of goods for resale

As disclosed in Note 4 (d), the Company negotiates commercial agreements with its suppliers of goods for resale, which may be of a particular or complex nature within the retail sector. In this context, there are different categories of agreements that are substantially linked to the resale of goods to obtain benefits by the Company. Therefore, it is necessary to carry out procedures on the part of management, in particular, analyze and conclude on the amounts and correct period in which the effects should be recognized in the cost of goods sold.

Due to this fact, we consider the recognition of the effects of the commercial agreements, especially regarding the completeness and its registration in the correct accounting period, to be a key audit matter.

How our audit conducted this matter

Our audit procedures included, among others, the following:

• Update of the understanding of the business process established by management for identification, measurement and timely accounting of commercial agreements, in addition to analysis of possible liability balances corresponding to commercial agreements;

• External confirmation of certain suppliers, considering the aspects of relevance of the amounts and representative sample

• Understanding of the main contractual terms, individually relevant or with particular characteristics and the corresponding performance indicators that, when reached, generate the Company's right to the agreed benefit, recalculation, as well to verification of its subsequent financial settlement based on sample tests; and

• Test of recognition of the effects in the correct competence period.

• Test of details in the recognition of commercial agreements in cost, with inspection of the terms of signed commercial agreements; evidence of supplier approval for balance clearing and/or subsequent financial settlement.

Based on the results of audit procedures performed on commercial agreements, which is consistent with management’s assessment, we understand that the criteria and assumptions adopted by

São Paulo Corporate Towers
Av. Presidente Juscelino Kubitschek, 1.909
Vila Nova Conceição
04543-011 - São Paulo – SP - Brasil

T: +55 11 2573-3000
ey.com.br

management, as well as the respective disclosures in Note 4(d) are acceptable in regard to the financial statements taken as a whole.

Measurement of lease liabilities and right-of-use assets

As described in note 16, the Company has registered right-of-use assets and lease liabilities for the contracts covered by NBC TG 06 (R3) (IFRS 16). As of December 31, 2024, the Company had a balance of right-of-use assets of R$3,881,567 thousand in the Parent Company and R$3,886,977 in the Consolidated Shareholder, in addition to lease liabilities of R$4,418,993 thousand in the Parent Company and R$4,424,537 thousand in the Consolidated Shareholder.

This matter was considered significant for our audit due to the relevance of the amounts involved, both in relation to the balance sheet and results of the year, the high volume of the contracts and amendments in stores and distribution centers, as well as the uncertainties inherent to this type of calculation and the degree of judgement that must be exercised by the company in determining the relevant assumptions, which include, among others, the discount rate used.

How our audit conducted this matter

Our audit procedures included, among others, the following:

• Analysis of the inventory of the Company's lease agreements, in addition to verifying the adherence of these contracts to the scope of the standards provided for in IFRS16 and NBC TG 06 (R3).

• Test of reasonableness of the criteria adopted by the Company for a sample of contracts selected at random, considering the information from the contracts and their amendments, in addition to recalculating the amounts measured by the Company for these transactions.

• Testing of the recognition of effects in the correct period of accrual.

• Analysis of the criteria adopted by management to determine the discount rate (incremental financing rate) used to measure lease liabilities.

• Examining the adequacy of the disclosures made by the Company on the subject in the explanatory notes, including the requirements of NBC TG 06 (R3) (IFRS 16) and the guidelines of the Brazilian Securities and Exchange Commission (CVM).

Based on the results of the audit procedures carried out, which are consistent with the board's assessment, we consider acceptable the accounting records prepared by the board to measure the impacts of NBC 06 (R3) (IFRS 16) on lease agreements, as well as the respective disclosures in note 16, in the context of the individual and consolidated financial statements taken together.

Other matters

Statements of value added

São Paulo Corporate Towers
Av. Presidente Juscelino Kubitschek, 1.909
Vila Nova Conceição
04543-011 - São Paulo – SP - Brasil

T: +55 11 2573-3000
ey.com.br

The individual and consolidated statements of value added for the year ended December 31, 2024, prepared under the responsibility of Company's management, and presented as supplementary information for purposes of IFRS, were submitted to audit procedures conducted together with the audit of the Company's financial statements individual and consolidated. To form our opinion, we evaluated if these statements are reconciled to the financial statements and accounting records, as applicable, and if their form and content comply with the criteria defined by Accounting Pronouncement NBC TG 09 - Statement of Value Added. In our opinion, these statements of value added, individual and consolidated, were prepared fairly, in all material respects, in accordance with the criteria defined in abovementioned accounting pronouncement and are consistent in relation to the overall individual and consolidated financial statements.

Other information accompanying the individual and consolidated financial statements and the auditor's report

Management is responsible for such other information, which comprises the Management Report.

Our opinion on the individual and consolidated financial statements does not cover the Management Report and we do not express any form of assurance conclusion thereon.

In connection with our audit of the individual and consolidated financial statements, our responsibility is to read the Management Report and, in doing so, consider whether this report is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on our work, we conclude that there are material misstatements in the Management Report, we are required to communicate this matter. We have nothing to report in this respect.

Responsibilities of management and those charged with governance for the individual and consolidated financial statements

Management is responsible for the preparation and fair presentation of these individual and consolidated financial statements in accordance with accounting practices adopted in Brazil and in accordance with the International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB) (currently referred to by the IFRS Foundation as "IFRS accounting standards"), and for such internal controls as management determines is necessary to enable the preparation of financial statements that are free of material misstatement, whether due to fraud or error.

In preparing the individual and consolidated financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's and its subsidiaries' financial reporting process.

São Paulo Corporate Towers
Av. Presidente Juscelino Kubitschek, 1.909
Vila Nova Conceição
04543-011 - São Paulo – SP - Brasil

T: +55 11 2573-3000
ey.com.br

Auditor's responsibilities for the audit of individual and consolidated financial statements

Our objectives are to obtain reasonable assurance about whether the individual and consolidated financial statements as a whole are free of material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Brazilian and International Standards on Auditing will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with Brazilian and international standards on auditing, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identified and assessed the risks of material misstatement of the individual and consolidated financial statements, whether due to fraud or error, designed and performed audit procedures responsive to those risks, and obtained audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtained an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's and its subsidiaries' internal control.
- Evaluated the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Concluded on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the individual and consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluated the overall presentation, structure and content of the financial statements, including the disclosures, and whether the individual and consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other things, the planned scope, timing of the audit, and significant audit findings, including any significant deficiencies in internal controls that we have identified during our audit.

São Paulo Corporate Towers
Av. Presidente Juscelino Kubitschek, 1.909
Vila Nova Conceição
04543-011 - São Paulo – SP - Brasil

T: +55 11 2573-3000
ey.com.br

We also provided those charged with governance with a statement that we have complied with relevant ethical requirements, including applicable independence requirements, and to communicate

with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determined those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

São Paulo, February 25, 2025.

ERNST & YOUNG
Auditores Independentes S.S. Ltda.
CRC-SP-034519/O

Patricia Nakano Ferreira
Accountant CRC-SP234620/O

In this section, pursuant to CVM Resolution 80/2022, we compare the store opening projections for the Company with the data on pharmacies openings actually conducted every year. The projections for 2016 and 2017 were disclosed to the market on July 28, 2016, the projections for 2018 and 2019 were disclosed on November 9, 2017, the projections for 2020 were disclosed on October 3, 2019 and the projections for 2021 and 2022 were disclosed on September 29, 2020.

On July 28, 2016, we revised the prior projection of 165 openings in 2016 and 195 openings in 2017 to 200 store openings for both years. On October 27, 2021, we revised the prior projection of 240 openings per year in 2022 to 260 openings. On October 31, 2022, we revised the previous projection for the period from 2023 to 2025 from 240 openings per year to 260 openings per year. On November 8, 2023, we revised the prior projection of 260 gross openings per year in 2023, 2024 and 2025 to 270 in 2023 and between 280 and 300 gross openings per year for 2024 and 2025.

On November 29, 2024, we revised the prior projection of 280 to 300 openings per year to 330 to 350 openings per year in 2025.

YEAR	PRIOR PROJECTION	CURRENT PROJECTION	ACTUAL ACCUMULATED
2016	165 openings	200 openings	212 openings
2017	195 openings	200 openings	210 openings
2018	-	240 openings	240 openings
2019	-	240 openings	240 openings
2020	-	240 openings	240 openings
2021	-	240 openings	240 openings
2022	240 openings	260 openings	260 openings
2023	260 openings	270 openings	270 openings
2024	260 openings	Between 280 and 300 openings	300 openings
2025	Between 280 and 300 openings	Between 330 and 350 openings	-

Annual Report of the RD Saúde's Audit Committee

The Audit Committee of Raia Drogasil S.A. ("Committee" and "RD Saúde" or "Company"), of permanent and non-statutory nature, was established by the Board of Directors in February 2022.

The Committee's mission is to assist, within the scope of its competence, the Board of Directors in performing its functions, with full knowledge of the Company's principles and values and the purposes and beliefs of shareholders and other stakeholders, ensuring they are effectively practiced through the adoption and improvement of the best corporate governance practices.

Composed of three independent members, including an external and independent leader (who acts as coordinator), a specialist in corporate accounting and an independent advisor, the Committee exercises the duties and responsibilities established by the Board of Directors through the Audit Committee's Internal Regulations, which considers: (i) expressing an opinion on the hiring and termination of independent audit services and monitoring their work; (ii) analyzing the financial statements; (iii) monitoring the Annual Internal Audit Plan and supervising the area's activities; (iv) monitoring the activities of the internal controls area; (v) assessing and monitoring exposures and risk management; (vi) assessing, monitoring, and submitting related-party transactions to the Board of Directors; (vii) assessing, monitoring, and recommending to Management the correction or improvement of the Company's internal policies; (viii) monitoring the Compliance and *Canal Conversa Ética* (anonymous ethics hotline) processes; and (ix) reporting to the Board, annually, the Committee's summary report.

In its fourth year of full operation and throughout 2024, the Committee met in 12 ordinary meetings in accordance with the work plan previously approved by the Board of Directors, including 5 meetings with the Supervisory Board and 4 meetings with the Company's independent auditors. In addition, 2 extraordinary meetings were held to delve deeper into specific topics. In these meetings, sessions were held with the Internal Audit, Risk Management, Internal Controls, Controllership, Ethics and Compliance, Supplier Management, Cybersecurity and Data Privacy teams.

The report on the activities performed was submitted to the Board of Directors on a quarterly basis, along with an analysis of the interim financial statements, at which time the Committee's recommendations on topics within its competence were also submitted and discussed, such as related-party transactions carried out during the period.

Regarding the topics discussed, we highlight:

- Approval of the 2023 Financial Statements and 2024 interim financial statements;
- Internal Controls;
- Management of Investees;
- Related-party Transactions;
- Sustainability Commitments;
- Risk Management;
- Business Continuity, including disaster recovery, technology systems, and crisis committees;

- Monitoring of Ethics and Compliance processes;
- Cybersecurity mechanisms and artificial intelligence policies.

In carrying out its functions, the Committee reported to the Board of Directors the following topics during 2024, setting out its recommendations:

- Work plan and budget of the Audit Committee for 2024, comprising the Annual Internal Audit Plan;
- Related-party Transactions – approval of new contracts, annual review of current operations and reporting of those approved by the Board;
- Ethics and Compliance – review of certain processes of *Canal Conversa Ética* and periodic report on activities of the Compliance area, including training and communication actions;
- Risk Management - monitoring and controls;
- Cybersecurity and data privacy management.

Audit Committee Opinion

The Audit Committee of RD, in compliance with legal provisions and competence assigned by the Board of Directors, has reviewed the Management Report and the Financial Statements for the year ended December 31, 2024 and, based on the information contained therein, the work carried out during the year, and the information and clarifications provided by the Company's Management and by Ernest & Young Auditores Independentes, recommended its approval to the Board of Directors.

São Paulo, February 20, 2025.

Maria Fernanda dos Santos Teixeira

Audit Committee Leader

Sylvia de Souza Leão Wanderley

Pedro Guilherme Zan

To the Board of Directors and Shareholders

Raia Drogasil S.A.

The Company's Supervisory Board, in exercising its duties and legal responsibilities, has examined the financial statements for the year ended December 31, 2024 and, based on the examinations performed and on clarifications provided by management, and also considering the favorable Auditor's Report without exceptions, issued by the independent auditor Ernst & Young Auditores Independentes, the Supervisory Board members concluded that the documents above are fairly presented, in all material respects.

São Paulo, February 25, 2025.

Paulo Sérgio Buzaid Tohmé
Supervisory Board Member

Gilberto Lerio
Supervisory Board Member

Adeildo Paulino
Supervisory Board Member

Zeila Thoaldo Canter
Supervisory Board Member

In accordance with article 25, paragraph 1, items V and VI, of CVM Instruction 480/09, the Company's officers represent that they have reviewed, discussed and agree with the financial statements for the year ended December 31, 2024.

São Paulo, February 25, 2025.

Renato Cepollina Raduan
CEO

Marcello De Zagottis
COO

Antonio Carlos Coelho
Financial and Administrative Vice President

Melissa Teixeira Cabral
Pharmacy Operations Vice President

Fernando Kozel Varela
Digital Transformation Vice President

Juliana Lopes Marques Paixão
Commercial Vice President

Maria Susana de Souza
People, Culture and Sustainability Vice President

Bruno Wright Pipponzi
Health Business Vice President

Afonso Celso Florentino de Oliveira
Controlling Officer

Celso Pissi Filho
Accountant and Technical Officer
CRC 1SP236090/O-5

In accordance with article 25, paragraph 1, items V and VI, of CVM Instruction 480/09, the Company's officers represent that they have reviewed, discussed and agree with the conclusions expressed in the favorable Auditor's Report without exceptions issued by the independent auditors for the year ended December 31, 2024.

São Paulo, February 25, 2025.

Renato Cepollina Raduan
CEO

Marcello De Zagottis
COO

Antonio Carlos Coelho
Financial and Administrative Vice President

Melissa Teixeira Cabral
Pharmacy Operations Vice President

Fernando Kozel Varela
Digital Transformation Vice President

Juliana Lopes Marques Paixão
Commercial Vice President

Maria Susana de Souza
People, Culture and Sustainability Vice President

Bruno Wright Pipponzi
Health Business Vice President

Afonso Celso Florentino de Oliveira
Controlling Officer

Celso Pissi Filho
Accountant and Technical Officer
CRC 1SP236090/O-5